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Preface to ”Recent Advances in Enteral Nutrition”
Welcome to the interesting topic of enteral nutrition. Healthcare professionals including nurses,
doctors, nutritionists, dietitians and speech and language therapists who support people with nu-
tritional deﬁcit and/or swallowing difﬁculty recognize the need for enteral nutrition provision in
order to meet the nutritional requirements of these patients. Therefore, this book provides an up-
to-date research evidence covering the recent advances in enteral nutrition. It has been the result of
the contribution of a number of experts in this ﬁeld on a range of topical issues. These experts come
from different parts of the world and specialize in different aspects of enteral nutrition which should
provide the reader a better and broader understanding of this specialist area of nutrition.
The book is aimed at healthcare professionals and students involved in enteral nutrition support
and research as well as patients who may require enteral tube feeding. The book has fourteen chap-
ters. While the chapter on recent advances in enteral nutrition provides an overview of the broad
perspectives of the various topics discussed in the book, the other chapters capture detailed narra-
tives of original research and reviews that will guide healthcare professionals in their areas of practice.
These include the use of enteral nutrition in a range of long term conditions such as diabetes, demen-
tia and inﬂammatory bowel disease. In addition, discussion of the challenges of home enteral tube
feeding and the developments and evaluation of the home enteral nutrition team which are essential
for community enteral nutrition provision are some of the key elements of the book.
Omorogieva Ojo, Joanne Brooke
Special Issue Editor
vJi
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There have been signiﬁcant advances in the provision of enteral nutrition support in the acute
and community healthcare settings. Enteral nutrition is beneﬁcial to individuals who have functional
guts but may not be able to meet their nutritional requirements via a normal diet. Most of these people
have neurological conditions such as stroke, multiple sclerosis and dementia which could impact
on swallowing reﬂexes, leading to dysphagia [1]. Others may have cancer, intellectual disability or
conditions such as HIV and failure to thrive.
Therefore, the provision of nutrition support in the form of oral nutritional supplements (ONS)
and enteral nutrition support can help mitigate the challenges of nutritional deﬁcit [2]. Enteral feeding
can be delivered via a range of feeding tubes and through different methods of feeding including
continuous, bolus and gravity feeding [3]. While nasogastric tube (NGT) feeding is often provided
to individuals requiring short-term enteral nutrition provision, the percutaneous endoscopic
gastrostomy (PEG) tube is for long-term enteral feeding [4]. For individuals with partial/complete
gastrectomy and those who are at higher risk of aspiration, the use of the jejunostomy feeding tube
may help alleviate these problems [5]. On the other hand, the radiologically inserted gastrostomy (RIG)
tube may be the tube of choice in head and neck cancer patients who may have high risk of
malignant cell translocation from the primary site of disease to the stoma site. Similarly, the use
of the balloon gastrostomy feeding tube, following the dislodgement of the conventional enteral
feeding tube (PEG, RIG), is common, although there is evidence that the balloon gastrostomy feeding
tube is now used as a primary tube of choice in head and neck cancer patients [6].
Usually, the provision of enteral nutrition entails nutritional status assessment and the evaluation
of nutritional requirements of patients [7]. In addition, the development of feeding regimes, protocols,
guidelines, algorithms, and the management of patients, pumps, feeds, and feeding tubes are essential
aspects of enteral nutrition provision.
The developments in enteral nutrition appear to center on many aspects, including the increasing
use of enteral feeding in patients with long-term conditions, the development of multidisciplinary
teams including extended roles for dietitians and nurses and the use of guidelines. This may not be
unrelated to the worldwide increase in the aging population and increasing prevalence of long-term
conditions with associated complications, resulting in swallowing difﬁculties and malnutrition [8].
Therefore, the essence of the Special Issue on Recent Advances in Enteral Nutrition was to
capture key developments in this area of research and practice. For instance, dementia is a long-term
condition that impacts on people’s cognitive and physical abilities which can affect their nutritional
intake, leading to malnutrition [9]. Malnutrition in patients with dementia appears to correlate with
cognitive decline and the progression of the disease. The use of percutaneous endoscopic gastrostomy
which is used widely in supporting patients with a range of conditions seems to be discouraged in
dementia care [10]. In a systematic review on the use of enteral nutrition in patients with advanced
dementia, Finucance et al. [10] did not ﬁnd any improvements in the rates of aspiration, pressure sores
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and mortality and therefore concluded that enteral nutrition for patients with dementia should be
discouraged [10]. In contrast, recent recommendations from the systematic review by Brooke and
Ojo [9] challenged this position and instead suggested the need for a holistic assessment of patients
with dementia requiring enteral nutrition and PEG tube placement. These assessments should include
a diagnosis of patients—comorbidities, current stage of dementia, acute medical illness and its impact
on nutritional status [9].
Another area where enteral nutrition is being used to support patients with a long-term condition
is in diabetes care and management. The complications of diabetes are wide ranging and may include
stroke, which could impact on the swallowing ability of the individuals [4]. The use of enteral nutrition
to support these people who are unable to meet their nutritional requirements via oral intake alone
becomes imperative [11]. Therefore, Ojo and Brooke [12] evaluated the use of standard and diabetes
speciﬁc enteral formulas in the management of diabetes in a systematic review. Based on the response
of blood glucose and other parameters including HBA1c in the studies reviewed, it was concluded that
the use of diabetes speciﬁc formula may be effective in managing glucose in patients with diabetes
and on enteral nutrition [12].
There have been advances in the use of enteral nutrition to support patients with head and neck
cancer and other cancers through the use of different feeding tubes, both as prophylactic and reactive
treatments [13,14]. Patients with head and neck cancer are mostly malnourished and/or at risk of
malnutrition, therefore, prophylactic feeding through NGT or PEG aimed at improving weight gain
and promoting hydration is now common [15]. However, based on the narrative review by Bossola [15],
it would appear that the use of prophylactic enteral feeding does not offer advantages with respect to
nutritional outcomes, effect on radiotherapy treatment and survival compared with reactive feeding,
which involves patients being offered NGT or PEG when oral nutritional supplements are inadequate
in maintaining nutritional status [15].
In another study, Wang et al. [16] compared postoperative enteral nutrition with delayed enteral
nutrition in patients with oesophageal cancer with a view to establishing the most appropriate
time to commence enteral nutrition provision. It was concluded that early enteral nutrition started
within 48 hours was safe for postoperative oesophageal cancer patients [16]. Based on this study, it was
shown that early enteral nutrition is effective in reducing the incidence of postoperative pulmonary
infection, promoting postoperative nutrition status, enhancing early recovery of intestinal movement
and reducing the length of hospital stay and hospital cost [16].
Apart from patients with head and neck cancer, enteral nutrition is also used to support
patients with other forms of cancer including pancreatic cancer. According to Buscemi et al. [17],
pancreaticoduodenectomy is used for the treatment of periampullory carcinomas and patients who
have undertaken this procedure are often malnourished with signiﬁcant impact on postoperative
wound healing and recovery. Following this review, it was concluded that enteral nutrition appeared
safe and tolerated by patients who have had pancreaticoduodenectomy although it did not provide
any advantage in terms of postoperative pancreatic ﬁstula, postpancreatectomy haemorrhage, length
of hospital stay and infectious complications [17].
Inﬂammatory bowel disease, which includes at least three clinical conditions (ulcerative colitis,
Crohn’s disease and indeterminate colitis), is another condition that may beneﬁt from advances in
enteral nutrition support [18]. There is evidence that malnutrition is a common effect of inﬂammatory
bowel disease and diet has been implicated in its pathogenesis and clinical manifestation [18].
In addition, diet also has a role in the management of inﬂammatory bowel disease and the need
for enteral nutrition support becomes critical when oral dietary intake is not sufﬁcient to offer all the
nutritional requirements [19]. Enteral nutrition has shown promising results in the management of
Crohn’s disease as it provides equal or higher remission rates than current medications in use [18].
In a related study, exclusive enteral nutrition—the monotonous enteral delivery of complete
liquid nutrition—has been explored in the management of Crohn’s disease [19]. Exclusive enteral
nutrition is usually in the form of liquid enteral formulas which may be elemental (e.g., in the form of
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amino acids) or polymeric (e.g., in the form of intact protein) [19]. Although the mechanism of action
of exclusive enteral nutrition is still evolving, there is evidence that it could modify the composition of
intestinal microbiome which are essential in the pathogenesis of Crohn’s disease [19]. It would appear
that exclusive enteral nutrition is better than steroids in the induction of mucosal healing and may
provide long-term remission in some cases of Crohn’s disease [19].
The efﬁcacy and safety of the use of an enteral immunomodulatory diet (omega-3 fatty acid,
γ-linolenic acid and antioxidant supplementation) for acute lung injury and acute respiratory distress
syndrome are also areas of interest in enteral nutrition provision. This view relies on the understanding
that this therapy may be used for the treatment of these conditions, although researchers are not
unanimous on this position [20]. Based on the current systematic review [20], it is now clear that
an enteral immunomodulatory diet could not reduce the severity of acute lung injury and acute
respiratory distress syndrome.
In Very Low Birth Weight (VLBW) infants, feeding methods in enteral nutrition have been
explored based on the observation that continuous enteral feeding methodmay result in signiﬁcant loss
of fat and micronutrients [21]. Therefore, Tabata et al. [21] examined the fat loss in enteral nutrition
based on the current methods of providing fortiﬁed human milk in high risk infants. In addition, the
study evaluated whether fortiﬁer and cream improved fat delivery in continuous enteral infant feeding
of breast milk [21]. Based on this study, it was clear that fat and nutrient loss in continuous enteral
feeding was presenting a challenge to the provision of nutrients to Very Low Birth Weight infants [21].
Therefore, the bolus feeding method is recommended where possible and for infants who are unable
to tolerate bolus feeding, the addition of fortiﬁers and/or cream to human milk, in order to increase
fat percentage, is recommended [21].
The use of human milk fortiﬁed with donor human milk-derived fortiﬁer (HMDF) in premature
infants has been reported to increase serum phosphorus although the evidence appears anedoctal [22].
Therefore, the study by Chetta et al. [22] investigated this phenomenon and concluded that the
incidence of elevated serum phosphorus was mild and not permanent in premature infants receiving
human milk with HMDF.
Despite the merits of enteral nutrition, there are a number of challenges militating against the
use of enteral feeding. These include problems of funding, inadequate or lack of standards, policies,
management approaches, guidelines and infrastructure for the delivery of enteral nutrition [23].
Therefore, strategies for ameliorating these challenges should include the development of the Home
Enteral Nutrition (HEN) service which should promote multi-disciplinary team working and the
development of national and international standards and guidelines [23]. The National Institute
for Health and Care Excellence (NICE) guidance on nutrition support [24] emphasizes the quality
standard for nutrition support in adults and stresses the need for all care services to be responsible in
identifying those who are at risk of malnutrition and providing nutrition support for the people who
need it. In addition, Dutta et al. [25] conducted a comprehensive literature review and developed a set
of guidelines for feeding Very Low Birth Weight (VLBW) infants. It was concluded that there is a need
to aim for full feeds at about 2 weeks of age in neonates weighing <1000 g at birth and for 1 week
in those neonates weighing 1000–1500 g at birth [25]. The use of trophic feeds (10–15 mL/kg/day)
should commence within 24 h of birth although caution is required in extremely pre-term, extremely
low birth weight and infants with growth restriction [25].
The development of multidisciplinary teams, including primary care teams involved in enteral
nutrition provisions, has been shown to improve cost effectiveness [26]. A Home Enteral Nutrition team
comprising dietitians, nurses and speech and language therapist has the potential to improve patient
satisfaction and reduce the costs which are associated with enteral tube feeding in the community [27].
This is often achieved through the development and implementation of care pathways for the
management of patients on enteral tube feeding by the HEN team and effective multidisciplinary
team working [26]. The use of the HEN service has increased signiﬁcantly in the past few decades
and this has led to the development of various policies and guidelines for the management of enteral
3
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nutrition [28]. This has also contributed to the promotion of multidisciplinary team working and the
extension of roles of the different professionals that make up the HEN team [27,29].
Conﬂicts of Interest: The authors declare no conﬂict of interest.
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Abstract: The aim of this systematic review is to evaluate the role of enteral nutrition in managing
patients with diabetes on enteral feed. The prevalence of diabetes is on the increase in the UK and
globally partly due to lack of physical activities, poor dietary regimes and genetic susceptibility.
The development of diabetes often leads to complications such as stroke, which may require
enteral nutritional support. The provision of enteral feeds comes with its complications including
hyperglycaemia which if not managed can have profound consequences for the patients in terms of
clinical outcomes. Therefore, it is essential to develop strategies for managing patients with diabetes
on enteral feed with respect to the type and composition of the feed. This is a systematic review of
published peer reviewed articles. EBSCOhost Research, PubMed and SwetsWise databases were
searched. Reference lists of identiﬁed articles were reviewed. Randomised controlled trials comparing
enteral nutrition diabetes speciﬁc formulas with standard formulas were included. The studies which
compared diabetes speciﬁc formulas (DSF) with standard formulas showed that DSF was more
effective in controlling glucose proﬁles including postprandial glucose, HbA1c and insulinemic
response. The use of DSF appears to be effective in managing patients with diabetes on enteral feed
compared with standard feed.
Keywords: enteral nutrition; diabetes; diabetes speciﬁc formula; standard formula; hyperglycaemia;
glycaemic index
1. Introduction
The prevalence of diabetes and the cost to the National Health Service (NHS) have been on the
increase in the UK [1,2]. Various factors including the failure to maintain a healthy lifestyle such as
regular physical activity and healthy dietary regimes, and genetic susceptibility have been ascribed
as possible reasons for the high incidence of the condition [3,4]. The manifestation of diabetes comes
with various complications such as cerebrovascular accident, which may result in dysphagia, often
requiring nutritional support [5,6]. This is especially evident in patients with diabetes who may be
unable to maintain their nutritional requirements through the use of oral dietary intake alone and thus
may require enteral feed. In addition, their involvement in physical activity that would ensure the
maintenance of normal glucose levels may be compromised due to their neurological conditions and
poor mobility [7,8]. Therefore, managing a person with diabetes on enteral nutrition could present
some difﬁculties for the multidisciplinary healthcare professional (HCP) team if there are no effective
strategies for managing the enteral feed [9]. There could be increased risk of the patient with diabetes
on enteral feed developing hyperglycaemia or hypoglycaemia, which can result in potentially poorer
clinical outcomes [10–12].
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In a study by Ojo [13], comparison of patients on home enteral tube feeding (HETF) with the
Quality and Outcome Framework (QOF) data revealed that diabetes prevalence in people on HEFT in
Lambeth, Lewisham and Southwark primary care trusts in the UK was signiﬁcantly higher (7.78%)
than in the general population (3.63%) not on enteral nutrition and living in the same area. Ojo [13]
showed that more patients who have diabetes are now requiring enteral nutrition support.
The role of enteral nutrition in patients with diabetes is to provide the required macro- and
micro-nutrients including energy, protein, vitamins and minerals in part or whole in order to reduce
the risk of malnutrition in these patients [14]. However, due to the nature of the different food
formulas, the risk of hyperglycemia could be a major challenge in these patients and newly diagnosed
hyperglycaemia could be considered an independent prognostic factor of mortality in patients with
enteral feeding [15,16]. Hyperglycaemia can have profound impacts on a range of patients with
diabetes including those hospitalised, such as patients with diabetic ulcers or undergoing limb
amputations. Hyperglycemia may impact on wound healing, time spent in hospital and lead to
complications including diabetic ketoacidosis and hyperosmolar non-ketotic state [17,18]. Therefore,
there is the need to ensure adequate management of patients with diabetes, especially those on enteral
feed because of the effects on blood glucose levels. The cost of major complications resulting from
hyperglycaemia to the UK economy has been estimated to be between £872 for blindness in one eye
to £8459 for amputation per patient, although the total cost of type 2 diabetes to the UK economy
appears difﬁcult to evaluate [19]. However, in 2007 estimates of 7%–12% of the total NHS budget,
which could be £2.8 billion associated cost for the UK has been reported [1,20].
Nutritional requirements of patients with diabetes on enteral nutrition are met with the use of
standard enteral feeds or diabetes speciﬁc feeds. Diabetes speciﬁc formulas contain speciﬁc ingredients
that often include fructose and a large amount of monounsaturated fatty acids, which are aimed
at controlling postprandial glucose [21,22]. The effects of these feeds in maintaining the nutritional
requirements and physiological state of patients with diabetes continue to generate debate and attract
the interest of researchers. A scoping exercise of the literature revealed two systematic reviews on the
role of enteral nutritional support and the use of diabetes speciﬁc formulas for patients with diabetes
carried out at various times with different ﬁndings [19]. A systematic review and meta-analysis of
enteral nutritional support and use of diabetes speciﬁc formulas conducted by Elia et al. [19] aimed to
determine the beneﬁts of nutritional support in patients with types 1 and 2 diabetes. It compared the
use of nutritional support with routine care, and standard formulas with diabetes formulas. Although
the study concluded that the use of diabetes speciﬁc formulas (DSF) as oral nutrition supplements
and tube feeds improve blood glucose levels when compared with standard formulas, controversies
still surround the use of DSF. In particular, there are clinical interests in establishing the safety and
tolerance of relatively high levels of fat and fructose in patients with underlying dysmotility disorders
such as irritable bowel syndrome and with respect to lipid metabolism and lactic acidosis [22]. Since
the study by Elia et al. [19], a number of randomised controlled trials based on patients with diabetes
on enteral nutrition have been published. In addition, the American Society of Parenteral and Enteral
Nutrition (ASPEN) Clinical Guidelines: nutrition support of adult patients with hyperglycaemia
which was developed in order to provide the desired blood glucose goal in hospitalized patients
receiving nutritional support could not recommend whether diabetes speciﬁc formulas can be used for
hospitalised adult patients with hyperglycaemia [23].
The ASPEN Clinical Guidelines recommendation for the use of diabetes speciﬁc formula was
based on only two studies published in 2003 and 2005. It was therefore not surprising that the ASPEN
guideline recommended that further research was required in the use of diabetic speciﬁc formulas [23].
According to Cheng [24], two strategies for managing hyperglycaemia of enteral feeding are adjustment
of the enteral feed carbohydrate content and pharmacological therapy to lower glucose levels although
the current review is focused on the former.
Drawing from the above reviews and guidelines, the need to examine the role of standard versus
diabetes speciﬁc formulas has become pertinent. Therefore, the aim of the present study is to carry out
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a systematic review of the role of enteral nutrition in supporting patients with diabetes. However, the
use of insulin and oral hypoglycaemic agents was not examined in this review.
The objective is as follows:
• To examine the effects of standard and diabetes speciﬁc enteral formulas in the management
of diabetes.
The research question is:
• Is diabetes speciﬁc formula more effective than standard formulas in managing patients with
diabetes on enteral feed?
2. Experimental Section
A systematic review was carried out based on published guidelines [25,26]. This involved a
literature search of articles of interest relating to the use of enteral nutrition in diabetes management,
including a general scoping of the data bases which found only two systematic reviews that were
relevant to the population and intervention of interest. A search of the Cochraine library and databases
of abstracts of reviews and effects found one article by Elia et al. [19], which was published in 2005. A
further search of SwetsWise and EBSCO host databases found the ASPEN guidelines; nutrition support
of adult patients with hyperglycaemia [23]. Although this guideline was published in 2013, it derived
most of its limited evidence with respect to the question on the use of diabetes speciﬁc formulas in
adult hospitalised patients with hyperglycaemia from studies published between 2003 and 2005.
The research question was deﬁned into the component parts; the Population (P), the
Interventions (I), Comparative interventions (C) and Outcomes (O) based on PICO framework [25].
Table 1 shows the results of the various searches. The databases searched included EBSCO Host/Health
Sciences Research databases (encompassing Academic search premier, Medline, Psychology and
Behavioural sciences collection, PSYCINFO, SPORTDISCUSS and Cumulative Index to Nursing and
Allied Health Literature (CINAHL) Plus) and SwetsWise. The reference list of relevant systematic
reviews and articles were checked in order to identify studies that could be useful to the present review.
Table 1. Literature search strategy.
Database Dates Covered Date Searched Hits Search Terms
EBSCO Host (Health Sciences
Research Databases) 2005–2014 04.06.14 469,184 Diabetes
EBSCO Host (Health Sciences
Research Databases) 2005–2014 04.06.14 323 Diabetes and Enteral Nutrition
EBSCO Host (Health Sciences
Research Databases) 2005–2014 04.06.14 13
Diabetes and Enteral Nutrition and
Diabetes Speciﬁc formula
EBSCO Host (Health Sciences
Research Databases) 2005–2014 04.06.14 2
Diabetes and Enteral Nutrition and
Standard Feed
EBSCO Host (Health Sciences
Research Databases) 2005–2014 04.06.14 1
Diabetes and Enteral Nutrition and
Glycated Haemoglobin
EBSCO Host (Health Sciences
Research Databases) 2005–2014 04.06.14 4
Diabetes and Enteral Nutrition and
Fasting Blood Glucose
EBSCO Host (Health Sciences
Research Databases) 2005–2014 04.06.14 28
Diabetes and Enteral Nutrition and
Hyperglycaemia
EBSCO Host (Health Sciences
Research Databases) 2005–2014 04.06.14 11
Diabetes and Enteral Nutrition and
Hypoglycaemia
SwetsWise 2005–2014 04.06.14 46 Diabetes and Enteral Nutrition
SwetsWise 2005–2014 04.06.14 47 Diabetes and Standard feed
SwetsWise 2005–2014 04.06.14 73 Diabetes and Diabetes Speciﬁc feed
2.1. Inclusion and Exclusion Criteria
Only randomised controlled trials were selected for inclusion in the current review.
The participants in the studies included in the systematic review were adult males and females
who had diabetes and were on enteral nutrition while the interventions were standard enteral feed
and DSF.
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The outcome measures included in the search were; HbA1c, fasting blood glucose, hyperglycaemia
and hypoglycaemia.
In terms of the years of publication, searches were conducted between 2005 and 2014 while only
studies written in English language were included. Studies that did not meet the above inclusion
criteria were excluded from the study.
2.2. Data Analysis
Based on the criteria outlined for exclusion and inclusion of various studies, 469,184 articles
were initially available. This number was further reduced to 323 articles with the inclusion of enteral
nutrition as part of the search term (Table 1). Of these articles, ﬁve articles that met the requirements
for selection were included in the review (Table 2).
3. Results
All the studies included in the systematic review involved patients who had type 2 diabetes
and these were clearly speciﬁed in the method section in the respective studies. While three
studies compared DSF with standard formula [21,27,28], one study [29] compared slowly digested
carbohydrate formula with DSF and standard formula (Table 2). The ﬁnal study compared diabetes
speciﬁc enteral formula with 49.95% calories provided by fat and diabetes speciﬁc enteral formula
with 34% calories provided by fat [30].
In the study by Ceriello et al. [21], glucose proﬁles were signiﬁcantly better after administering
DSF compared with standard formula. In addition, diabetes speciﬁc formula signiﬁcantly improved
postprandial glucose compared with the standard, ﬁbre-containing formula.
With respect to the study by Vaisman et al. [28], HbA1c decreased over time in the diabetes speciﬁc
diet group and increased in the standard feed group. Similarly, in the randomised double-blinded
study evaluating the postprandial glycaemic and insulinemic response conducted by Alish et al. [27],
differences in adjusted peak plasma glucose levels were signiﬁcantly lower in DSF compared with
standard formulas (STF) (p < 0.001). In addition, differences in adjusted peak insulin levels were
signiﬁcantly lower in DSF compared with STF (p = 0.017). In other words, the use of DSF produced
signiﬁcantly lower postprandial and insulinemic response.
Voss [29] revealed that adjusted glucose concentrations were signiﬁcantly higher at all points after
feeding the STF compared with the slowly digested carbohydrate formula (SDC) or DSF (p < 0.001).
In addition, adjusted plasma glucose concentrations for the SDC were observed to be signiﬁcantly
lower than those for the DSF from 30 to 120 min (p < 0.05). In relation to the adjusted insulin
responses, these were signiﬁcantly higher for the STF compared with the SDC at each time point, while
the SDC had a signiﬁcantly lower insulinemic response compared with the DSF at 90 and 120 min
(p < 0.05) [29]. Finally, the adjusted results for postprandial glucagon-like polypeptide-1 (GLP-1) levels
at 30 and 60 min in this study were signiﬁcantly lower for the STF compared with SDC (p < 0.05),
but not different from the DSF [29].
In the study byDe Luis et al. [30] which compared diabetes speciﬁc enteral supplement with 49.95%
calories provided by fat (Gp 1) and diabetes speciﬁc enteral supplement with 34% calories provided by
fat (Gp 2), a signiﬁcant decrease of glucose and HbA1c was observed in Gp 1 compared with Gp 2.
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With respect to the study by Vaisman et al. [28], HbA1c decreased over time in the diabetes speciﬁc
diet group and increased in the standard feed group. Similarly, in the randomised double-blinded
study evaluating the postprandial glycaemic and insulinemic response conducted by Alish et al. [27],
differences in adjusted peak plasma glucose levels were signiﬁcantly lower in DSF compared with
STF (p < 0.001). In addition, differences in adjusted peak insulin levels were signiﬁcantly lower in
DSF compared with STF (p = 0.017). In other words, the use of DSF produced signiﬁcantly lower
postprandial and insulinemic response.
Voss [29] revealed that adjusted glucose concentrations were signiﬁcantly higher at all points
after feeding the STF compared with the SDC or DSF (p < 0.001). In addition, adjusted plasma
glucose concentrations for the SDC were observed to be signiﬁcantly lower than those for the DSF
from 30 to 120 min (p < 0.05). In relation to the adjusted insulin responses, these were signiﬁcantly
higher for the STF compared with the SDC at each time point, while the SDC had a signiﬁcantly lower
insulinemic response compared with the DSF at 90 and 120 min (p < 0.05) [29]. Finally, the adjusted
results for postprandial GLP-1 levels at 30 and 60 min in this study were signiﬁcantly lower for the
STF compared with SDC (p < 0.05), but not different from the DSF [29].
In the study byDe Luis et al. [30] which compared diabetes speciﬁc enteral supplement with 49.95%
calories provided by fat (Gp 1) and diabetes speciﬁc enteral supplement with 34% calories provided by
fat (Gp 2), a signiﬁcant decrease of glucose and HbA1c was observed in Gp 1 compared with Gp 2.
4. Discussion
Diabetes speciﬁc formula seems to be effective in managing glucose proﬁles including
postprandial glucose and insulinemic response and HbA1c compared with standard formula in patients
with diabetes on enteral nutrition. The effectiveness of DSF in patients with diabetes on enteral feed
may be partly due to the form of carbohydrate used in its formulation. Diabetes speciﬁc formulas often
contain carbohydrate that are more slowly digested and absorbed compared with standard formula
that contain carbohydrates that are more rapidly digested and absorbed [27]. Postprandial blood
glucose response, which is a risk factor for micro- and macro-vascular complications, has been shown
to be inﬂuenced profoundly by the speciﬁc composition of the diet [31]. The measure of how soon
glucose reaches the blood stream is often termed the glycaemic index (GI) of food while the glycaemic
load (GL) shows the overall glycaemic effect of a speciﬁc amount of food item [1]. It is possible that
DSFs are formulated with carbohydrates which have lower GI compared with standard formulas.
In a study conducted by Hofman et al. [32], it was shown that the GI of the 12 enteral formulas
determined in the study varied widely from GI = 12 for a diabetes speciﬁc feed up to GI = 61 for a
standard supplement. High GI foods have GI value ≥70 while medium GI values range from 55 to 70
compared to low GI foods that have GI value ≤55 [33]. According to Hofman et al. [32], in general,
a low GI formula (DSF) is characterised by reduced carbohydrate content, presence of fructose, a
higher fat content containing monounsaturated fatty acids (MUFA) and high amounts of ﬁbre while
standard formulas, especially sip feeds, often do not contain ﬁbre. This view is reinforced by Charney
and Hertzler [34] who noted that diets containing up to 30% of total calories as MUFA have led to
improvements in lipoprotein levels and glycaemic control in patients with diabetes. In addition, small
doses of fructose (5 g to 10 g) have been found to be effective in reducing acute glycaemic response to
a carbohydrate challenge partly because of the low GI of fructose, which is 19 compared with the GI
of glucose which is 100 [34]. On the other hand, standard enteral formulas, whether oral or enteral,
are high in carbohydrate, low in fat and ﬁbres compared with DSFs which contain deﬁned nutrient
composition such as fructose, ﬁbre, MUFA, soy bean and antioxidants which are designed to improve
glycaemic control [19]. The source of carbohydrate in DSF includes increased amount of fructose
relative to standard formulas and fat often in the form of higher amounts MUFA when compared with
standard formulas although issues around tolerance on high levels of fats and fructose in feed have
been subjects of discussion [22,35]. The main sources of ﬁbre in DSF are usually fruits and vegetables
and the levels are relatively higher than in standard formulas.
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Evidence of a meta-analaysis demonstrates that low GI foods have clinically more useful effect
on medium-term glycaemic control (glycated proteins) in patients with diabetes [32]. According
to Widanagamage et al. [36], the long-term use of foods that have high GI can place a higher
metabolic demand on the body in terms of higher insulin requirement with the potential to lead
to insulin resistance.
5. Conclusions
The outcomes of the studies that compared Diabetes speciﬁc formula with standard formulas
appear to show a trend with respect to the response of glucose and other parameters such as HbA1c,
which deﬁne diabetes. Based on the evidence in the present review, there are indications that the
use of Diabetes speciﬁc formula could be effective in managing glucose in patients with diabetes on
enteral nutrition.
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Abstract: One of the most effective forms of therapeutic enteral nutrition is designated as “exclusive
enteral nutrition” (EEN). EEN constitutes the monotonous enteral delivery of complete liquid
nutrition and has been most explored in the treatment Crohn’s disease (CD), a form of inﬂammatory
bowel disease. While EEN’s mechanisms of action are not clearly understood, it has been shown to
modify the composition of the intestinal microbiome, an important component of CD pathogenesis.
The current literature on the intestinal microbiome in healthy individuals and CD patients is reviewed
with respect to EEN therapy. Further investigations in this ﬁeld are needed to better understand the
role and potential for EEN in chronic human disorders.
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1. Introduction
Therapeutic enteral nutrition describes the provision of deﬁned nutritional support with the
goal of treating a disease state. Despite a long history using therapeutic enteral nutrition, the critical
mechanisms of action by which dietary changes can exert beneﬁcial effects in speciﬁc human disorders
are incompletely understood. Multiple hypotheses have been put forward in this regard, which
include reduction in antigen exposure, overall nutritional repletion, improvement in intestinal barrier
function, provision of micronutrients and reduction in dietary fat or carbohydrate, leading to reduced
byproducts producing inﬂammation [1,2].
Exclusive enteral nutrition (EEN) is a subtype of therapeutic nutrition where dietary intake is
conﬁned to the persistent delivery of the same complete food preparation. Most commonly, EEN is
achieved by liquid enteral formulas. Liquid formulations of EEN are typically divided into either being
elemental or polymeric. Elemental formulas deliver a protein source as individual amino acids, and
polymeric formulas provide intact protein. EEN has been most commonly employed to treat Crohn’s
disease (CD) [3]. CD is an incurable subtype of inﬂammatory bowel diseases (IBDs) characterized by
transmural inﬂammation of the intestine anywhere from the mouth to the anus. The pathogenesis of
CD is believed to involve the interaction between a defective intestinal barrier, environmental risk
factors, the intestinal microbiome and host genetics [4,5]. Many of these biological systems, apart from
genetics, are suspected to be modulated by EEN [2], which may explain its efﬁcacy in treating CD.
More recently, the microbiome related effects of this therapeutic nutrition are coming into focus. EEN
has also been explored in the treatment of other autoimmune diseases, such as juvenile idiopathic
arthritis [6] and ulcerative colitis [7], but these studies are rather limited. Therefore, this review will
focus on CD with respect to the microbiome-related inﬂuences of EEN.
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2. Treatment of CD with EEN
Induction and maintenance of remission (symptom free disease) are the current treatment goals
for CD. The available medical therapies to achieve these goals include 5-aminosalicyclic acid (5-ASA)
derivatives, immunosuppressive or immunomodulator agents (azathioprine, methotrexate), biologic
medications (molecularly-engineered antibodies against key components of the human intestinal
inﬂammatory cascade: inﬂiximab, adalimumab, certolizumab, natalizumab, vedolizumab, etc.) or
steroids (prednisone, budesonide). For severe CD, induction is typically achievable with either
biologics or steroids. Thereafter, the continuation or transition to immunomodulators or biologic
agents can substantiate remission. This approach, however, has limitations, including increased
risk of adverse events (pancreatitis, hepatitis, neutropenia/bone marrow suppression) and potential
long-term complications, such as a higher risk of malignancies [8,9]. Secondary to the limitations of
conventional medical treatments, EEN has been explored as an adjunct or monotherapy for CD.
Since steroids are commonly used to induce remission, studies compared the efﬁcacy of EEN
to steroids during early CD treatment. Small, randomized trials found that children treated with
elemental nutrition or steroids had similar rates of clinical improvement. Elemental EEN, however,
was superior to steroids in terms of improved growth velocity [10,11]. Though these results were
encouraging, the treatment durations were only 4–6 weeks, leaving questions about the potential for
EEN as a maintenance therapy. Another limitation of these studies was non-compliance, since 8%–11%
of children were unable to tolerate the elemental diet due to bad taste.
To overcome the limitations of elemental EEN, some trials have used polymeric formulas to
induce or maintain remission in CD patients. Early investigations comparing polymeric formulations
to steroids suggested that steroids were superior for inducing remission [12,13]; however, more recent
work demonstrated equal efﬁcacy of the two treatments [14,15]. Comparison between these trials
is difﬁcult, since they used different formulations of polymeric nutrition and for varied durations.
Small cohort studies have examined if patients maintained on EEN (elemental or polymeric) remain in
remission, but the results suggested that approximately 40%–60% will relapse within a year [16–18].
However, a signiﬁcant proportion of this relapse rate may be attributed to discontinuation of EEN,
which occurred in 20%–50% of the patients. These studies indicate that elemental and polymeric
nutrition have equal therapeutic efﬁcacy in CD, so either may be considered. Despite encouraging
efﬁcacy results for polymeric nutrition, high relapse rates likely arising from patient non-compliance
and deliberate discontinuation due to taste limit EEN as a maintenance therapy for CD.
The discussed studies predominantly used clinical scores (Crohn’s Disease Activity Index, CDAI)
to determine treatment efﬁciency. More recently, the demonstration of intestinal mucosal healing is
becoming a favored treatment endpoint [19]. Mucosal healing has been correlated with reduced risk
of disease relapse, for example [20]. Steroids do not effectively induce mucosal healing, but several
studies have shown that EEN can [21–24]. Borrelli et al. demonstrated in a randomized controlled
trial of 37 children with CD that EEN induced mucosal healing in a greater proportion of patients
compared to corticosteroids (p < 0.001) at 10 weeks. A single small cohort trial observed that polymeric
nutrition induced mucosal healing by magnetic resonance enterography imaging [25]. Magnetic
resonance enterography (MRE) can noninvasively detect small bowel mucosal damage with a high
sensitivity [26,27]. These studies suggest that EEN may be an efﬁcacious therapy for healing mucosal
injury related to CD, but deﬁnitive conclusions are limited by patients frequently receiving concomitant
IBD medications (6-mercaptopurine, mesalamine, etc.). Further well-designed studies will be needed
to conﬁrm these ﬁndings while controlling for other confounding factors.
Based on the above, EEN appears to be as efﬁcacious and perhaps even superior to steroids, for
inducing remission in CD. EEN has several other beneﬁts compared to steroids, including improved
growth [10,11] and quality of life [28], optimized bone metabolism [29] and induction of mucosal
healing [21–23]. Another common complication of CD is intestinal stricturing, which can necessitate
intestinal resections. The risk of recurrence and subsequent surgeries remains high after resections [30].
Interestingly, a recent prospective cohort study from Japan indicated that even partial (50% caloric
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requirements) delivery of EEN can signiﬁcantly reduce the endoscopic (mucosal) recurrence of the
disease at the surgical site after a year of surgery [31]. The overall need for re-operation tended to be
less as well (p = 0.08) in the partially EEN-treated group.
Despite the encouraging ﬁndings above, EEN has to be further explored to clearly determine
its therapeutic potential as an induction and/or maintenance therapy for CD. The questions of its
utility as a mono- versus combination therapy and as exclusive versus partial nutrition remain to be
answered, as well. Community-based data from Spain suggested that physicians are frequently (63%)
recommending EEN to CD patients [32], but several barriers (poor long-term compliance, lack of
optimized teaching, variable patient acceptance) create practical limitations for exploring the full
potential of this promising treatment modality. Additionally, the mechanism of action for EEN would
be important to deﬁne for the optimization of this practically challenging treatment, which carries a
desirable side effect spectrum, compared to other available medical therapies. In the next section, we
will review our limited understanding of EEN biology.
3. EEN Mechanisms of Action
Several hypotheses have been proposed to explain the efﬁcacy of EEN for CD. The most likely
mechanisms include direct anti-inﬂammatory effects, improvement of intestinal barrier function and
modulation of the intestinal microbiome (Figure 1).
Figure 1. Schematic representation of the gut microbiota, the intestinal epithelium and immune system;
and how exclusive enteral nutrition (EEN) may affect these systems. Crohn’s disease is associated with
dysbiosis of the gut microbiota, increased permeability of the intestinal epithelium and dysregulated
immunity. Studies suggest that EEN can alter the composition of the gut microbiota (A), reduce
intestinal permeability through modulation of tight junctions either directly (B) or through modulating
the intestinal microbiome (A) and downregulate the production of inﬂammatory cytokines either
directly (C) or through modulating the intestinal microbiome (A).
CD is characterized by increased production of multiple pro-inﬂammatory cytokines (TNF-alpha,
IL-1, IL-6, etc.) [33]. Studies in children have shown that treatment with polymeric enteral nutrition can
downregulate mucosal concentrations of these cytokines, as well as improve mucosal integrity [34].
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Similar results were found using in vitro techniques, where pro-inﬂammatory signaling pathways were
downregulated in the presence of polymeric formula [35,36]. These studies, however, were limited,
since a precise molecular mechanism could not be deﬁned, and the authors acknowledged the need
for further work in this area.
Mucosal barrier integrity is vital to the proper functioning of the intestines. Mucosal barrier
function is maintained in part by structures designated as tight junctions, which join epithelial cells
and participate in the regulation of ion, nutrient and water transport. In CD, the mucosal barrier
is dysfunctional, which can be beneﬁcially modiﬁed with EEN [37]. In vitro models using colonic
epithelial cells have demonstrated that EEN can reduce intestinal permeability after the induction
of colitis [38,39]. Interestingly, clinical studies have also shown that ﬁrst-degree family members of
CD patients have increased intestinal mucosal permeability when compared to non-IBD controls [40].
These ﬁndings suggest that patients with CD have intrinsic mucosal barrier defects, which could be
modulated by EEN. However, the exact means by which EEN may improve mucosal permeability are
not well understood.
Recent advances in sequencing technologies and bioinformatics have also allowed for examining
the potential inﬂuence of EEN on the intestinal microbiome, which is another critically important
biological system in the pathogenesis of CD. We will next review the human gut microbiome and its
potential importance in CD and EEN therapy.
4. Microbiome Basics
The human intestinal microbiome comprises a diverse, highly-interactive ecological system of
bacteria, Archaea, viruses and fungi [41]. Classically, the intestinal microbiome was characterized
by standard microbiological techniques, but those were inherently limited by the inability to culture
over 60% of intestinal bacteria. Recently, investigators have leveraged the conserved 16S rRNA gene
present in all bacteria to characterize the intestinal microbiome with sequencing techniques. This gene
has taxon-specific variable regions, the sequencing of which can allow for bacterial classification.
Additional techniques have been developed to sequence all genes present in a tissue sample (whole
genome sequencing, WGS) and characterize the overall gene content attributed to microbes [42,43].
These techniques allow for bacterial classification and examination of overall gene content, but
lack the ability to provide information about the actual biological activity or function of a specific
microbiome. The functional activity of microbiomes is more specifically examined by the maturing
fields of metatranscriptomics and metabolomics [42,44].
In parallel with the application of these new sequencing techniques, bioinformatic tools have
been developed to process and interpret large datasets [42,45,46]. These tools enable the generation
of common ecological measures (richness and diversity) to characterize the intestinal microbiome
community. Richness describes the number of unique bacterial (or other microbial) species present
in a sample, and diversity accounts for both the number and the relative abundance of the different
species. As microbial clinical studies incorporate these metrics, investigators are ﬁnding signiﬁcant
associations with multiple diseases, such as obesity [47] and IBD [48].
Results from the American Human Microbiome Project (HMP) and European metagenomics of
the human intestinal tract (MetaHIT) projects have provided composition and functional information
for the healthy human microbiome [49,50]. These studies showed highly varying intestinal microbiome
composition between subjects, but an overall similar functional capacity. From these and subsequent
work, we gained an appreciation for the multitude of factors inﬂuencing microbiome composition
(age, diet, sampling method). Microbiome composition appears to ﬂuctuate rapidly early in life,
remain relatively stable during adulthood and change again towards the seventh decade of life [41].
In addition to age, long-term dietary patterns strongly inﬂuence the intestinal microbiome [51–53].
Additionally, the intestinal microbiome can rapidly respond to short-term dietary interventions, as
well, but reverts to its prior composition once the interventions cease [54–56]. Furthermore, the gut
microbiome is different at the mucosal surface from that of luminal content. Therefore, the clinical
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sample type (feces versus mucosa) has to be taken into consideration [57,58], when planning and
comparing microbiome studies of the gut speciﬁcally.
5. EEN Effects on the Intestinal Microbiome
A limited number of studies have described the intestinal microbiome of healthy subjects during
EEN. Using a cross-over design, Whelan et al. examined the effect of fructooligosaccharide and
ﬁber supplemented EEN on intestinal microbiota. They found that total intestinal bacterial counts
were reduced during EEN [59]. However, this work utilized ﬂuorescent in situ hybridization (FISH)
techniques, which carry signiﬁcant limitations compared to the current high-throughput technologies.
Subsequently, the same group re-analyzed this data to describe the change in Faecalibacterium prausnitzii
during EEN. F. prausnitzii is a commensal, Gram-positive bacterium with anti-inﬂammatory properties,
which has been implicated in CD pathogenesis [60]. Their group found signiﬁcant reductions in
F. prausnitzii abundance during ﬁber supplementation, which demonstrated that diet can modulate
speciﬁc bacterial concentrations [61]. Associations between F. prausnitzii, CD and EEN will be discussed
in detail in the subsequent sections.
After characterizing the healthy human microbiome by state-of-the-art technology, investigators
are now exploring the differences present in diseases. The term dysbiosis refers to the abnormal
composition of the intestinal microbiome and has been studied in multiple disease states (obesity,
diabetes, etc.). Reduced fecal microbiome richness [47] and diversity [62] were found in obese
individuals. WGS revealed compositional differences between those with type 2 diabetes and
non-diabetic controls, which may inﬂuence overall insulin resistance [63,64]. These and many other
association studies indicate that abnormal composition and subsequent pathologic functioning of the
microbiome may contribute to human disease.
6. The Gut Microbiome of Crohn’s Disease
The intestinal microbiome of CD patients has been found to have overall dysbiosis compared
to the datasets from HMP and MetaHIT [65,66]. Hansen et al. studied colon biopsy specimens from
treatment-naive pediatric CD patients and detected signiﬁcant reductions in diversity compared to
healthy controls and patients with ulcerative colitis (UC, the other form of IBD) [65]. Gevers and
colleagues examined both stool and mucosal samples from a very large cohort of treatment-naive
pediatric CD patients and found modest overall differences compared to controls, which was increased
in patients with higher disease activity (Table 1) [66]. Detailed bioinformatic analyses revealed further
functional differences between CD and controls. CD microbiomes expressed pathways involved
in inﬂammation and had reduced functionality related to amino acid, carbohydrate and nucleotide
metabolism [66]. Other investigations in treatment-experienced CD patients have identiﬁed similar
functional changes [67,68].
Table 1. Description of mucosal microbiota changes found in treatment-naive Crohn’s disease [65,
66]. Several bacterial taxa are increased or decreased compared to non-IBD controls. * Changes in
Faecalibacterium were inconsistent across studies, with one study reporting an increase and the other
a decrease.
Crohn’s Disease
Increased Decreased
Enterobacteriaceae Bacteroidales
Pasteurellaceae Clostridiales
Fusobacteriaceae Erysipelotrichaceae
Neisseriaceae Biﬁdobacteriaceae
Veillonellaceae Coriobacteriaceae
Gemellaceae Faecalibacterium *
Faecalibacterium
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The role of speciﬁc bacteria in CD is less understood. The difﬁculties in making a deﬁnite
conclusion about single species are well demonstrated by the example of F. prausnitzii. Previous
observations noted reduced concentrations of F. prausnitzii in the terminal ileum of CD patients and
higher concentrations correlated with reduced risk of recurrence [69,70]. These studies, however, were
confounded by examining treatment-experienced patients, where microbiome composition may have
been modiﬁed by the treatments themselves [67,71]. Explorations in treatment-naive patients led to
conﬂicting results on F. prausnitzii, with one small cohort reporting higher abundance of the bacterium
compared to controls [65], as opposed to a lower abundance found in a recent large-scale study [66].
These studies emphasize the complexity of the microbiome in IBD and underscore the need for
careful planning (i.e., accounting for confounding factors, recruiting adequate number of patients) to
enable the detection of meaningful differences. These limitations have to be taken into account when
interpreting the available literature on EEN-microbiome effects in CD patients.
7. EEN Induced Microbiome Changes in CD Patients
Only a few studies have examined the microbial effects of EEN in CD patients. Lionetti et al.
reported results from a small case series of nine pediatric CD patients treated with polymeric enteral
nutrition. They noted that eight of nine children obtained clinical remission, and all experienced
signiﬁcant shifts in intestinal microbiome composition [72]. These shifts were determined using the
gel electrophoresis banding pattern, resulting in a limited depth of interrogation when compared to
high-throughput technologies. Similar results were found in a study of six children with CD treated
with EEN, as well as correlations between speciﬁc bacterial taxa and the degree of inﬂammation [73].
In a recently published work on EEN treatment for pediatric CD (utilizing gel electrophoresis and
quantitative real-time PCR), investigators found decreases in overall microbiome diversity and
reductions in F. prausnitzii abundance during EEN therapy [74]. These ﬁndings challenge the previous
notions of increased microbiome diversity associated with health and higher concentrations of F.
prausnitzii associated with reduced CD activity. In accordance with the difﬁculties for interpreting the
role of F. prausnitzii in CD, some observations indicate that regardless of disease activity, the abundance
of it remains low in CD [75] and can even further decrease upon clinical improvement with elemental
enteral therapy [76]. Clearly, further work is required to understand the role of F. prausnitzii in CD
and IBD in general. Such controversies emphasize the challenges of microbiome research, even in the
current era of advanced technology.
To gain a better understanding of EEN’s effects on the intestinal microbiome, our lab explored
this interaction in a mouse model. We set up the hypothesis that it is the monotonous nature of EEN
that is critical to its therapeutic effect and not the liquid nature or low antigenicity of it. Healthy mice
were assigned to either a single chow or alternating chows. This was meant to mimic either EEN or
a more free (liberalized) diet, respectively. After 20 days of the monotonous or the alternating diet
feeding, mice were given dextran sulfate sodium (DSS), an intestinal irritant that induces acute large
bowel inﬂammation (colitis) and is an accepted model of human IBD. Mice given the single chow diets,
similar to EEN, had higher overall microbiome diversity compared to alternating chow fed mice [77].
These results were consistent with the prior human ﬁndings described by Leach et al. [73]. However,
the results of Gerasimidis and colleagues [74] oppose the observations in the murine experiment.
Regardless, the mice provided alternating chow were also more susceptible to intestinal injury from
DSS, supporting an association between reduced microbiome diversity and susceptibility to colitis
in mammals. This observation is also consistent with the reduction of microbiome diversity in IBD
patients [65,66]. Altogether, our murine model work supported the hypothesis that the monotonous
nature of EEN may be a key component to its efﬁcacy. Epidemiologic observations correlating
agricultural import with the incidence of CD in a European country further substantiated the possible
validity of the “monotonous diet” hypothesis [77]. Further high-throughput studies will need to
explore the effects of EEN on microbiome composition in both healthy people and CD patients to
elucidate the exact effects of this nutritional therapy in health and disease.
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8. Future Considerations and Conclusions
Several randomized clinical trials have shown the efﬁcacy for partial and exclusive elemental or
polymeric nutritional therapies to induce clinical improvement and even remission in CD. EEN appears
to be superior to steroids with respect to the induction of mucosal healing during induction therapy
and may have the potential to provide long-term remission in some cases of CD. The highlighted
limitations of the existing clinical studies and the practical challenges for this drastic nutritional
therapy warrant further intense work towards the optimization of this treatment modality. Though the
mechanism(s) of action of nutritional therapy remains unknown, the detected changes in the intestinal
microbiome composition and function induced by EEN provide new routes for research. The ﬁndings
from such investigations may facilitate the development of novel treatment strategies, not only for CD,
but for other autoimmune disorders, as well.
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Abstract: The present review aimed to deﬁne the role of nutritional interventions in the prevention
and treatment of malnutrition in HNC patients undergoing CRT as well as their impact on CRT-related
toxicity and survival. Head and neck cancer patients are frequently malnourished at the time
of diagnosis and prior to the beginning of treatment. In addition, chemo-radiotherapy (CRT)
causes or exacerbates symptoms, such as alteration or loss of taste, mucositis, xerostomia, fatigue,
nausea and vomiting, with consequent worsening of malnutrition. Nutritional counseling (NC)
and oral nutritional supplements (ONS) should be used to increase dietary intake and to prevent
therapy-associated weight loss and interruption of radiation therapy. If obstructing cancer and/or
mucositis interfere with swallowing, enteral nutrition should be delivered by tube. However, it
seems that there is not sufﬁcient evidence to determine the optimal method of enteral feeding.
Prophylactic feeding through nasogastric tube or percutaneous gastrostomy to prevent weight loss,
reduce dehydration and hospitalizations, and avoid treatment breaks has become relatively common.
Compared to reactive feeding (patients are supported with oral nutritional supplements and when
it is impossible to maintain nutritional requirements enteral feeding via a NGT or PEG is started),
prophylactic feeding does not offer advantages in terms of nutritional outcomes, interruptions
of radiotherapy and survival. Overall, it seems that further adequate prospective, randomized
studies are needed to deﬁne the better nutritional intervention in head and neck cancer patients
undergoing chemoradiotherapy.
Keywords: head and neck cancer; chemoradiotherapy; malnutrition; nutrition; nutritional counseling;
oral nutritional supplements; enteral nutrition; gastrostomy
1. Introduction
Head and neck cancer (HNC) (cancer of the oral cavity, oropharynx, hypopharynx and larynx) is
the seventh most common malignancy in the world [1]. The majority of patients with HNC present
with locally advanced disease [1], for which treatment is complex and aggressive, with a therapeutic
goal of achieving a cure while minimizing toxicity. The standard of care is multidisciplinary, utilizing
bimodality or trimodality therapy where appropriate. Recent advances have led to alterations in
radiotherapeutic technologies, the introduction of sequential (induction) systemic chemotherapy, and
the inclusion of targeted agents in combination chemotherapy regimens [2].
Head and neck cancer patients are frequently malnourished at the time of diagnosis and prior
to the beginning of treatment [3–7]. In addition, chemo-radiotherapy (CRT) causes or exacerbates
symptoms, such as alteration or loss of taste, mucositis, xerostomia, fatigue, nausea and vomiting,
with consequent worsening of malnutrition [8–12]. It is well known that radiotherapy is invariably
associated with mucositis, xerostomia, dysphagia, hematological toxicities and other acute side effects,
whose incidence increases when chemotherapy is also administered, and that oral mucositis incidence
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leads to higher unplanned breaks and delays in radiotherapy administration [13–16]. In addition, in
many patients such toxicities may be very severe and even life threatening and may lead to treatment
interruptions that are invariably associated with poorer outcome [13–16]. To this regard, it has been
shown that during radiotherapy or CRT 55% of the patients may lose an additional 10% or more of
body weight [11,12]. Deterioration of the nutritional status results in an increase in CRT-related toxicity
and this may increase the prolonged treatment time, which has been associated with poor clinical
outcome [17,18].
In the current clinical practice, nutritional counseling with or without oral nutritional supplements
patients receiving CRT for head and neck cancer is considered adequate [19] but its real role still remains
to be clearly deﬁned with regard to CRT-related toxicity.
If obstructing cancer and/or mucositis interfere with swallowing, enteral nutrition should be
delivered by tube. However, it seems that there is not sufﬁcient evidence to determine the optimal
method of enteral feeding [19].
Prophylactic feeding through nasogastric tube or percutaneous gastrostomy has become relatively
common. It remains to be deﬁned if prophylactic feeding, compared to reactive feeding (patients
are supported with oral nutritional supplements and when it is impossible to maintain nutritional
requirements enteral feeding via a NGT or PEG is started), offers advantages in terms of nutritional
outcomes, interruptions of radiotherapy and survival.
This review aimed to deﬁne the role of nutritional counseling, oral nutritional supplements, enteral
nutrition through nasogastric tube or gastrostomy, and prophylactic gastrostomy in the prevention
and treatment of malnutrition in HNC patients undergoing CRT as well as their impact on CRT-related
toxicity and survival.
2. Methods
The following databases were searched for relevant studies up to October 2014: Medline, PubMed,
Web of Science, and the Cochrane Library. The search terms and mesh headings included “head and
neck neoplasms” OR “head and neck cancer” AND “nutrition” OR “nutrition support” OR “dietary
counselling” OR “nutritional counselling” or “ nutritional supplements” OR “nutrition therapy” OR
“gastrostomy” OR enteral nutrition” OR “enteral feeding” OR “prophylactic gastrostomy” OR “reactive
gastrostomy” OR “prophylactic nutrition” OR “prophylactic nutritional support”. Reference lists of
relevant studies and previous systematic reviews were manually searched for additional articles.
Studies were eligible for inclusion if they were English language papers published in a
peer-reviewed journal and met the following inclusion criteria: primary research studies in adult
patients (over 18 years of age), included patients with head and neck cancer receiving radiotherapy or
radiochemotherapy as the primary treatment, and investigated nutritional interventions in the form
of oral supplements or dietary counseling or both or enteral nutrition through nasogastric tube or
gastrostomy with primary outcomes, including dietary intake, weight, nutritional status, quality of
life, functional status, treatment response, radiotherapy toxicity, or survival. None of the studies with
such characteristics was excluded.
3. Nutritional Counseling and Oral Nutritional Supplements
International guidelines suggest that intensive nutritional counseling (NC) and oral nutritional
supplements (ONS) should be used to increase dietary intake and to prevent therapy-associated weight
loss and interruption of radiation therapy in patients undergoing radiotherapy or chemoradiotherapy
of head and neck areas [20–22].
This evidence is based essentially on a randomized study performed in 60 oncology outpatients
receiving radiotherapy to the gastrointestinal (12%) or head and neck areas (78%). This study
documented statistically smaller deteriorations in weight, nutritional status and global quality
of life when intensive, individualized NC and ONS were used instead of standard nutritional
care [4,5,21]. Indeed, Ravasco et al. [23], two years earlier, randomized 75 HNC patients referred
26
Nutrients 2015, 7, 265–276
for radiotherapy/chemoradiotherapy to dietary counseling with regular foods (Group 1), usual diet
plus supplements (Group 2) and food intake ad libitum (Group 3). At three months, Group 1 maintained
intakes, whereas Groups 2 and 3 returned to or below baseline levels. In addition, at three months, the
reduction of incidence/severity of symptoms (anorexia, nausea/vomiting, xerostomia, and dysgeusia)
improved in 90% of the patients in Group 1 vs. 67% in Group 2 and 51% in Group 3 (p < 0.0001). QOL
function scores improved (p < 0.003) proportionally with improved nutritional intake and status in
Group 1/Group 2 (p < 0.05) and worsened in Group 3 (p < 0.05).
Thereafter, few studies have been conducted on this topic (Table 1). The recent prospective
study of van den Berg et al. [24] has clearly conﬁrmed that early and intensive individualized dietary
counseling by a dietitian produces clinically relevant effects in terms of decreasing weight loss and
malnutrition compared with standard nutritional counseling. All these data are in accordance with
previous studies that have evaluated the effects of nutritional counseling and/or ONS in head and
neck cancer undergoing radiotherapy only [25,26].
Table 1. Nutritional counseling (NC) and oral nutritional supplements (ONS) in head and neck cancer
patients receiving radiotherapy (RT) or chemoradiotherapy (CRT).
Author Number of Patients Cancer Therapy Nutritional Outcome Interruption of RT
Arnold and Richter, 1989 [25]
Group 1: no nutritional
supplements; Group 2:
nutritional supplements
RT No differences between the groups No differencesbetween the groups
Nayel et al., 1992 [26]
Group 1: 12 pts; radiotherapy
alone; Group 2: 11 pts;
radiotherapy and ONS
RT
Group 1: in all increase in body
weight and in triceps skin-fold
thickness, Group 2: 58% had WL (p =
0.001)
Group 1: 41.6%;
Group 2: 0%;
(p < 0.001)
Goncalves Diaz et al., 2005 [27]
Group 1: 32 pts; adapted oral diet;
Group 2: 16 pts; enteral nutrition
via a NG tube (6x/day); Group 3:
16 pts; oral diet associated to ONS
between meals (3×/day).
RT
All of the groups presented an
increase in the ingestion of calories
and proteins (p < 0.001).
Not assessed
Ravasco et al., 2005 [23]
Group 1: 25 pts; NC with regular
foods; Group 2: 25 pts; usual diet
with ONS; Group 3: 25 pts; intake
ad lib.
CRT
Reduction of anorexia,
nausea/vomiting, xerostomia, and
dysgeusia: Group 1: 90% of pts;
Group 2: 67% of pts; Group 3: 51% of
pts
No differences
among the groups
Isenring et al., 2007 [21]
Group 1: 31 pts; standard practice;
Group 2: 29 pts; individualized
NC
CRT
Smaller deteriorations in weight,
nutritional status and global quality
of life in group 2
Not assessed
Paccagnella et al., 2010 [28]
Group 1: 33 pts; early nutritional
intervention before they were
submitted to CRT; Group 2: 33 pts;
CRT alone
CRT Group 1: WL (%) 4.4 ± 4.2; Group 2:WL (%) 8.1 ± 4.8; (p < 0.01)
Group 1: 30.3%;
Group 2: 63.6%;
(p < 0.01)
Van den Berg, 2010 [24]
Group 1: 20 pts; individual
dietary counseling; Group 2: 18
pts; standard dietary counseling
CRT Group 1: WL (%) 2.3 ± 1.2; Group 2:WL (%) 4.8 ± 2.2 Not assessed
Valentini et al., 2012 [29] 21 pts with NC and ONS CRT -
28% for ≥6 days,
28% for 3–5 days
and 44% for
0–2 days
In the current clinical practice, NC with or without ONS in patients receiving CRT for head and
neck cancer are considered useful but its real role still remains to be clearly deﬁned with regard to
CRT-related toxicity. It is possible, in fact, that the improvement of nutritional status obtained through
NC and/or ONS may translate in reduced CRT-related toxicity. Unfortunately, data on this issue are
few. Among the studies, which included patients receiving radiotherapy, CRT-related toxicity was
not assessed in one study and assessed in two (with no differences in one study and with a beneﬁcial
effect of ONS on CRT-related toxicity in the other one). Among the studies which included patients
receiving chemo-radiotherapy, three did not assess CRT-related toxicity, one found no differences in
CRT-related toxicity between patients receiving or not receiving counseling/ONS, and two found
such differences. Paccagnella et al. [28] showed that the frequency of grade 3–4 mucositis was 45.5%
and 39.4% in patients with head and neck cancer undergoing concurrent chemoradiotherapy and
receiving, respectively, early nutritional intervention (individualized nutritional counseling and oral
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supplements or enteral nutrition) or standard practice (general nutrition counseling). However, the
percentage of patients who had radiotherapy breaks >5 days for toxicity was signiﬁcantly lower in
the early intervention group than in the standard practice group as well as the number of days of
radiotherapy delayed for toxicity and the frequency of hospitalization. The study of Valentini et al. [29]
has shown that, in patients with head and neck cancer receiving CRT, nutritional counseling combined
with ONS was associated with relatively low CRT-related toxicity and with a percentage of patients
interrupting anti-neoplastic treatment for 6 or more days lower than 30%.
Taken together, all these data support the concept, suggested by some authors [22,27], that
head and neck cancer patients undergoing CRT need early and regular nutritional assessment
and interventions during treatment and that dieticians need to adapt to the needs of each patient
and provide individualized care. This is particularly true in patients with diabetes, which are not
uncommon in such population.
4. Enteral Nutrition via Nasogastric Tube or Gastrostomy
International guidelines also suggest that if an obstructing head and neck cancer interferes with
swallowing, enteral nutrition (EN) should be delivered by tube [20]. Tube feeding is also suggested if
severe local mucositis is expected, which might interfere with swallowing, e.g., in radio-chemotherapy
regimens, including radiation of throat [20].
Tube feeding can either be delivered via the nasogastric tube (NG) or percutaneous gastrostomy
(PEG). Because of radiation induced oral and esophageal mucositis, PEG may be preferred and it
has been demonstrated clearly that early and appropriate supplementary enteral nutrition via a PEG
system is more effective than oral nutrition alone in those cases in which the patient undergoes several
weeks of chemotherapy/radiotherapy [30]. However, PEG has a rate of complications that is estimated
to be in the range 8%–30%, including local wound infection, occlusion of the tube, leakage from the
tube, cellulitis, eczema or hypergranulation tissue [30].
Unfortunately, only three studies have compared NG and PEG in terms of nutritional outcomes,
complications, and radiation treatment interruption (Table 2). Of these, two studies were retrospective
and one prospective. In the study of Magnè et al. [31], 50 HNC patients were managed by PEG and 40
by NG. The feeding methods were found to be equally effective at maintaining body weight and
body mass index at time 1 (three weeks) and at time 2 (six weeks). In the study of Mekhail et al. [32],
NG tubes were placed in 29 patients and PEG in 62. PEG patients had more dysphagia at three
months (59% vs. 30%, respectively; p = 0.015) and at six months (30% vs. 8%, respectively; p = 0.029)
than NG patients. The median tube duration was 28 weeks for PEG patients compared with eight
weeks for NG patients, (p < 0.001). Twenty-three percent of PEG patients needed pharyngo-esophageal
dilatation compared with 4% of NG patients (p = 0.022). In the prospective study of Corry et al. [33],
there were 32 PEG and 73 NGT patients. PEG patients sustained signiﬁcantly less weight loss at six
weeks post-treatment (median 0.8 kg gain vs. 3.7 kg loss, p < 0.001), but had a high insertion site
infection rate (41%), longer median duration of use (146 vs. 57 days, p < 0.001), and more grade 3
dysphagia in disease-free survivors at six months (25% vs. 8%, p = 0.07). Patient self-assessed general
physical condition and overall quality of life scores were similar in both groups. Overall costs were
signiﬁcantly higher for PEG patients. At six months post-treatment, there was no signiﬁcant difference
between the NGT and PEG groups in complete response at the primary site, weight, dysphagia grade 3
or performance status. Thirty-ﬁve percent of evaluable patients in the NGT group (18/52) had ≥10%
loss of their body weight compared to 13% (3/23) in the PEG group (p = 0.09).
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Table 2. Enteral feeding in head and neck cancer patients receiving chemoradiotherapy (CRT):
comparison of nasogastric tube (NGT) and percutaneous gastrostomy (PEG). WL, weight loss; QOL,
quality of life.
Author Type of Study Number ofPatients
Cancer
Therapy Nutritional Outcome
Interruption
of RT Other Outcomes
Magnè et al., 2001 [31] Retrospective PEG: 50 pts;NGT: 40 pts CRT
Weight and BMI
comparable at week 3
and 6
Not assessed Better QOL with PEG
Mekhail et al., 2001[32] Retrospective PEG: 62 pts;NGT: 29 pts CRT Not assessed Not assessed
Dysphagia more persistent
with PEG at 3 and 6 months; By
12 months, difference
disappeared
Corry et al., 2009 [33] Prospective PEG: 32 pts;NGT: 73 pts CRT
WL (kg) at 6 weeks:
PEG = +0.8 vs. NGT =
−3.7; p < 0.001; WL
(kg) at 6 months: PEG
= +1 vs. NGT = −4.3;
p = 0.04
Not assessed
PEG patients: high insertion
site infection rate (41%), longer
duration of use (146 vs. 57 days,
p < 0.001), more grade 3
dysphagia at 6 months;
higher costs
Interestingly, long-term swallow function after chemoradiotherapy for head and neck cancer
seems to be similar in patients receiving prophylactic gastrostomy and nasogastric tube [34].
Little is known about the number of hospitalizations as well as the costs of the two different
feeding approaches. In the study of Corry et al. [33], the number of days of hospitalization and costs in
the PEG group were signiﬁcantly higher than in the NGT group. However, if it is considered that PEG
is now placed without hospitalization, it is possible that the cost consistently decrease signiﬁcantly.
It seems that there is not sufﬁcient evidence to determine the optimal method of enteral feeding
for patients with head and neck cancer receiving chemoradiotherapy. Further trials comparing the two
methods of enteral feeding and including an appropriate number of patients are required.
5. Prophylactic Nutritional Support
In the last decade, the prophylactic feeding (P-FT) through NGT or PEG, before beginning CRT, to
prevent weight loss, reduce dehydration and hospitalizations, and avoid treatment breaks has become
relatively common. Alternatively, patients are supported with oral nutritional supplements and, when
it is impossible to maintain nutritional requirements, enteral feeding via a NGT or PEG is started
(reactive feeding; R-FT).
Numerous studies have compared these two approaches as detailed in Table 3. Six studies
were retrospective and two prospective, randomized [35–42]. In the majority of these studies, the
nutritional outcome was similar in patients receiving prophylactic and reactive feeding. The number of
interruptions of anti-cancer treatment was not assessed in two studies and did not differ signiﬁcantly
in ﬁve studies. In the study of Lewis et al., patients with P-FT completed a higher proportion of
chemotherapy cycles compared to no-FT (p = 0.002) and RFT (p < 0.001). When assessed, overall and
disease-free survival were similar in the different groups of nutritional treatment. One study has
shown that quality of life at six months was signiﬁcantly higher in the group receiving systematic
prophylactic gastrostomy [43].
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It seems that prophylactic feeding, compared to reactive feeding (patients are supported with
oral nutritional supplements and when it is impossible to maintain nutritional requirements enteral
feeding via a NGT or PEG is started), does not offer signiﬁcant advantages in terms of nutritional
outcomes, interruptions of radiotherapy and survival. However, considering the limited number
of prospective, randomized studies, deﬁnitive conclusions cannot be drawn and it is desirable that
further investigations will be conducted on this issue in the next future.
Interestingly, Baschnagel et al. [44] have recently shown that there was no difference in the PEG
tube dependence rates between PEG placed prophylactically vs. reactively. However, patients who
received a PEG tube reactively had a signiﬁcantly higher stricture rate and aspiration rate compared to
the prophylactic group. In addition, there were signiﬁcantly fewer hospitalizations in the prophylactic
group compared to the reactive group. Overall, when accounting for both PEG placement and
hospitalizations, the prophylactic approach was found to be more cost effective.
In 2013, Hughes et al. [45] retrospectively examined the data of HNC patients, who underwent
CRT for the years before (2005) and after (2007) implementation of internal guidelines, in terms of
number of hospitalization and costs. Only ﬁve patients (6.5% of all patients treated) in the 2005 cohort
received prophylactic gastrostomy tubes compared with 39 patients (44.3%) in the 2007 cohort. Patients
in 2007 had signiﬁcantly fewer hospital admissions, unexpected admissions, and a shorter mean
duration of hospital stay in comparison with those in 2005.
Noteworthy, a recent retrospective study has identiﬁed independent risk factors (BMI >25, a
tumor classiﬁcation ≥3, a cumulative cisplatin dose of 200 mg/m2) associated with symptomatic
requirement for the reactive placement of a PEG tube [46].
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6. Conclusions
Head and neck cancer patients undergoing chemoradiotherapy are at risk of malnutrition before
and during treatment. Nutritional counseling and oral nutritional supplements should be used to
increase dietary intake and to prevent therapy-associated weight loss and interruption of radiation
therapy. If obstructing cancer and/or mucositis interfere with swallowing, enteral nutrition should be
delivered by tube. However, it seems that there is not sufﬁcient evidence to determine the optimal
method of enteral feeding. Prophylactic feeding through nasogastric tube or percutaneous gastrostomy
to prevent weight loss, reduce dehydration and hospitalizations, and avoid treatment breaks has
become relatively common. However, compared to reactive feeding (patients are supported with oral
nutritional supplements and when it is impossible to maintain nutritional requirements enteral feeding
via a NGT or PEG is started), prophylactic feeding does not offer advantages in terms of nutritional
outcomes, interruptions of radiotherapy and survival.
Overall, it seems that further adequate prospective, randomized studies are needed to deﬁne the
better nutritional intervention in head and neck cancer patients undergoing chemoradiotherapy and to
eventually change the current practice, having in mind that the nutritional treatment of these patients
is complex and requires a multidisciplinary approach.
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Abstract: Despite the fact that feeding a very low birth weight (VLBW) neonate is a fundamental and
inevitable part of its management, this is a ﬁeld which is beset with controversies. Optimal nutrition
improves growth and neurological outcomes, and reduces the incidence of sepsis and possibly even
retinopathy of prematurity. There is a great deal of heterogeneity of practice among neonatologists
and pediatricians regarding feeding VLBW infants. A working group on feeding guidelines for VLBW
infants was constituted in McMaster University, Canada. The group listed a number of important
questions that had to be answered with respect to feeding VLBW infants, systematically reviewed the
literature, critically appraised the level of evidence, and generated a comprehensive set of guidelines.
These guidelines form the basis of this state-of-art review. The review touches upon trophic feeding,
nutritional feeding, fortiﬁcation, feeding in special circumstances, assessment of feed tolerance, and
management of gastric residuals, gastro-esophageal reﬂux, and glycerin enemas.
Keywords: feeding; very low birth weight; neonate; review
1. Introduction
Adequate nutrition is essential for the optimal growth and health of very low birth weight
(VLBW) infants. Enteral nutrition is preferred to total parenteral nutrition (TPN) because the former
avoids complications related to vascular catheterization, sepsis, adverse effects of TPN, and fasting.
Early parenteral nutrition in these babies remains critical and should be used as an adjunct to enteral
nutrition. The overarching goal while feeding VLBW infants (VLBWI) is to reach full enteral feeding
in the shortest time, while maintaining optimal growth and nutrition and avoiding the adverse
consequences of rapid advancement of feeding. Attaining this goal is more difﬁcult than it sounds,
and controversies abound.
A multi-disciplinary working group in McMaster University (comprised of staff neonatologists,
fellows, nutritionists, nurse practitioners, nurses, lactation consultants, and occupational therapists)
conducted a structured literature search, critically appraised the evidence, presented it to a wider
group of neonatologists, and came up with practical suggestions to feed VLBWI—the basis for this
review. There are some areas where there is limited evidence, and in these areas we have suggested
reasonable approaches based on expert consensus. Wherever possible, we have stated the level of
evidence (LOE) as per the Centre for Evidence-based Medicine, United Kingdom [1]. The outline of
the LOE for therapy trials is as follows:
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1a Systematic review (with homogeneity) of randomized controlled trials (RCT)
1b Individual RCT with narrow conﬁdence interval (CI)
2a Systematic review (with homogeneity) of cohort studies
2b Individual cohort studies and low-quality RCTs
3a Systematic review (with homogeneity) of case-control studies
3b Individual case-control studies
4 Case series, poor-quality cohort and poor-quality case-control studies
5 Expert opinion without explicit critical appraisal
If a minus sign is sufﬁxed (e.g., 1a− or 1b−), it denotes either a single study with wide CI or a
systematic review with troublesome heterogeneity.
2. Time to Reach Full Feeds
2.1. Suggestion
Aim to reach full enteral feeding (~150–180 mL/kg/day) by about two weeks in babies
weighing <1000 g at birth and by about one week in babies weighing 1000–1500 g by implementing
evidence-based feeding protocols. It may be noted that some babies, especially those less than 1000
grams, will not tolerate larger volumes of feedings (such as 180 mL/kg/day or more) and thus may
need individualization.
2.2. Rationale
Reaching full enteral feeding faster results in earlier removal of vascular catheters, and less sepsis
and other catheter-related complications (LOE 2b) [2–4]. Standardized feeding protocols improve
outcomes in VLBWI [4,5]. Reaching full feeds within a week is achievable—in an RCT on VLBWI, the
median time to reach 170 mL/kg/day was 7 days after fast advancement of enteral feeding, with no
increase in apneas, feed interruptions, and intolerance [6].
3. Frequency of Feeds
3.1. Suggestion
Administer three-hourly feeds for babies weighing >1250 g. There is not enough evidence to
choose between two-hourly versus three-hourly feeds for babies weighing ≤1250 g.
3.2. Rationale
In an RCT, 92 neonates weighing <1750 g were allocated to either three- or two-hourly feeds [7].
The incidence of feed intolerance, apnea, hypoglycemia, and necrotizing enterocolitis (NEC) did not
signiﬁcantly differ, and nursing time spent on feeding was signiﬁcantly less in the three-hourly group
(LOE 2b).
Two retrospective studies on this issue were contradictory. In one that compared 2-h and 3-h
enteral feeding in ELBW babies, the time to full enteral feeding, enteral morbidity, hospital stay, and
growth parameters were similar in the two groups (LOE 4) [8]. In another, VLBWI (mean birth weight
~1200 g) fed twice hourly reached full feeds faster, received less prolonged TPN, and were less likely to
have feeds held, compared to those fed three times hourly (LOE 4) [9]. Putting this limited information
together, we propose that babies weighing ≥1250 g be fed three times hourly and those weighing
<1250 g preferably twice hourly.
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4. Trophic Feeds: Time of Starting, Volume, Duration
4.1. Suggestion
Trophic feeds are deﬁned as minimal volumes of milk feeds (10–15 mL/kg/day). Start trophic
feeds preferably within 24 h of life. Exercise caution in extremely preterm, extremely low birth weight
(ELBW), or growth-restricted infants. If, by 24–48 h, no maternal or donor milk is available, consider
formula milk. There is not enough evidence to recommend the maximum duration of trophic feeding
before starting nutritional feeds.
4.2. Rationale
In a systematic review (nine trials, 754 VLBWI), the actual volume of trophic feeds ranged
from 10 to 25 mL/kg/day; and onset from day one of life onwards [10]. Early introduction of
trophic feeds compared to fasting had a non-signiﬁcant trend towards reaching full feeds earlier (mean
difference− 1.05 days (95% CI−2.61, 0.51)) and no difference in NEC (LOE 1a−). More data is required
before one can generalize these ﬁndings to extremely preterm, ELBW, or growth-restricted infants.
There was no subgroup analysis on formula milk. Among the included studies, there were two
studies in which trophic feeding was provided exclusively by preterm formula (LOE 1b−) [11,12].
In both, the trophic feeding group had less feeding intolerance and reached full feeds faster without
increase in NEC. Hence, formula milk may be used after exhausting other options. We suggest a
reasonable waiting period of 24–48 h for obtaining maternal or donor milk.
In a systematic review (seven trials, 964 VLBWI) on timing of introduction of nutritional enteral
feeding to prevent NEC, early introduction of progressive enteral feeding (1 to 2 days of age) did not
increase the risk of NEC (typical relative risk (RR) 0.92 (95% CI 0.64, 1.34)), mortality (typical RR 1.26
(95% CI 0.78, 2.01)), or feed intolerance (LOE 1a) [13]. We converted this into a practical suggestion of
the maximum number of days for trophic feeding before introducing progressive enteral feeding.
5. Contraindications for Trophic Feeds
5.1. Suggestion
Withhold trophic feeds in intestinal obstruction or a setting for intestinal obstruction or ileus.
Asphyxia, respiratory distress, sepsis, hypotension, glucose disturbances, ventilation, and
umbilical lines are not contraindications for trophic feeds.
5.2. Rationale
The studies included in a Cochrane review included VLBWI with asphyxia, respiratory distress,
sepsis, hypotension, glucose disturbances, ventilation, and umbilical lines, without any excess adverse
effects being reported (LOE 1a−) [10].
6. Nutritional Feeds: Day of Starting, Volume, Frequency, Increase
6.1. Suggestion
In babies weighing <1 kg at birth, start nutritional feeds at 15–20 mL/kg/day and increase
by 15–20 mL/kg/day. If the feeds are tolerated for around 2–3 days, consider increasing faster.
For babies weighing ≥1 kg at birth, start nutritional feeds at 30 mL/kg/day and increase
by 30 mL/kg/day.
6.2. Rationale
A Cochrane review (four RCTs, 588 subjects) compared slow daily increments
(ranging from 15 to 20 mL/kg/day) versus fast daily increments of enteral feeding volume
(ranging from 30 to 35 mL/kg/day) (LOE 1a) [14]. Fast increment did not increase the risk of NEC
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(pooled RR 0.97 (95% CI 0.54, 1.74)), mortality (pooled RR 1.41 (95% CI 0.81, 2.74)), or interruption of
feeds (pooled RR 1.29 (95% CI 0.90, 1.85)). The trials individually reported that the fast daily increment
group regained birth weight and reached full feeds faster (LOE 1b and 2b). As there was no subgroup
analysis of ELBW babies, we suggest starting with a lower feed volume in ELBW babies—as in the
control arm (15–20 mL/kg/day)—until more studies are available.
7. Type of Milk for Starting Feeds
7.1. Suggestion
The ﬁrst choice is own mother’s expressed breast milk or colostrum. This should preferably be
fresh; if not, provide previously frozen milk in the same sequence in which it was expressed.
Second choice: donor human milk.
Third choice: preterm formula.
7.2. Rationale
Freshly expressed human milk has numerous beneﬁts for preterm babies [15]. Although there is
no direct evidence comparing fresh versus frozen mother’s milk, the use of fresh milk makes sense
because of the depletion of commensals, immune cells, immune factors, and enzyme activity that
occurs with freezing. Neonates who receive an exclusively human milk-based diet (mother’s milk or
donor human milk with human milk-based fortiﬁer) have signiﬁcantly lower rates of NEC compared
to those who receive preterm formula or human milk with a bovine milk-based fortiﬁer (LOE 1b) [16].
In another RCT, preterm infants who received an exclusively human milk diet (donor human milk and
human milk-based human milk fortiﬁer) had a lower incidence of NEC (21% versus 3%, p = 0.08) and
surgical NEC (p = 0.04) compared to infants who received bovine milk-based preterm formula [17].
The use of donor human milk (while continuing bovine milk-based fortiﬁer) versus preterm formula as
a substitute for mother’s own milk does not reduce the rates of NEC [18]. The prohibitively high cost of
human milk-based human milk fortiﬁer is often quoted as an obstacle to using an exclusively human
milk diet; however, a cost-effectiveness analysis showed that use of exclusively human milk-based
products resulted in shorter duration of hospitalization (less by an average of 3.9 days in neonatal
intensive care unit (NICU)) and savings of $8167 per extremely premature infant (p < 0.0001) because
of the reduction in NEC [19].
8. Feeding Small for Gestational Age (SGA) Babies with/without History of Absent/Reversed
End Diastolic Umbilical Flow (AREDF)
8.1. Suggestion
If the abdominal examination is normal, start feeding within 24 h of life, but advance slowly with
volumes at the lowest end of the range. Advance feeds extremely slowly in the ﬁrst 10 days among
preterm SGA babies with gestation <29 weeks and AREDF. Make every effort to feed human milk,
especially in SGA babies with AREDF and gestation <29 weeks.
8.2. Rationale
Mihatsch et al. [20] fed 124 VLBWI (35 had intra-uterine growth retardation (IUGR)) with a
standardized protocol (LOE 2b). There was no statistical difference in the age to reach full feeds in
the IUGR and non-IUGR groups (p = 0.6). In a multiple regression model, increased umbilical artery
resistance, brain sparing, Apgar scores, umbilical artery pH, and IUGR did not predict the age to reach
full feeds. In an RCT on SGA preterm babies (gestation of 27–34 weeks) who had abnormal antenatal
umbilical Doppler ﬂows, the incidence of NEC and feeding intolerance was not signiﬁcantly different
(p = 0.35 and p = 0.53, respectively) between the early feeders (n = 42; median age 2 days) and delayed
feeders (n = 42; 7 days) (LOE 2b) [21].
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In an RCT on preterm SGA infants, comparing minimal enteral feeding and no enteral feeding for
ﬁve days, there was no difference in the rate of NEC (p = 0.76) and there was a trend towards shorter
NICU stay in the enteral feeding group (p = 0.2) (LOE 2b) [22].
In the Abnormal Doppler Enteral Prescription Trial (ADEPT) RCT, 402 preterm SGA
infants (<35 weeks gestation, birth weight < 10th centile) with absent or reversed end diastolic
umbilical blood ﬂow and cerebral redistribution were allocated to early or late onset of enteral feeding
(Day 2 or 6, respectively) (LOE 1b) [23].The early feeding group reached full enteral feeds faster
than the late feeding group (median (IQR) days: 18 (15–24) versus 21 (19–27), respectively; p = 0.003).
There was no difference in the incidence of all-stage NEC (18% versus 15%, respectively; p = 0.42)
and stage II–III NEC. Infants in the early feeding group had a signiﬁcantly shorter duration of total
parenteral nutrition (median difference 3 days, p < 0.001), a shorter duration of high dependency care
(p = 0.002), and a lower incidence of cholestasis (p = 0.02). Eighty-six (21%) infants in this trial were
below 29 weeks of gestation. The statistical test of interaction between treatment group and gestational
age group (<29 weeks versus ≥29 weeks) was non-signiﬁcant for age to reach full feeds (p = 0.38)
and incidence of all stage NEC (p = 0.47), suggesting that the treatment effect was consistent across
subgroups. The investigators published additional analysis from the ADEPT trial comparing infants
of <29 weeks and ≥29 weeks of gestation [24]. The former group took signiﬁcantly longer to reach
full feeds compared to the latter (median age 28 days (Inter-quartile range (IQR) 22–40) versus 19 days
(IQR 17–23), respectively; hazard ratio 0.35 (95% CI 0.3, 0.5)) and had a signiﬁcantly higher incidence
of NEC (39% versus 10%, respectively; RR 3.7 (95% CI 2.4, 5.7)). Infants <29 weeks in this trial tolerated
very little milk in the ﬁrst 10 days. Exclusive human milk feeding was the only protective factor.
9. Feeding Babies on Non-Invasive Ventilation
9.1. Suggestion
Increase feeds cautiously. Do not rely on abdominal distension as a sign of feeding intolerance,
especially in babies weighing <1000 g.
9.2. Rationale
Non-invasive ventilation can cause abdominal distension, and nasal continuous positive airway
pressure (nCPAP) decreases pre-and post-prandial intestinal blood ﬂow in preterm infants (LOE 4) [25].
Jaile et al. [26] compared 25 premature infants on nCPAP with 29 premature infants not on CPAP
(LOE 2b). Gaseous bowel distension due to CPAP developed in 83% of infants below 1000 g versus 14%
of those weighing ≥1000 g. No cases of NEC were reported in the study; however, the sample size
was too small to draw conclusions about NEC.
10. Feeding Babies with Systemic Arterial Hypotension
10.1. Suggestion
There is not enough evidence to make a suggestion.
10.2. Rationale
There is no published literature on feeding policies during systemic arterial hypotension.
11. Feeding Babies on Indomethacin or Ibuprofen
11.1. Suggestion
If the neonate is already on minimal feeds, continue to give trophic feeds until the indomethacin
course ﬁnishes. If the neonate is fasting, introduce trophic feeds with human milk as per Section 3.
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While there are no RCTs comparing feeding during indomethacin therapy versus ibuprofen,
indirect evidence suggests ibuprofen may be the safer of the two.
11.2. Rationale
In the Ductus Arteriosus Feed or Fast with Indomethacin or Ibuprofen (DAFFII) trial, 117
infants (26.3 ± 1.9 weeks) who were on ≤60 mL/kg/day feeds and required treatment for patent
ductus arteriosus (PDA) (75% to 80% received indomethacin) were randomized at 6.5 ± 3.9 days to
receive trophic feeds or no feeds during the drug administration period [27]. Infants randomized to the
trophic feeding subsequently required fewer days to reach 120 mL/kg/day (10.3 ± 6.6 days vs. 13.1 ±
7.8 days, p < 0.05). There is one retrospective study on 64 preterm infants (<29 weeks of gestation), half
of whom had received indomethacin for PDA (LOE 4) [28]. There were no differences between the
groups regarding feeding volumes, NEC incidence, or gastric residuals up to Day 7.
Ibuprofen is safer than indomethacin as it does not reduce mesenteric blood ﬂow [29]. In a
meta-analysis of 19 studies (956 infants), NEC rates were lower in the Ibuprofen group (typical RR 0.68
(95% CI 0.47, 0.99)) (LOE 1a) [30].
12. Assessment of Feed Tolerance
12.1. Suggestion
Do not check gastric residuals routinely. Check pre-feed gastric residual volume (GRV) only after
a minimum feed volume (per feed) is attained. We suggest the following thresholds: <500 g: 2 mL,
500–749 g: 3 mL, 750–1000 g: 4 mL, >1000 g: 5 mL.
Do not check abdominal girth routinely.
Isolated green or yellow residuals are unimportant. Vomiting bile may indicate an intestinal
obstruction or ileus. Withhold feeds in case of hemorrhagic residuals, as hemorrhagic residuals
are signiﬁcant.
12.2. Rationale
GRV is not as important a predictor of NEC as earlier thought. Below a certain feed volume, there
is no point in checking the GRV. Among preterm babies on TPN, the mean + 2 SD value for GRV is
about 4 mL (LOE 4) [31]. Mihatsch et al. [32] tolerated GRV up to 2 mL in infants <750 g and up to 3 mL
in infants >750 g to 999 g. In a multiple regression model, the mean GRV and green residuals had no
relationship with enteral feeding volume achieved by Day 14 (LOE 2b). In recent studies, ≤5 mL/kg
has been used as a criterion for permissible GRV, but there are no comparisons between different cutoff
values [33]. In a prospective study on 50 preterm infants, there was no correlation between feeding
outcomes and GRV (mL/day) (LOE 2b) [34]. In a pilot RCT, 61 infants (24–32 weeks of gestation) were
randomly allocated to receive routine evaluation of gastric residuals versus no routine evaluation [35].
There was no difference between the groups regarding volume of feeds at 3 weeks of age, growth, and
days on TPN. Infants without routine evaluation of gastric residuals reached full feeds six days earlier.
In a case-control study on VLBWI with (n = 17) and without (n = 17) NEC, the mean maximum
GRV as a percentage of the previous feed was 113% among subjects with NEC and 43% in controls
(LOE 4) [36]. Hemorrhagic residuals, but not green residuals, were associated with NEC.
A study that suggested a relationship between modest GRV and NEC was a case-control study
on 51 VLBWI with proven NEC and 102 healthy controls (LOE 4) [37]. The study was criticized for its
choice of controls. There was a difference in the maximum GRV as a percentage of the corresponding
feed volume between the NEC group and the controls (median (IQR): 40 (24, 61) vs. 14 (4, 33), p < 0.001),
but with a large overlap between groups.
Although most studies have downplayed the importance of GRV, two retrospective studies,
mentioned above, suggest there could be a relationship with NEC.
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Green residuals could be due to duodenogastric reﬂux or overzealous aspiration, which could
suck back duodenal contents (LOE 5) [38,39]. Studies have not found an association between green
residuals and NEC (LOE 2b and 4) [32,36].
Abdominal girth is not a reliable measure of feed tolerance. There is a paucity of studies evaluating
an increase in girth with clinical outcomes. It is highly prone to intra- and inter-observer variation.
Abdominal circumference may vary by 3.5 cm during one feeding cycle in normal premature infants
(LOE 4) [40]. It correlates with time from last defecation (p = 0.0001). Among term infants, the mean
inter-observer difference is up to 1 cm [41].
13. Management of Residuals
13.1. Suggestion
Push back GRV of up to 5 mL/kg or 50% (whichever is higher) of the previous feed volume. If it
recurs, subtract the residual volume from the current feed.
If the GRV is >5 mL/kg and >50% of the previous feed volume, push back the GRV up to 50% of
the feed volume and do not give the current feed. If this happens again, consider slow bolus feeds or
withholding feeds, depending on the clinical condition.
If the problem of residual volumes persists despite slow bolus feeds, consider decreasing the feed
volume to the last well-tolerated feed volume.
Use the smallest volume syringe for checking residuals. Take care to aspirate gently.
After a feed, nurse the baby in the prone position for half an hour.
13.2. Rationale
The rationale for 5 mL/kg is covered in Section 11. The criterion of 50% is a round ﬁgure
approximately equal to the cutoff from the study by Cobb et al. [37]. Pushing back partially digested
gastric aspirates may replenish acid and enzymes that aid in the digestive process [42].
There is a paucity of data regarding the role of slow bolus feeding. In a physiologic study on
pre-terms comparing a 120-min infusion of feeds compared to bolus feeds, the former was associated
with faster gastric emptying, lower GRV, and more frequent duodenal motor responses (LOE 2b) [43].
Whether these theoretical advantages of slow bolus translate into clinical beneﬁts is unclear, but there
is a physiological basis for trying. In a Cochrane meta-analysis comparing continuous nasogastric
versus intermittent bolus feeding in VLBWI, the continuous method resulted in a longer time to reach
full enteral feeding (weighted mean difference (WMD) 3 days (95% CI 0.7, 5.2)), with no difference in
growth or incidence of NEC (LOE 1a−) [44].
The narrower the diameter of the syringe, the less pressure is applied while pulling (as opposed
to pushing) (LOE 4) [45]. Hence, smaller volume syringes are preferred.
In an RCT, the decrease in the volume of gastric residuals was lower in the prone position than in
supine, and the rate of decrease of gastric residual volume was highest in the ﬁrst half hour after the
feed [46].
14. Clinical Diagnosis of Gastro-Esophageal Reﬂux (GER)
14.1. Suggestion
Do not rely on apnea, desaturation, or bradycardia; or behavioral signs, such as gagging, coughing,
arching, and irritability, as signs of GER in preterm babies.
14.2. Rationale
The relationship between GER and cardio-respiratory events is controversial. Early studies either
used a pH probe, which is unable to detect non-acid reﬂux; or used only the multi-channel intraluminal
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impedance (MII) probe, which underestimates acid GER events. The modality of choice is combined
MII-pH monitoring.
In MII-pH studies on 71 preterm infants (mean birth weight 1319 g) there were 12,957
cardiorespiratory events and 4164 GER episodes, but GER preceded less than 3% of all cardiorespiratory
events (LOE 2b) [47].
In another MII study on 19 preterm infants, the frequency of apneas occurring within 20 s of
reﬂux episodes was not signiﬁcantly different from that during reﬂux-free periods (LOE 2b) [48].
In a 24-h pH-MII study on 21 healthy premature infants, only 25% of reﬂux events were acidic [49].
Episodes that reached the proximal esophagus were also unassociated with cardio-respiratory events.
Contrary to the above, a group from Italy has published two reports using pH-MII monitoring
that support the relationship between GER and apnea ≥5 s (LOE 2b) [50,51]. The frequency of apnea in
the 30 s after GER was greater than in the 30 s before GER (p = 0.01). Apnea was shown to be associated
with non-acid MII-GER episodes (p = 0.000), but not with acid GER episodes (p = 0.137).
We conclude that GER is probably not associated with cardio-respiratory events. At worst, it may
cause brief episodes of apnea, and these are primarily from non-acidic episodes.
Snel et al. [52] studied 14 preterm infants (gestation of 26–35 weeks) who underwent continuous
esophageal pH monitoring and videography (LOE 4). For each episode of acid GER, a 10-min video
recording was analyzed and compared with a 10-min clipping when the esophageal pH exceeded 4.
The recordings were randomized and viewed independently by two masked observers. There was no
relationship between behavioral cues and reﬂux. The association of behavioral patterns with GER has
only been reported in a study on eight term babies [53].
There is no difference in behavioral symptom scores after treatment with cisapride or omeprazole,
emphasizing that they are possibly not because of GER (LOE 2b) [54,55].
15. Body Position for Treatment of GER
15.1. Suggestion
Place the baby in the left lateral position after a feed and turn over to the prone position about
half an hour later. Elevate the head end to 30◦. Place the infant supine for sleeping at home.
15.2. Rationale
Among 22 preterm infants with regurgitation who underwent 24-h recording of pH-MII in four
body positions, the left lateral position showed the lowest esophageal acid exposure in the early
post-prandial period and the prone position in the late post-prandial period (LOE 2b) [56].
Preterm infants are not an exception to the supine sleep recommendation for home care, because
of the increased risk of sudden infant death syndrome (SIDS) among preterm infants [57,58].
16. Medications for Treatment of GER
16.1. Suggestion
Do not use domperidone, H2-blockers, or proton-pump inhibitors for the treatment of GER.
16.2. Rationale
In the only study evaluating domperidone, 13 infants with suspected GER treated with
domperidone were compared to 13 untreated controls with suspected GER (LOE 2b) [59]. On 24-h
pH-MII monitoring, the frequency of GER episodes was higher in the domperidone group (p = 0.001).
A crossover trial on 18 infants comparing metoclopramide with a placebo had similar ﬁndings [60].
Domperidone is associated with prolongation of QTc interval in neonates above 32 weeks of
gestation [61]. QTc prolongation has not been demonstrated in more premature infants (n = 40);
however, we need additional data to declare domperidone as safe [62].
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Ranitidine is associated with a higher incidence of late onset sepsis (LOE 4) [63] and NEC in
preterm neonates (LOE 3b) [64]. In a study on VLBWI comparing n = 91 who had received ranitidine
with n = 183 who had not, the odds of developing sepsis in the ranitidine group was 5.5-fold higher
and of NEC 6.6-fold higher (LOE 2b) [65]. Mortality was also higher in neonates receiving ranitidine
(p = 0.003).
In a double-blind placebo-controlled crossover study in preterm neonates, omeprazole reduced
intra-gastric acidity but not the frequency of reﬂux symptoms (L4E 2b) [66]. In another double-blind
RCT on 52 premature neonates with suspected GER, there were no differences between the
esomeprazole and placebo groups with respect to percentage change from baseline in total number of
signs and symptoms related to GER and number of reﬂux episodes [67].
The association of GER and cardio-respiratory events is itself questionable. The only study that
shows an association concluded that it is with the non-acid reﬂux [51]. Observational data suggests
that gastric acid suppression is associated with serious adverse events. Hence, there is little justiﬁcation
for pharmacological gastric acid suppression in the treatment of GER.
17. Thickening Feeds for GER
17.1. Suggestion
Avoid thickeners in the treatment of presumed GER.
17.2. Rationale
There are no RCTs evaluating the thickening of feeds in an exclusively neonatal population [68].
One non-randomized trial compared smectite in neonates with GER measured by 24-h pH monitoring
(LOE 4) [69]. The use of open-label thickeners contaminated the groups. Postural therapy combined
with smectite was followed by a decrease in GER (p < 0.05). In another non-randomized trial on 24
infants, a formula thickened with amylopectin did not decrease the incidence of GER-related apneas or
apnea of prematurity [70]. There is no evidence to support the use of rice cereal or thickened formulae.
The safety of thickeners in preterm neonates is questionable. Xanthan gum-based, carob bean
gum-based, and pectin-based thickeners have all been reported to cause NEC (LOE 4) [71–73].
18. Feed Duration and Route of Feeding for Treatment of GER
18.1. Suggestion
If one strongly suspects GER, and re-positioning does not help, one may increase the feed duration
to 30–90 min. Make all attempts to reduce the duration back to a shorter duration as soon as possible.
Use continuous or trans-pyloric feeding as a last resort for the management of GER and avoid them
as far as possible. There is still insufﬁcient evidence to recommend the use of erythromycin for the
prevention or treatment of feed intolerance.
18.2. Rationale
The association of cardio-respiratory events with GER is itself questionable. Hence, the evaluation
of any intervention to “treat” GER is fraught with problems. Altering feed duration and body position
is probably less harmful than medications for GER.
The physiological beneﬁts of slow gavage feeds have been described earlier (Section 12) [43].
However, in a cross-over RCT on 30 preterm infants who received 21 ± 1.5 mL/kg of milk per feed
using bolus gavage feeding over 10 min or slow gavage feeding over 1 h, there was no difference in
terms of frequency of apneas (>4 s), bradycardias, and desaturations (LOE 2b) [74]. The Cochrane
meta-analysis comparing continuous nasogastric milk feeding versus intermittent bolus feeding in
VLBWI has been described earlier (Section 12) [44].
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In view of the above information, there may be limited justiﬁcation for trying out slow enteral
feeding but no justiﬁcation for prolonged slow gavage feeds or continuous feeds.
A Cochrane review on nine RCTs of transpyloric versus gastric feeding in preterm infants
concluded that transpyloric feeding did not improve feed tolerance or growth and had an increased
risk for cessation of feeds and mortality (LOE 1a) [75]. Moreover, this review is not directly applicable
because the trials were on transpyloric enteral feeding as an initial feeding strategy, rather than as
treatment for GER.
In a retrospective study on 72 VLBWI with apnea/bradycardia due to presumed GER, the authors
observed a reduction in the average number of apnea/bradycardia episodes with transpyloric feeding
(p = 0.02) (LOE 4) [76].
A Cochrane review on erythromycin (three prevention and seven treatment RCTs until 2007)
included studies that varied in deﬁnition of feed intolerance and in the measurement, analysis,
and reporting of outcomes [77]. Therefore, meta-analysis could not be done. Subsequently, in a
placebo-controlled RCT on high-dose oral erythromycin (50 mg/kg/day), there was no signiﬁcant
difference reported in the time to reach full feeds [78]. Another RCT on the efﬁcacy of intermediate-dose
erythromycin in 45 VLBW infants >14 days of age with feed intolerance reported a signiﬁcantly lower
number of days to achieve full feeds (36.5 ± 7.4 days versus 54.7 ± 23.3 days; p = 0.01) and a lower
number of days on TPN in the erythromycin group [79].
19. Prevention of Nutrient Loss during Slow Gavage or Continuous Feeds
19.1. Suggestion
Use the shortest possible extension tubing from the syringe to the baby to prevent nutrient loss.
Do not draw up extra milk—other than that used for priming—into the syringe. If slow bolus feeds
have to be used, keep the duration to a minimum.
19.2. Rationale
In an experimental study, continuous feeding resulted in (mean) 40% loss of fat, 33% of calcium,
and 20% of phosphorus (LOE 2b) [80]. Infusion via gravity resulted in 6%, 9%, and 7% losses,
respectively. Infusion by pump over 30 min resulted in intermediate losses. Fat adheres to the inner
wall of the tubing, resulting in losses.
20. Human Milk Fortiﬁcation
20.1. Suggestion
Start fortiﬁcation when enteral intake reaches 100 mL/kg/day. Start at a concentration of 1:50
and if this is tolerated for 48 h increase to 1:25.
20.2. Rationale
Most authors have started human milk fortiﬁcation at 100 mL/kg/day and at a concentration
of 1:50 (LOE 5) [81–83]. In the only RCT that compared starting fortiﬁcation with a human milk-based
fortiﬁer at 100 mL/kg/day versus starting at 40 mL/kg/day, there was no difference in outcomes
(LOE 1b) [16]. However, it is unclear whether this can be extrapolated to a bovine milk-based fortiﬁer.
In a retrospective study on infants <31 weeks of gestation, the authors compared 53 infants who
received HMF from the ﬁrst feed with n = 42 who received it after reaching a feed volume of 50–100
mL/kg/day [84]. There were no differences in weight gain, but the early fortiﬁcation group had
a lower incidence of elevated alkaline phosphatase levels. Thus, more RCTs are required before
recommending fortiﬁcation at less than 100 mL/kg/day or an initial concentration less than 1:50.
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21. Glycerin Enemas to Promote Feed Tolerance
21.1. Suggestion
Do not use daily glycerin suppositories to reduce the time to full enteral feeding. If one uses a
trial of glycerin tips on a case-by-case basis, one should take into account the normal stooling pattern
in preterm infants and volume of milk ingested to decide on the need for a glycerin tip.
21.2. Rationale
There is a relationship between gestation and the time of passage of the ﬁrst stool: the lower the
gestation, the longer the time taken [85].
In a study on 41 ELBW infants, there was an inverse correlation between feed volume on Day 14
and the last day of passing meconium but there was no correlation with the ﬁrst day of passing
(LOE 2b) [86]. In an observational study involving historical controls, VLBWI undergoing meconium
evacuation by routine glycerin enema starting from Day 1 of life achieved full enteral feeding faster
than controls (hazard ratio 2.9; 95% CI 1.8, 4.8) (LOE 2b) [87]. A subsequent RCT showed that daily
glycerin suppositories did not reduce the time to full enteral feeding in infants born at less than 32
weeks of gestation (LOE 1b) [88]. Glycerin enemas may also cause rectal tears.
22. Conclusions
We suggest that physicians taking care of VLBW infants should aim to reach full feeds
by about 2 weeks of age in neonates weighing <1000 g at birth and by about one week in
neonates weighing 1000–1500 g at birth. A 3-hourly feeding regimen can be introduced for infants
weighing >1250 g. Trophic feeds (10–15 mL/kg/day) should be started preferably within 24 h of
life, but caution should be exercised in extremely preterm, ELBW or growth restricted infants. For
babies weighing ≥1 kg at birth, we suggest starting nutritional feeds at 30 mL/kg/day and increase
by 30 mL/kg/day. The ﬁrst choice of milk is mother’s own fresh milk. Among SGA infants with
AREDF and a normal abdominal examination, feeding can be started within 24 h of life, and advanced
cautiously. Feeds should be advanced cautiously in VLBW infants on non-invasive ventilation. If
the neonate is already on minimal feeds, trophic feeds should be continued until the indomethacin
course ﬁnishes. We advise against checking gastric residuals routinely. Abdominal girth should
not be checked routinely. Isolated green or yellow residuals are unimportant. We suggest that GRV
of 5 mL/kg or 50% (whichever is higher) of the previous feed volume should be pushed back and the
amount subtracted from the current feed. One should not rely on apnea, desaturation or bradicardia;
or behavioural signs as markers of GER in preterm babies. Body positioning in the left lateral or prone
position may help with GER but medications and thickeners are not recommended. Slow gavage
feeding may be attempted in GER after taking care to prevent nutrient losses. Human milk may be
fortiﬁed after enteral intake of 100 mL/kg/day is reached. Glycerin enemas should not be used with
the intention of reducing the time to full enteral feeding.
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Abstract: Premature and high-risk infants require accurate delivery of nutrients to promote
appropriate growth. Continuous enteral feeding methods may result in signiﬁcant fat and
micronutrient loss. This study evaluated fat loss in enteral nutrition using current strategies for
providing high-risk infants fortiﬁed human milk (HM). The fat content of HM was measured by IR
analyzer in a simulated feeding system using the Kangaroo ePump™ and the MedFusion™ 2010
pump. Comparisons in fat loss were made between HM, HM supplemented with donor HM-derived
fortiﬁer Prolacta + H2MF™ (H2MF), and HM supplemented with H2MF and donor HM-derived
cream ProlactCR™ (cream). When using the Kangaroo ePump™, the addition of H2MF and cream to
HM increased fat delivery efﬁciency from 75.0% ± 1.2% to 83.7% ± 1.0% (p < 0.0001). When using
the MedFusion™ 2010 pump, the addition of H2MF to HM increased fat delivery efﬁciency from
83.2% ± 2.8% to 88.8% ± 0.8% (p < 0.05), and the addition of H2MF and cream increased fat delivery
efﬁciency to 92.0% ± 0.3% (p < 0.01). The addition of H2MF and cream to HM provides both the
beneﬁts of bioactive elements from mother’s milk and increased fat delivery, making the addition of
H2MF and cream an appropriate method to improve infant weight gain.
Keywords: enteral nutrition; breast milk; human milk-derived fortiﬁer; human milk-derived cream
supplement; very low birth weight; neonates; Kangaroo ePump™; MedFusion™ pump; neonatal
intensive care units
1. Introduction
Very low birth weight (VLBW) and other high-risk infants require accurate delivery of nutrients in
order to optimally grow during their hospital stay. The current feeding methods include syringe, bolus,
and pump feeding. Human milk (HM) provides a wide range of beneﬁts due to bioactive elements [1].
However, as previously shown [2–6], substantial amounts of fat and nutrients are lost throughout
the delivery of HM by continuous syringe and pump feeding methods, due to fat adherence to the
feeding bag, syringe and tubing. This fat adherence has been visually observed in previous studies [5].
Furthermore, limited assessment of the nutrients that reach the infant has been performed [7]. While
minimal fat and nutrients from HM are lost through bolus feeding, many VLBW infants cannot tolerate
the high ﬂow rates required for bolus feeding.
The Kangaroo ePump™ and MedFusion™ syringe pumps are prevalent in many neonatal
intensive care units (NICUs), although a substantial amount of phosphorus, calcium, and other
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nutrients that bind to fat are lost in these delivery processes when used for continuous feedings [5].
When mother’s milk contains inadequate fat levels, many NICUs either replace HM with formula,
which is not affected by fat adherence to tubing but does not contain bioactive elements found in
HM, or add fortiﬁers such as HM-derived fortiﬁer Prolacta + H2MF™ (H2MF) with or without donor
HM-derived cream ProlactCR™ (cream) to HM to increase the fat content. ProlactCR™ cream is a
pasteurized donor HM-derived fat from HM which yields 2.5 calories·mL−1 and is intended as a
supplement for mother’s own milk or donor HM in order to provide the infant with an exclusively
HM-based diet. Evidence shows that an exclusively HM-based diet is associated with signiﬁcantly
lower rates of necrotizing enterocolitis (NEC) and surgical NEC when compared with preterm
formula and with a mother’s milk-based diet supplemented with bovine milk–based products [8,9].
Furthermore, an exclusiveHM-based diet is associatedwith lowermortality andmorbidity in extremely
preterm infants [10].
In order to improve the growth rate of premature and other high-risk infants, evaluations must
be conducted to determine fat and nutrient losses due to different feeding methods and how it may
be feasible to minimize these losses. The objective of this study was to evaluate fat loss in enteral
nutrition using current strategies for delivering fortiﬁed HM to high-risk infants. We explore the use
of HM-derived fortiﬁer and cream to improve fat delivery efﬁciency, making it possible to deliver the
bioactive elements of HM while increasing fat delivery to infants.
2. Experimental Section
2.1. Human Milk Sample Preparation
All HM used in this study was obtained through the mother’s milk bank of Texas Children’s
Hospital in Houston, Texas and was designated for research purposes. HM from ﬁve anonymous
mothers was pooled into a 4 L container, separated into aliquots in 50 mL VWR™ conical tubes, and
stored in a freezer at −20◦C. Before testing, HM was thawed with warm water and agitated using a
common lab vortexer at 500 rpm to ensure homogeneity of the HM. No HM was used that had been
thawed for over 24 h, which is the limit used by lactation services in the Texas Children’s Hospital
NICU for feeding infants.
HM with H2MF was prepared by mixing 20 mL of H2MF with 80 mL of HM, resulting in a 1:4
ratio of H2MF to HM. HM with H2MF and cream was prepared by combining 8 mL of cream with 20
mL of H2MF and 80 mL of HM, resulting in a 2:5:20 ratio of cream to H2MF to HM. These ratios follow
clinical guidelines for HM containing 15–15.9 kcal·oz−1 [11]. Although the average energy content
of HM is approximately 20 kcal·oz−1, there is great variability, and in the United States, values have
been reported ranging from 13.8 kcal·oz−1 to 25.1 kcal·oz−1 with 51% of HM having less than 19.2
kcal·oz−1 [12]. Fortiﬁcation is recommended for HM containing less than 20 kcal·oz−1 [11]. Thus,
adding fortiﬁer and cream in the ratio for HM containing 15–15.9 kcal·oz−1 presumes the HM has a
mid-range energy content of HM requiring fortiﬁcation.
2.2. Experimental Setup/Feeding Simulations
All experiments in this study were conducted using a simulated continuous enteral feeding
system, representing a typical NICU enteral feeding setup with variations between simulating feedings
only in pump type and milk given. Variations of HM tested were HM, HM + H2MF, and HM + H2MF
+ cream. All simulated feedings used either the MedFusion 2010™ or the Kangaroo ePump™.
Before starting simulated feeds, 5 mL aliquots of HM were collected in 15 mL VWR™ tubes and
processed for analysis of fat content directly thereafter, representing a “pre-feeding” aliquot.
The Kangaroo ePump™ was set up as it would be in typical NICU procedures. The bag (1000 mL
Kangaroo ePump™ enteral pump set) was set 18 inches directly above the pump, and the collection site
was level with the pump. The MedFusion™ pump was set up in the horizontal position and used with
Monoject 35 mL syringes, which are made of polypropylene. Simulated feeds using the MedFusion™
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pump were given through Covidien 60ES tubing extensions, which are made of polyvinyl chloride.
Simulated feeds using the Kangaroo ePump™ were given through Kangaroo ePump™ 1000 mL Pump
Sets (part #773656), which are made of polyvinyl chloride.
All simulated feeds were given at a ﬂow rate of 20 mL·h−1 for 60 min. Aliquots at 5, 10, 15, 30, 45,
and 60 min after the start of the feed were collected in 15 mL VWR™ tubes and were processed for
analysis of fat content directly after collection.
2.3. Human Milk Sample Analysis
Prior to analysis, samples were warmed to 25–33 ◦C and homogenized using a probe sonicator
(Q55 sonicator; Misonix Qsonica, Newton, Connecticut) for 10 s. HM samples were analyzed for fat
concentration (g·mL−1) and energy content (kcal·oz−1) using a near-infrared milk analyzer (sample
volume of 2 mL, Spectrastar™; Unity Scientiﬁc, Brookﬁeld, Connecticut), following the Unity Scientiﬁc
Procedure for Analyzing Breast Milk. For each milk sample, the average of three readings from the
milk analyzer was recorded. The Spectrastar™ has been shown to measure fat content precisely but
has room for improvement in accuracy [13].
2.4. Statistical Analysis
Total mass of fat as well as energy delivered throughout the entire duration of the simulated feed
were calculated by right-handed integral approximation. The percentages of these approximations
compared to the baseline fat content (“pre” feeding) integrated over the length of the feed represent
the overall fat delivery efﬁciency. Data was analyzed using StatPlus®mac: LE (Copyright © 2010).
Unpaired Student’s t-tests assuming unequal variances were performed to determine statistically
signiﬁcant differences between fat delivery efﬁciencies of these categories of HM. Statistical signiﬁcance
was reached if p < 0.05.
3. Results
The addition of H2MF to HM affected overall fat delivery efﬁciency when the MedFusion™ pump
was used but not when the Kangaroo ePump™ was used. When the Kangaroo ePump™ was used,
simulated feeds with HM produced an overall fat delivery efﬁciency of 75.0 ± 1.2%, while simulated
feeds with HM + H2MF produced an overall fat delivery efﬁciency of 75.9 ± 1.1% (Table 1). Thus, no
signiﬁcant difference in fat delivery efﬁciency was observed with the addition of H2MF to HM when
using the Kangaroo ePump™ (p > 0.05). However, when the MedFusion™ pump was used, simulated
feeds with HM produced an overall fat delivery efﬁciency of 83.2 ± 2.8%, while simulated feeds with
HM + H2MF produced an overall fat delivery efﬁciency of 88.8 ± 0.8% (Table 1). Thus, a signiﬁcant
increase in fat delivery efﬁciency was observed with the addition of H2MF to HM when using the
MedFusion™ pump (p < 0.05).
Table 1. Fat delivery efﬁciency of HM, HM + H2MF, and HM + H2MF + cream.
HM HM + H2MF HM + H2MF + cream
Kangaroo ePump™ 75.0% ± 1.2% (n = 8) 75.9% ± 1.1% (n = 8) 83.7 ± 1.0% (n = 8) *
MedFusion™ 83.2% ± 2.8% (n = 9) 88.8% ± 0.8% (n = 6) * 92.0 ± 0.3% (n = 6) *
* Denotes statistical signiﬁcance compared to corresponding simulated feed with HM; HM: human milk; H2MF:
HM supplemented with donor HM-derived fortiﬁer Prolacta + H2MF™; Cream: HM supplemented with H2MF
and donor HM-derived cream ProlactCR™.
The addition of H2MF and cream to HM increased the overall fat delivery efﬁciency of both
pumps. When the Kangaroo ePump™ was used, simulated feeds with HM + H2MF + cream resulted
in an overall fat delivery efﬁciency of 83.7 ± 1.0%, compared to 75.0 ± 1.2% when HM alone was
provided (p < 0.0001) and to 75.9 ± 1.1% when HM+H2MF was provided (p < 0.0001) (Table 1). When
the MedFusion™ pump was used, simulated feeds with HM + H2MF + cream resulted in an overall
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fat delivery efﬁciency of 92.0 ± 0.3%, compared to 83.2 ± 2.8% when HM alone was provided (p <
0.01) and to 88.8 ± 0.8% when HM + H2MF was provided (p < 0.05) (Table 1). Therefore, when the
MedFusion™ pump was used, the addition of cream further improved upon the fat delivery efﬁciency.
When the Kangaroo ePump™ was used, an increase in fat delivery efﬁciency was observed only when
both H2MF and cream were added to HM.
The average total fat (grams) and energy (kcal) delivered by the simulated one-hour feed increased
with the addition of H2MF and further increased with the addition of cream (Table 2).
Table 2. Total fat/calories delivered over 20 mL, one-hour feeds (calculated with right-handed integral
approximation).
HM
Fat (g)/Cal (kcal)
HM + H2MF
Fat (g)/Cal (kcal)
HM + H2MF + cream
Fat (g)/Cal (kcal)
Kangaroo ePump™ 0.681/12.60 0.873/14.35 1.047/16.04
MedFusion™ 0.765/13.55 0.986/16.01 1.178/17.91
HM: human milk; H2MF: HM supplemented with donor HM-derived fortiﬁer Prolacta + H2MF™; Cream: HM
supplemented with H2MF and donor HM-derived cream ProlactCR™.
The average fat values at each time point were plotted to show how fat content decreased
throughout one-hour simulated feeds (Figures 1 and 2). During simulated feeds using the Kangaroo
ePump™, between t = 0 to 10 min, the fat content dropped by approximately half of the difference
between the fat content at t = 0 min and t = 60 min (Figure 1). This revealed that a signiﬁcant proportion
of the total fat loss occurred in the ﬁrst 10 min with all HM variations. By t = 60 min, the fat content
of HM + H2MF and HM + H2MF + cream appeared to stop decreasing, but the fat content of HM
continued to decrease after t = 60 min due to the negative slope seen in Figure 1. During simulated feeds
using the MedFusion™ pump with HM and HM + H2MF, fat content dropped sharply between t = 0
to 5 min and then rose slightly between t = 5 to 10 min. After t = 15 min, fat levels gradually decreased.
Figure 1. Fat values over one-hour feeds with HM, HM + H2MF, and HM + H2MF + cream with
Kangaroo ePump™, HM: human milk; H2MF: HM supplemented with donor HM-derived fortiﬁer
Prolacta + H2MF™; Cream: HM supplemented with H2MF and donor HM-derived cream ProlactCR™.
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Figure 2. Fat values over one-hour feeds with HM, HM + H2MF, and HM + H2MF + cream with
MedFusion™ syringe pump. HM: human milk; H2MF: HM supplemented with donor HM-derived
fortiﬁer Prolacta + H2MF™; Cream: HM supplemented with H2MF and donor HM-derived
cream ProlactCR™.
Lastly, all data supports the assertion that the MedFusion™ pump resulted in greater fat delivery
than the Kangaroo ePump™, in agreement with previous studies. An increase was observed in overall
fat delivery efﬁciency when using the MedFusion™ pump, compared to the Kangaroo ePump™,
with each corresponding variation of HM (HM, HM + H2MF, and HM + H2MF + cream) (Table 1).
Additionally, the MedFusion™ pump resulted in greater total fat and energy delivered in each variation
of HM (Table 2).
4. Discussion
Rogers et al. reported that the loss of fat, phosphorus, and calcium during continuous feeding
pump methods is substantial, compared to the losses during gravity feeding [5]. Brooks et al. also
showed a signiﬁcant increase in fat loss with the MedFusion™ syringe pump compared to gravity
feeding [4]. As the amount of fat lost over one-hour feeds is comparable to that lost during two-hour
feeds, it appears that most of the fat loss occurs in the ﬁrst hour.
Few data are available regarding methodologies to decrease fat loss during continuous human
milk feedings. Martinez et al. results indicate that fat separation can be prevented by ultrasonic
homogenization of HM [14]. Furthermore, ultrasonic homogenization of HM appears to improve
weight gain and triceps skin-fold thickness in premature neonates by minimizing fat loss, although
further testing needs to be done on the safety of this technique [7]. Minibore tubing delivers
more fat than standard bore tubing [2], although both types of tubing result in signiﬁcant fat loss.
Increased hydrophilicity of the feeding tube may help minimize clogging [15], and emulsiﬁers such
as carrageenan may increase fat delivery but are currently limited by potential toxicity and lack of
practical applicability to human milk feedings [16]. Supplementing enteral nutrition intakes of VLBW
infants with H2MF and cream resulted in increased weight gain and length compared to the standard
feeding regimen, supporting the use of H2MF and cream as a promising method to promote growth of
infants [17].
We evaluated the addition of H2MF and cream as a potential practical method to increase fat
delivery with HM. Results suggest that H2MF and cream can be used together to increase the fat
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delivery efﬁciency by almost 10% when using the Kangaroo ePump™ or the MedFusion™ syringe
pump. The use of H2MF and cream increases fat delivery while maintaining the beneﬁts of bioactive
elements from HM, which may lead to improved weight gain and long-term outcomes.
The calculations in Table 2 can be utilized to approximate the total fat and calories delivered by
one-hour feeds at 20 mL·h−1 with the corresponding pump type, liquid type, and initial fat content
(Figures 1 and 2). The duration of the feed, the ﬂow rate, and the initial fat content of milk affect
overall fat delivery efﬁciency due to fat molecules occupying binding sites on the tubing and bag or
syringe. Therefore, in order to accurately predict the total fat and calories delivered by feeds with
various conditions, additional experiments must be performed with various feed duration, feed ﬂow
rate, and initial fat content. Calculations from these experiments could be utilized to more accurately
track the fat that reaches the infant and to plan the appropriate mass of fat delivery in order to achieve
proper infant growth rates. Excess fat consumption by infants, as well as insufﬁcient fat consumption,
can have negative impacts on childhood health, increasing the importance of tracking fat delivery [18].
Because the addition of H2MF and cream increases fat delivery efﬁciency, H2MF and cream
appear to reduce the rate at which fat is lost to the tubing and bag or syringe. H2MF and cream were
formulated through processes involving pasteurization [19], which induces changes in micelles [20],
making it possible that H2MF and cream act as emulsiﬁers, preventing some of the fat from HM from
separating out of the mixture. Alternatively, H2MF and cream may lose fat at a lower rate than HM
loses fat, thereby increasing overall fat delivery efﬁciency without affecting the fat loss dynamics of HM.
Lastly, a combination of these two possibilities may work to increase the overall fat delivery efﬁciency.
When using the Kangaroo ePump™, signiﬁcant fat loss in the ﬁrst 10 minutes of feeds with all
HM variations suggests that binding sites on the tubing and bag become saturated more quickly with
fat during early stages of the feed. Later in the feed, the rate of fat loss decreases due to the decreased
available binding sites. When using HM + H2MF and HM + H2MF + cream, which have high initial
fat contents, these binding sites ﬁll quickly, causing fat content to approach a lower limit by t = 60 min.
Different trends of loss occur with the MedFusion™ pump than those with the Kangaroo ePump™,
and these differences must be due to the differences between fat loss dynamics in the feeding bag
versus the syringe because all other variables were held constant.
Compared to the Kangaroo ePump™, when using the MedFusion™ pump, fat loss in the ﬁrst 10
min is less rapid, and the overall trend of fat loss appears to be approximately linear. This may occur
because the rate of fat molecule separation from the aqueous portion of milk is slower in a horizontal
syringe than it is in a vertical feeding bag. The linear trend may be inﬂuenced by gradual, continuous
fat separation in the syringe coupled with plunger movement. As fat separates toward the plunger
end of the syringe, the plunger moves towards the syringe exit, pushing the fat in the same direction.
Fat separation may explain the initial sharp drop in fat content, and plunger movement may explain
the subsequent slight increase in fat content seen with HM and HM + H2MF from t = 5 to 10 min
(Figure 2).
While this study suggests a practical method to increase fat delivery in enteral feeding with HM
and provides insight into possible mechanisms of fat loss and retention, it contains the following
limitations. Only one ﬂow rate (20 mL·h−1) was tested, and it is known from previous studies that
higher ﬂow rates result in greater percent fat retained [7]. All simulated feeds were one hour in
duration, but longer feeds will have decreased overall fat delivery efﬁciencies. Additionally, in a
clinical setting, a nasogastric tube is attached to the end of the tubing used in this study, and additional
fat loss may occur due to this extra tubing. However, to our knowledge, no studies have quantiﬁed the
fat lost in nasogastric tubing, and this data can be used as a basis for further investigations designed to
evaluate characteristics of fat loss from human milk-based diets.
5. Conclusions
Fat and nutrient loss in continuous enteral feeding methods of HM remains a barrier to providing
VLBW infants proper nutrients to grow and survive. Whenever possible, bolus-feeding methods
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should be utilized in lieu of syringe and pump methods with slow ﬂow rates. However, for those
infants who cannot tolerate bolus-feeding, this study proposes the addition of H2MF and/or cream
to HM as a method to increase the percentage of fat delivered during infant enteral feeding. Our
results suggests that the addition of H2MF + cream to HM is a practical method to increase fat delivery
to VLBW infants while retaining the beneﬁts of HM, which may lead to increased growth rates and
improved long-term outcomes. Exploration of additional solutions to increase fat delivery efﬁciency
at slow ﬂow rates, particularly practical solutions, will provide further beneﬁt for infants requiring
enteral nutrition.
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Abstract: The organisation of services to support the increasing number of people receiving enteral
tube feeding (ETF) at home varies across regions. There is evidence that multi-disciplinary primary
care teams focussed on home enteral nutrition (HEN) can provide cost-effective care. This paper
describes the development and evaluation of a HEN Team in one UK city. A HEN Team comprising
dietetians, nurses and a speech and language therapist was developed with the aim of delivering
a quality service for people with gastrostomy tubes living at home. Team objectives were set and
an underpinning framework of organisation developed including a care pathway and a schedule
of training. Impact on patient outcomes was assessed in a pre-post test evaluation design. Patients
and carers reported improved support in managing their ETF. Cost savings were realised through:
(1) prevention of hospital admission and related transport for ETF related issues; (2) effective
management and reduction of waste of feed and thickener; (3) balloon gastrostomy tube replacement
by the HEN Team in the patient’s home, and optimisation of nutritional status. This service evaluation
demonstrated that the establishment of a dedicated multi-professional HEN Team focussed on
achievement of key objectives improved patient experience and, although calculation of cost savings
were estimates, provided evidence of cost-effectiveness.
Keywords: Enteral tube feeding; home enteral nutrition; primary care
1. Introduction
The number of people receiving food and ﬂuid intake via a gastrostomy tube in primary care
has increased [1,2] and it is now a relatively common intervention in the UK [3]. Poorly managed
gastrostomy tubes and enteral feeding in the community setting can lead to complications, hospital
admission [3] and dissatisfaction with care provision [4]. Other aspects of poor management include
wastage of feeds and equipment. Therefore, it is important that people with gastrostomy tubes, their
carers and primary care services are supported to manage the therapy effectively.
Management of a gastrostomy tube at home requires development of knowledge and skills and
life style adaptations. People with a gastrostomy tube report it to be a burden, time-consuming and
disruptive to their lives [5,6]. Further, relatives of people living at home with a feeding tube have
described managing the new life situation it presents as a struggle [4]. Appropriate education, training
and support is required both to ensure a smooth transition between care settings and safe and effective
management within the primary care setting [7,8]. UK NICE guidelines [9] outline that people receiving
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enteral tube feeding (ETF) in the community should “be supported by a coordinated multidisciplinary
team”. There are a number of ways services can be organised to support people with home enteral
feeding (HEF) [10] and a range of intervention strategies have been described [11]. A recent systematic
review highlighted that a standardised care coordination model with a multidisciplinary team can
improve patient outcomes and reduce health care costs, but there is insufﬁcient evidence to determine
the effectiveness of a particular intervention or team composition [11]. Outpatient-based services, such
as enteral nutrition support clinics, have been suggested to improve care quality and reduce hospital
readmissions, tube-related complications and costs [12]. In some areas, teams based in community
settings (often termed Home Enteral Nutrition (HEN) teams) have been formed to provide a service
for patients in their own homes [13] and these have been associated with improved care outcomes. For
example, Klek et al. [14] report cost savings following the introduction of commercial formulas and
guidance from a nutrition support team. In the UK, Kurian et al. [3] suggested that the direct actions of
a HEN Team comprising dietitians and assistants in one UK city potentially resulted in the avoidance
of 227 hospital admissions over a year. This paper aims to describe the development, interventions
and evaluation of a multidisplinary HEN Team in one city in England.
2. Materials and Methods
2.1. Team Development
Local funding was secured for six months to form a HEN Team and scope the potential for
improved patient care and cost savings. Following this, a further 12 months of funding totaling £84,071
was awarded, which allowed the service to be embedded in local healthcare provision. The Team
comprised a dietitian, a speech and language therapist, a homecare company nurse and a nutrition
nurse. All Team members worked part-time with the Team whilst holding other professional roles
within their contracted time.
2.2. Team Aim and Objectives
The aim of the HEN Team was to provide a service for people over the age of 18 with gastrostomy
tubes in a UK city (population approximately 265,000) focussed on improving patient experience and
quality of nutritional care. The key objectives for the Team and how they were achieved are outlined
below to give information on the interventions and how they were implemented.
2.2.1. Objective: Development of a Care Pathway and Links with Other Services
An integrated care pathway in the form of a ﬂow chart was developed and embedded into practice
(Figure 1). The pathway outlined the stages of management for people concerning their feeding tubes,
including how referrals were created, timeframes for assessment and review, and discharge from
the service. The roles and responsibilities of each Team member were also outlined. The pathway
provided a framework for activity and acted as a point of reference. Communication with other teams
(such as the acute dietetic service and the local Nutrition Support Team) involved in caring for people
with enteral feeding tubes enabled the development of professional networks which facilitated and
improved coordination of care.
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2.2.2. Objective: Care Provision with Reference to NICE Guidelines [8,9]
The Team provided a service delivering multidisciplinary care concerning nutrition for adults with
gastrostomy tubes in the home setting. The following activities were undertaken with each patient:
• Review of use of feed ancillaries (giving sets, syringes, connectors, replacement parts), feed,
thickener prescription and adjustment of plan of care if required on admission to the service and
at least 6 monthly subsequently
• Review of stoma and tube and adjustment of plan of care if required
• Repair of tube as required
• Planned and emergency balloon-retained gastrostomy tube replacement at home where not
clinically contraindicated
• Review of type of balloon-retained gastrostomy tubes and change to longer-lasting tubes requiring
fewer balloon volume checks where possible
• Review of route and preparation of medication and suggestions for change if appropriate
An individualised care plan for gastrostomy and nutritional management was developed for each
patient. As well as providing support for patients and carers, the Team worked to reduce risks through
the early identiﬁcation of problems.
2.2.3. Objective: Provision of Specialist Advice, Training and Education
The Team acted as a source of specialist advice on home ETF for patients, carers and other
community practitioners. Members of the Team could be contacted by telephone during ofﬁce hours.
The Homecare Company continued to provide a 24 h helpline as part of their service contract. Relevant
training and education was delivered to patients, carers, family members and nursing home staff in
the form of in-house training and a study day.
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Figure 1. Care pathway for management of patients with enteral tubes by Home Enteral Nutrition
(HEN) Team, Key: GP: General practitioner, DN: district nurse, SLT: Speech and language therapist.
2.2.4. Service Evaluation
A pre-post evaluation of the impact of the presence of the HEN Team on selected patient outcomes
derived from the HEN Team objectives outlined above was undertaken. Outcomes (except those
related to hospital admission) for all 70 patients in the caseload were compared at one time point in
the 12 months pre-HEN Team development (2011) and one time point following the ﬁrst three months
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of the Team development (2012) or at the point of discharge from the Team. From this, the mean cost
per day for each patient was calculated.
Hospital admission costs were calculated for 28 patients. This convenience sample was selected
on the basis of known hospital admission. Sample size was determined by the time available to extract
data from the hospital medical records recorded over a 24-month period. For these 28 patients, the
mean cost per year of hospital admission was calculated from the review of 24 months of medical
records pre-HEN Team development. These were then compared with the mean cost for 2012.
2.2.5. Outcomes Included
• Number of patients whose risk of malnutrition decreased (measured using the Malnutrition
Universal Screening Tool (MUST) [15])
• Number of patients, carers, healthcare staff and nursing home trained in gastrostomy tube care
• Number of patients who had tubes removed
• Estimates of cost of:
 enteral feed prescription
 thickening agents for dysphagia
• Frequency and length of hospital admission and hospital transport costs for ETF related problems
for 28 patients in the caseload.
Data was obtained from hospital medical, dietetic, and community and homecare nursing records. A
patient satisfaction survey in the form of a written questionnaire was undertaken at one time point
during the 12 months. The survey comprised a 15-item anonymous postal questionnaire which was
adapted from an existing service evaluation. The two items reported here concern the questions
“Before your ﬁrst appointment, did you know what to expect from the HEN Team?” (yes or no) and
“How they would you rate the overall service received? (very poor, poor, OK, good or excellent).
This was distributed to all patients in the caseload by post with a stamped addressed envelope
for return.
2.3. Statistical Analysis
SPSS 17.0 was used to record and analyse data using descriptive statistics and frequencies. Actual
cost savings were estimated. Values for bed days were calculated using the following estimates derived
from service managers and a Trust Finance Department: day case £250, general medical ward £177,
acute medical unit (AMU) £240, critical care £1100, specialist rehabilitation unit £470. If the admission
location was unclear, costs were calculated as 2 days on AMU and the remainder on a general medical
ward. The cost of patient transport relating to hospital admissions was calculated using an average
price of £55.77 per trip. The cost of feed and thickener for each patient per day was calculated and
then an estimated cost per year obtained for each patient. These were then summed to produce an
annual cost. Products were costed using the invoice supplied by the provider or from the current
British National Formulary. Costs of gastrostomy tubes were obtained from manufacturers. Scheduled
time in the radiology department was estimated at £250 per case.
2.4. Ethics and Governance
The study was registered as a service evaluation with the Trust and deemed not to require ethical
committee approval. Conﬁdentiality was maintained during the recording and analysis of the data.
Personal identifying information was not recorded and patients were allocated a unique anonymous
identiﬁcation number.
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3. Results
3.1. Caseload Characteristics
People from the age of 18 years and older were admitted to the caseload, although the mean
age was 61 years (range 19 to 90 years). The majority of patients were female (60%). Nearly 70%
lived in their own homes with the remainder living in nursing homes. A high proportion of patients
(approximately 70%) had a percutaneously inserted gastrostomy tube. The remainder had a balloon
retained gastrostomy (about 20%), “low-proﬁle” gastrostomy or jejunostomy. The most frequently
reported medical condition causing the need for a tube was cerebrovascular accident (about 25%) but
other conditions that featured frequently in the population were neurological diseases and learning
disability [16].
The HEN Team made a total of 595 contacts (face to face and via telephone) over the course
of 2012, equating to a mean of 50 contacts per month or 8.5 contacts per patient over the year. A
breakdown of contacts per discipline is shown in Table 1.
Table 1. Contacts by discipline.
Dietitian Speech and Language Therapist Nurse TOTAL
Number of contacts 241 187 167 595
3.2. Must Score
The proportion of patients at medium or high risk of malnutrition (MUST score greater than 0)
was reduced from 41% to 25% suggesting reduced risk of malnutrition.
3.3. Training
Each patient, and where appropriate their carers, received training at the point of care. A study
day entitled “Caring for tube feeds in the community” was held by the HEN Team and attended by 20
healthcare professionals and carers during the intervention period. The study day was not available in
the pre-intervention period.
3.4. Number of Patients Who Had Tubes Removed
Over the course of the intervention period (2012) eight patients had their tubes removed, which is
broadly in line with other published reports [3].
3.5. Estimated Cost Savings
Table 2 shows estimates of the cost savings for speciﬁc components of the care provision pre and
post intervention.
Review of each patient’s enteral feed prescription by the dietitian, to ensure patient nutritional
needs were being met, resulted in cost savings because some feeds were reduced or changed to
standard feeds and bolus feeds (Table 2). Review of water and feed ancillaries for each patient resulted
in some adjustments made to their equipment supply to ensure unnecessary components were not
ordered and supplies were not excessive. For example, one patient was initially receiving two 500 mL
bags of a concentrated feed with a two-pack connector. Following dietetic assessment, the patient was
changed over to one bag of a high-energy feed, thus removing the need for the two-pack connector as
well as reducing the number of bags of feed. This prescription was more appropriate for the patient as
it was less labour-intensive. The cost savings as a result of review of water and feed ancillaries are not
included in the calucation of the cost savings.
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Table 2. Estimated costs pre and post introduction of the Home Enteral Nutrition Team (n = 70).
Component of provision Calculation of estimatedcosts
Pre introduction
estimated cost
(2011)
Post introduction
estimated cost
(2012)
Estimated Cost
differential
Enteral feed prescription per year
2011: mean cost of feed £9.18
per patient per day
2012: mean cost of feed £7.41
per patient per day
£234,505 £189,326 £45,179
Thickening agents for dysphagia
2011: daily thickener costs
per patient £0.53
2012: daily thickener costs
per patient £0.48
£13,542 £12,264 £1,278
Review of thickening agent use and type by the speech and language therapist resulted in cost
savings as swallow ability of some patients improved (Table 2).
There were fewer hospital admissions for tube-related problems recorded in 2012 compared
to 2010/2011 (Table 3). There were also fewer hospital admissions for routine balloon gastrostomy tube
replacement. Over the course of 2012, the Team undertook tube replacement in the home for fourteen
patients. Prior to the introduction of the HEN Team, some patients were attending radiology to have
their balloon gastrostomy tube replaced. Manufacturers guidelines for the type of tube routinely used
within the local area suggest three monthly replacements, so this potentially saved four radiology
appointments yearly per patient. Additionally, over the course of 2012, seven patients were changed
to a tube type which requires checking of the balloon volume and changing less frequently than the
previous tube routinely used. This resulted in a reduction in tube cost of £93 per patient or £651 for the
year. Cost of nurse visits to change the balloon volume were not calculated.
3.6. Patient Satisfaction Survey
Fourteen people returned the patient satisfaction survey (30% response rate). All respondents
stated that they were were extremely satisﬁed with the services provided by the HEN Team, with 100%
of respondents rating the overall service received as good or excellent. Over half the respondents to
the survey indicated that they had not known what to expect from the HEN Team before the ﬁrst visit,
suggesting that the role of the HEN Team was unclear.
Table 3. Estimated costs of hospital admission pre and post introduction of the Home Enteral Nutrition
Team (n = 28).
Costs component Calculation of
estimated saving
Pre-introduction
estimated cost
(mean per year)
Post-introduction
estimated cost (2012)
Estimated cost differential
Hospital admission
(frequency and bed days) for
balloon gastrostomy tube
replacement and tube
related problems
2010/2011:
• 25 admissions
• 740 bed days
• 10 day cases
2012:
• 7 admissions
• 98 bed days
• 2 day cases
£82,943 £18,602 £64,341
Hospital transport for
balloon gastrostomy tube
replacement in hospital and
tube related problems
2010/2011:
Transport based on
25 admissions and
10 day cases 2012:
Transport based on
7 hospital
admissions and 2
day cases
£976 £502 £474
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4. Discussion
Increasingly, community services are required to support people with ETF [17]. It is important to
consider how a service can be provided that effectively meets the needs of patients, as currently there
is little guidance on who should be included in the Team, the implementation process or evaluation
of effectiveness [11]. The introduction of a new team to deliver a service previously not available in
the local area was approached by forming team aims and objectives linked with clear measurable
outcomes. This enabled care provision concerning ETF via gastrostomy to align closely with national
guidelines [8,9] and expected standards of care [18]. The service evaluation measured by the outcomes
generated from the team objectives indicated that the Team was able to provide a cost-effective
community service, which improved the experience and quality of care of people with gastrostomy
tubes. For a cohort of 70 patients, the introduction of a HEN Team was associated with crude estimated
cost savings of £111,272 over one year. The service cost £84,071 to deliver, giving rise to an estimated
net saving of £27,201 to the NHS.
Previous evaluations of similar teams have demonstrated greater cost savings [3]. Other activities
of the HEN Team linked to the Team objectives potentially generated further costs savings but were
not included in the cost savings analysis presented in this paper. These included review of ancillaries
and water ordered for each patient, review of medications and transfer to oral medication with
improved swallow, reduction in dressing use as a result of improved training, reduction in district
nursing time for balloon volume changes, and recommendation for removal of gastrostomy tubes
where swallow function improved sufﬁciently to enable adequate oral intake to maintain health.
Calculating cost savings was a challenge for the Team, as it was an activity that none of the members
had previously undertaken. The estimates of savings were crude, being based on ﬁgures that were
estimates of cost. Nevertheless, some cost savings were clearly made. Other reported evaluations of
teams have focussed on measurement of patient-reported outcome measures to demonstrate clinical
effectiveness [19]; however, we considered it essential to demonstrate cost effectiveness in addition
to patient satisfaction. A recent systematic review identiﬁed that evaluation of cost effectiveness of
nursing practice is limited [20] and there is a need to consider cost implications in service delivery
within community settings.
The multidisciplinary nature of the Team enabled rapid referral to other disciplines, consistent
advice, more regular review, timely and appropriate clinical care and better provision of training.
The speech and language therapist was a key member of the Team. She supported and empowered
patients with dysphagia to comply with clinical recommendations concerning food and ﬂuid intake.
In addition, as each patient’s ability to swallow was reviewed regularly, any patient with the potential
for improved swallow received ongoing speech and language therapy at home. This potentially
reduced the risk of aspiration pneumonia and, for some patients, resulted in timely removal of their
gastrostomy tube. This has a signiﬁcant impact on patient experience. The psychosocial beneﬁts of
receiving oral intake should not be underestimated.
4.1. Limitations
The time since insertion of the tube was not taken into account in calculation of the cost savings.
This is a limitation of this study as it has been suggested that there is a substantial risk of complications
in the ﬁrst few months of placement [21]. A design that allowed for a control group would have been
preferable but was not feasible as a result of service requirements. Calculated cost savings were crude
estimates due to the clinical Team’s inexperience in undertaking robust economic evaluation. However,
it was considered important to attempt to demonstrate the value for the service to the local NHS
economy, and demonstrates the need for clinicians to develop skills in evaluation of cost effectiveness
of services. The pre-post intervention evaluation design did not allow for temporal variations in care
environment to be evaluated, and the changes seen may have occurred without the introduction of
the Team.
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4.2. Practice Recommendations
A HEN Team has the potential to increase patient satisfaction and reduce costs associated with
ETF in the community. The process of team development requires the setting of clear aims and key
objectives focussed on enhancing patient experience. When implementing a specialist community
healthcare service, it is important to consider how the service can be evaluated robustly so patient
satisfaction and cost-effectiveness can be demonstrated.
5. Conclusion
ETF is a costly therapy, and a dedicated HEN Team can help to minimise the signiﬁcant costs
related to tube feeding and enhance the experience of people receiving tube feeding at home. These
ﬁndings are consistent with other similar studies [11]. Through effective management and care delivery,
it was shown that patients supported by the HEN Team were admitted to hospital less frequently,
used less hospital transport and had reduced costs for feed and thickener. The reduction in hospital
admissions is likely to be due to risk management by the HEN Team for complications such as tube
blockage and deterioration. However, as the study design was pre- and post-evaluation, hospital
admission may have been reduced as a function of time. Other components of the provision not
measured would have been likely to contribute to costs savings.
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Abstract: Malnutrition is a common consequence of inﬂammatory bowel disease (IBD). Diet has an
important role in the management of IBD, as it prevents and corrects malnutrition. It is well known
that diet may be implicated in the aetiology of IBD and that it plays a central role in the pathogenesis
of gastrointestinal-tract disease. Often oral nutrition alone is not sufﬁcient in the management of
IBD patients, especially in children or the elderly, and must be combined with oral supplementation
or replaced with tube enteral nutrition. In this review, we describe several different approaches
to enteral nutrition—total parenteral, oral supplementation and enteral tube feeding—in terms of
results, patients compliance, risks and and beneﬁts. We also focus on the home entaral nutrition
strategy as the future goal for treating IBD while focusing on patient wellness.
Keywords: enteral feeding; malnutrition; nutrients supplementation; inﬂammatory bowel disease;
tube feeding; home enteral nutrition
1. Introduction
Enteral nutritional therapy aims to maintain or restore the nutritional status of individuals who
fail to maintain a sufﬁcient oral intake, despite having a fully or partially functioning gastrointestinal
tract. Its administration is related to the reduction of infectious complications and maintenance of
the integrity of intestinal ﬂora [1]. Lesions of the jaw and central nervous system, anorexia, cancer,
hypermetabolic conditions such as burns and severe infections, and, above all, IBD are examples for
enteral nutrition indicators [1,2].
The term IBD includes at least three clinical conditions: ulcerative colitis (UC), Crohn’s disease
(CD) and indeterminate colitis (IC). IBD can occur at all ages and in both genders. Patients usually
complain of severe diarrhea, abdominal pain, weight loss and fever, which severely interfere with their
quality of life. Understanding the aetiology of IBD is still controversial as it is a multifactorial pathology;
it likely depends on an interaction between susceptible genes and environmental factors leading to
an abnormal chronic immunological response that causes tissue injury with bowel inﬂammation and
ulceration [2,3].
It is known that the diet plays a role in the pathogenesis of IBD, as has been demonstrated by
exclusion diets in several studies [4]. However, it is possible that some nutrients act either as antigens
or have therapeutic effects in the intestinal mucosa [2].
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In both UC and CD, nutritional deﬁciencies of various severities are often found. These
include protein-energy malnutrition and various vitamin, mineral and trace element deﬁciencies [5].
Malnutrition in IBD depends on several factors such as inﬂammatory processes, impaired intestinal
absorption, nutrients loss through the inﬂamed and ulcerated gut, bacterial overgrowth, medical
management with steroids or imposed dietary restrictions [2,5].
These observations suggest that nutritional support may be the best approach to treat IBD instead
of using drugs, as it could control inﬂammation and treat malnutrition without side effects.
The ﬁrst attempt to use enteral nutrition as primary therapy in IBD was made with amino
acid-based elemental diets in patients with active CD. The concept was that providing amino acids
(elemental diets) instead of intact proteins (polymeric diets) would decrease the intestinal antigenic
load in the gut lumen, which in turn would decrease the chances of triggering or maintaining the
abnormal or up-regulated inﬂammatory bowel response. Elemental diets have been shown to decrease
intestinal permeability and diminish the excretion of pro-inﬂammatory cytokines in the stools in CD
patients [6,7].
One of the most important goals of nutritional therapy should be to prevent and treat
undernutrition, improving the growth and development of children and adolescents using total
parenteral nutrition (TPN), enteral nutrition (EN), or by correcting micronutrient deﬁciency [8,9].
2. Feeding Methods and Patients Management
Sip feeding, tube feeding and parenteral nutrition have all been tested and found to be comparably
effective. The selection of the form of nutritional therapy is therefore dependent on secondary factors
such as cost, side effects and inconvenience for the patient. Based on these considerations, enteral
tube feeding is the primary choice for nutritional therapy of an active phase of Crohn’s disease. The
mechanism by which nutritional therapy affects the active phase of Crohn’s disease is not clear. Two
hypotheses have been discussed: (1) bowel rest with reduction of luminal bacteria and antigens leading
to a decrease in inﬂammation; and (2) induction of anabolism changing the immune reaction and
thereby reducing inﬂammation. It is likely that both mechanisms contribute.
Tube feeding is the preferred nutritional therapy for the active phase of Crohn’s disease. Sip
feeding is similarly effective, provided that patients drink enough from the diet to meet their
requirements. This is difﬁcult to achieve, however. Sip feeding is hampered by a high rate of
non-compliance due to the poor palatability of the diets. Therefore, until more palatable diets are
available, patients should be offered tube feeding as the treatment of ﬁrst choice [10].
2.1. Total Parenteral Nutrition (TPN)
TPN, although it is the only way of putting the bowel at complete rest, has not been shown to be
superior to tube feeding. It may be indicated in some restricted cases, such as in an obstructed bowel
that is not amenable to feeding tube placement beyond the obstruction, a short bowel resulting in
severe malabsorption or ﬂuid and electrolyte loss that cannot be managed enterally, severe dysmotility
in which enteral feeding is impossible, a leaking intestine from high-output intestinal ﬁstula or surgical
anastomotic breakdown, in patients intolerant to EN whose feeding cannot be maintained orally, when
there is an inability to access the gut for enteral feeding, and in patients undergoing IBD-related bowel
surgery in the perioperative period [8,11].
Available data so far show that while artiﬁcial nutrition seems to play a primary role in the
management of patients with active CD, it does not have a primary therapeutic effect in active UC and
does not induce clinical remission of this type of IBD [12].
The use of TPN in the management of active CD is based on theoretical advantages including
bowel rest, which could reduce the motor and transport functions of the diseased bowel; reduction
of antigenic stimulation, which could eliminate the immunological response to food favored by the
presence of impaired intestinal permeability; and stimulation of protein synthesis, which could lead
to cell renewal and mucosal healing in the intestine [13]. Nevertheless, few controlled clinical trials
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have been conducted on the use of TPN to induce remission in active CD. The remission rate three
months after starting TPN varied from 20% to 79%, depending on the patient population, length of
TPN administration, deﬁnitions of remission or recurrence, and concomitant use of medication [14].
TPN has also been shown to achieve ﬁstula healing in 43–63% of patients, accompanied by disease
activity reduction and weight gain [15]. TPN was also associated with an increased risk of adverse
events such as sepsis and cholestatic liver disease [12].
2.2. Enteral Nutrition (EN)
In addition to the fact that it delivers normal food, EN (with oral nutritional supplements or tube
feeding) may be more useful than TPN in the management of undernourished patients with IBD. If the
gut can be used safely, EN is actually the preferred feeding method for CD or UC patients who need
nutritional support. The advantages of EN include its stimulatory effects on gastrointestinal structure
and function as well as its reduced cost compared to parenteral feeding. Oral nutritional supplements
(with 500–600 kcal·day−1) and/or tube feeding improve the nutritional status in adults and especially
in children with CD [16]. In fact, 50% of growth-retarded CD patients cannot regain their body weight
through medical therapy alone and must use enteral tube feeding [17].
Several studies have demonstrated the efﬁcacy of EN in active CD. While EN’s mechanisms of
action remain unknown, several hypotheses have been proposed, including the ability of nutrients to
modulate the commensal microﬂora and the intestinal immune response by reducing antigen exposure.
In fact, EN seems to exert a direct antiinﬂammatory effect on the intestinal mucosa by reducing IL-6
production and increasing insulin-like growth factor (IGF)-1 production [18]. However, EN has been
proven to be effective in the treatment of the acute phase of CD, achieving remission rates from 20% to
84.2% regardless of disease location. The variability in these results may stem from differences among
study populations, administration protocols and outcome assessments [12].
To date, no deﬁnitive data has been published on supplementation with oral nutritional
supplements in UC patients, who should undergo enteral tube feeding only in exceptional cases [12].
2.2.1. Oral Nutritional Supplementation
Patients with IBD often report concern that their diet may exacerbate their symptoms, and many
modify their diet in the hope of controlling symptoms or preventing relapse [19].
This becomes a concern when patients drastically reduce or completely avoid nutritionally
important foods, which may put them at risk of developing nutritional deﬁciencies. Most patients
believe that diet inﬂuenced their disease and modify their diet. The most common behaviour is the
avoidance of milk and dairy products; this dietary change resulted in reduced calcium intakes but had
no apparent effect on the rate of relapse [20,21].
Moreover, the exclusion of fruit and vegetables is common (legumes 29.5%; vegetables 18% and
fruit 11%) [21]. Unnecessary dietary exclusions, particularly of milk and dairy products, are a concern
if initiated without appropriate nutritional or medical supervision.
Although some data suggest that dietary factors play a role in the onset and the course of IBD,
recommendations other than following a healthy and varied diet cannot currently be made for most
patients [22]. Prescribing a low-residue diet, low in insoluble ﬁber, may be advisable during acute
ﬂares of IBD, particularly in patients with stricturing CD or severe UC attacks [23]. Recently, several
hypotheses about the possibility that some speciﬁc nutrients can modulate inﬂammation have been
suggested. Speciﬁcally, the anti-inﬂammatory effects of n-3 (omega-3 fatty acids, ﬁsh oil) have been
suggested to be beneﬁcial in chronic inﬂammatory disorders such as inﬂammatory bowel disease [24].
At present, data are available mainly on the beneﬁcial effect of n-3 polyunsaturated fatty acids (PUFAs)
and fermentable ﬁber [22].
Fermentable ﬁber generates much less residue than insoluble ﬁber, and it is fermented by colonic
microﬂora, yielding several products, such as butyrate, than can be beneﬁcial for IBD. Butyrate is
the main metabolic substrate for colonic epithelial cells, and there is in vitro evidence suggesting
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that butyrate is able to down-regulate the production of pro-inﬂammatory cytokines, to promote the
restoration of intracellular reactive oxygen species (ROS) balance and the activation of NF-κB [25].
2.2.2. Enteral Tube Feeding
The mechanism underlying a therapeutic response to enteral diets remain unclear [19]. Initially, it
was thought that a low antigenic load (absence of whole protein) in the elemental diet was responsible
for inducing remission—but it is now known that whole protein enteral feeds are as effective as
elemental diets [26]. One of the theories that offers the most exciting possibilities concerns the potential
anti-inﬂammatory effect of an enteral diet on the gastrointestinal mucosa [27]. This may be related to
the provision of fatty acids in the feed [28] and/or the potential of the feed to alter gut ﬂora. There
is now stronger evidence that the clinical response to an enteral diet is accompanied by histological
healing of the mucosa and down regulation of mucosal pro-inﬂammatory cytokines [27].
Enteral feeding is largely free from side effects. Minor side effects may occur and nausea and
headaches may be reported, but these usually resolve after the ﬁrst few days of feeding. Gradual
introduction of the feed during the initial 3–4 days should limit diarrhea. Weight loss, abdominal
cramps and vomiting can also occur but they usually resolve as the patient adapts to the diet. The main
problems with this regime are often related to poor compliance and unpalatability. These problems may
be improved by administering this therapy as part of a multidisciplinary team approach involving the
medical, dietetic and nursing staff, as well as the patient and family members, and providing support
and education. It is important to acknowledge that exclusive enteral nutrition can, understandably, be
a demanding and difﬁcult therapy for many patients [19].
Patients should receive 25–35 kcal·kg−1·day−1 by continuous infusion via a nasogastric tube.
Infusion rates over 120 mL·h−1 frequently lead to diarrhea or reﬂux. To limit the infusion rate, nutrition
should be infused 24 h a day.
It is useful to start enteral nutrition at a low infusion rate of 20 mL h−1 and increase this over
2–3 days to the full dose. Additionally, in many patients who are dehydrated due to severe diarrhea,
electrolyte solutions have to be infused parenterally during the ﬁrst few days.
Enteral nutrition should be continued for a minimum of two and preferably four weeks. The dose
and duration is dependent on clinical parameters like nutritional status and decrease in disease activity.
When symptoms improve, the patient may be allowed some additional food and enteral nutrition may
be reduced, dovetailing with the increase in oral nutrition [10].
2.3. Home Enteral Nutrition (HEN)
The most common home infusion therapy today is home enteral nutrition (HEN) or home enteral
tube feeding (HETF). HEN should be used in patients who cannot meet their nutrient requirements by
oral intake but have a functional gastrointestinal tract, and who are able to receive therapy outside of
an acute care setting. It is estimated that more than 300,000 people of all ages in the USA are receiving
enteral nutrition at home, whereas in Europe, HETF in the community has also considerably increased
in the last few years [29]. Epidemiologic data from UK show that, at any one time, over 19,500 patients
receive HETF in the UK community, more than twice that in hospitals [30].
Several factors have contributed to the rapid growth of HEN, including increased awareness of
therapeutic nutrition, developments in artiﬁcial nutrition, a higher proportion of elderly people in the
population, and reduction in the number of hospital beds.
Gastrostomy and/or jejunostomy feeding tubes are frequently inserted and used for long-term
home enteral nutrition support. Although insertion of these tubes is usually related to minor morbidity,
their long-term use may contribute to various complications and problems which may affect quality of
life and have signiﬁcant economic consequences on health care use [29].
Percutaneous endoscopic gastrostomy (PEG) is actually indicated for patients requiring long-term
nutritional support (>30 day) who have a functional gastrointestinal tract but insufﬁcient oral intake of
nutrients. There are three techniques for PEG tube placement: the peroral pull technique, the peroral
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push technique and the direct percutaneous procedure [31]. The most widely-used technique for PEG
placement is the “pull” method introduced by Gauderer et al. in 1980 [32], which has replaced surgical
gastrostomy as the medium- and long-term solution to enteral nutrition delivery, being safer and more
cost-effective, with lower procedure-related mortality (0.5%–2%). Furthermore, tube displacement
occurs less frequently than with nasogastric tubes [31].
Long-term jejunal feeding can be achieved endoscopically with jejunal tubes through the PEG
(JET-PEG) and direct percutaneous endoscopic jejunostomy (DPEJ). Jejunal feeding is appropriate
for patients with recurrent vomiting and/or tube feeding-related aspiration, severe gastroesophageal
reﬂux, gastroparesis, gastric outlet obstruction, or total or partial gastrectomy [31].
A complication related to PEG tubes is the formation of gastrocolic, colocutaneous or
gastrocolocutaneous ﬁstulae, especially in IBD patients with an active disease. In contrast to the
gastrocolic ﬁstula, a ﬁstulous passage connecting the stomach with the colon, the gastrocolocutaneous
ﬁstula is deﬁned as an epithelial connection between the mucosa of the stomach, the colon, and the
skin. Its probable etiology is the penetration of a bowel loop (mostly transverse colon) interposed
between the stomach and the abdominal wall, either by inadvertent puncture during tube placement
or, more commonly, due to gradual erosion of the tube into the adjacent bowel [33].
3. Complications of Enteral Tube Feeding
Despite the overall safety of feeding tubes, a number of complications can occur following their
placement, though they are usually considered minor, including tube dislodgment, peristomal leakage,
and wound infection [34,35]; also, most studies have suggested that complications are more likely to
occur in elderly patients with comorbid illnesses, particularly those with an infectious process or who
have a history of aspiration [36].
Nevertheless, enteral tube feeding is considered “routine” by many health care professionals
involved with it, because these tubes are the most common and easiest to manage in the community.
However, as tube feeding can still be a daunting thought for patients and caregivers, careful
consideration should be given to predischarge planning and training. Planning for discharge on
HEN should begin at the earliest opportunity and involve all the relevant health care professionals
and community staff [37], while discussing with the patients and caregivers what to expect on a daily
basis when administering HEN [38]. Also, training patients and/or caregivers on caring for the tube,
hygiene issues, safety, and basic problem solving is of paramount importance, and they must be clear
regarding arrangements for supply of feed and equipment. Consequently, by the time of discharge,
patients and caregivers should be adequately trained on the various aspects of the tube feeding system,
to ensure safe and effective feeding at home [29].
As tube dysfunction is the most frequent complication related to its presence, some simple
measures must be taken to prevent or, at least, to decrease its incidence. For example, tubes may
become clogged or occluded if not ﬂushed with water after each feeding, or feedings may leak around
the exit site of the tube if tube is too loose, if the balloon is broken, if the tract is enlarged, or the
stomach too full. Consequently, the placement of the tube must be frequently checked, and it must be
resecured to keep it in place [29].
Recently, it was demonstrated that using a nasal bridle can decrease inadvertent removal of
nasally inserted enteral tubes and improve subsequent patient outcomes. The use of the bridles may
be beneﬁcal in patients with conditions that limit the effectiveness of traditional tubes [39].
4. Conclusions
Enteral nutrition should be used as primary therapy in CD for a number of reasons. First, it
fulﬁls the therapeutic criteria for use in a wide group of patients with CD, since it achieves equal
or higher remission rates than some of the drugs currently used. At the same time, it is free of the
aesthetic, haematologic, systemic and metabolic side effects commonly associated with steroids and
other immune modulators. In addition, in some cases, mucosal healing has been demonstrated with
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this therapy. Second, enteral nutrition treats or prevents nutritional deﬁcits associated with IBD. It
also enhances growth and sexual development in children and adolescents and partly prevents or
reverses osteopenia. Enteral nutrition should be the treatment of choice for children and adolescents,
not only for the ﬁrst attack but also for any relapse and as maintenance therapy. Similarly, it should
be seen as the ﬁrst possible treatment for elderly patients with CD in order to maintain their bone
mass, since there is a strong possibility that they may have received various long-term treatments with
glucocorticoids during their life. Third, enteral formulas should be tried for new onset attacks of CD
at all ages to avoid steroid side effects. It should also be the ﬁrst therapeutic approach in all mild to
moderate acute attacks, in particular when there is small intestine or ileocolonic involvement. Finally,
a further advantage of this approach is that it is a safer way of starting the treatment in patients with a
possible undiagnosed abdominal abscess [2].
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Abstract: The aim of this systematic review is to evaluate the role of enteral nutrition in dementia.
The prevalence of dementia is predicted to rise worldwide partly due to an aging population. People
with dementia may experience both cognitive and physical complications that impact on their
nutritional intake. Malnutrition and weight loss in dementia correlates with cognitive decline and
the progress of the disease. An intervention for long term eating difﬁculties is the provision of
enteral nutrition through a Percutaneous Endoscopic Gastrostomy tube to improve both nutritional
parameters and quality of life. Enteral nutrition in dementia has traditionally been discouraged,
although further understanding of physical, nutritional and quality of life outcomes are required. The
following electronic databases were searched: EBSCO Host, MEDLINE, PubMed, Cochrane Database
of Systematic Reviews and Google Scholar for publications from 1st January 2008 and up to and
including 1st January 2014. Inclusion criteria included the following outcomes: mortality, aspiration
pneumonia, pressure sores, nutritional parameters and quality of life. Each study included separate
analysis for patients with a diagnosis of dementia and/or neurological disease. Retrospective and
prospective observational studies were included. No differences in mortality were found for patients
with dementia, without dementia or other neurological disorders. Risk factors for poor survival
included decreased or decreasing serum albumin levels, increasing age or over 80 years and male
gender. Evidence regarding pneumonia was limited, although did not impact on mortality. No
studies explored pressure sores or quality of life.
Keywords: enteral nutrition; dementia; percutaneous endoscopic gastrostomy; nasogastric tube;
serum albumin
1. Introduction
Due to a global aging population the incidence and prevalence of dementia is predicted to rise
worldwide, with an estimated 81 million people diagnosed with dementia by 2040 [1]. Dementia is
an umbrella term for a number of speciﬁc conditions which are progressive in nature and impact on
multiple areas of functioning including decline in memory, reasoning, communication skills and ability
to carry out daily activities [2].
A common experience for people with dementia is the development of eating difﬁculties leading
to problems such as malnutrition and weigh loss [3,4]. The severity and progression of dementia is
closely related to weight loss [5,6]. In the early stages of dementia eating difﬁculties are attributed to
olfactory and taste dysfunction, executive planning difﬁculties, attention deﬁcits, dyspraxia, agnosia
and behavioural problems [7]. In advanced stages of dementia oral and pharyngeal phase dysphagia
may be present leading to the inability to coordinate chewing and swallowing, and disruption of the
food bolus from the oropharynx into the oesophagus without aspiration [8]. Reduced nutrition has
negative outcomes for patients with dementia including higher morbidity and mortality, reduced
quality of life and increased carer burden [9–11].
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An intervention for long term eating difﬁculties across different health conditions is the provision
of enteral nutrition through a Percutaneous Endoscopic Gastrostomy (PEG) tube. The provision of
enteral nutrition is both to provide complete nutrition and improve the patient’s quality of life [12]. A
systematic review in 1999 explored the impact of enteral nutrition in patients with advanced dementia
and found no improvements in the rates of aspiration, pressures sores or mortality [13]. No data was
found on quality of life, although many complications were reported including: gastric perforation,
gastric prolapse, aspiration, diarrhoea, gastrointestinal bleeding, nauseas and vomiting, ﬂuid overload
and loss of social aspects of feeding. Finucane et al. [13] concluded enteral nutrition for patients with
dementia should be actively discouraged.
A further review in 2001 explored nutritional parameters, quality of life and mortality of
older people with dementia receiving enteral nutrition [14]. A small number of studies (n = 3)
found improvements in nutritional parameters and an increased albumin was associated with
decreased mortality. Dharmarajan et al. [14] found quality of life was difﬁcult to analyse in this
population as patients with advanced dementia could not narrate their subjective feelings, and
family members reported conﬂicting opinions. Mortality ranged from 11%–27% across studies at 30
days post insertion of a PEG and commencement of enteral nutrition. However, mortality was not
uniformed: older patients, men and patients with an acute illness had higher mortality than women
and African-American patients. Dharmarajan et al. [14] recommended caution in decisions regarding
enteral nutrition in older people with dementia.
A more recent review in 2009 reported no signiﬁcant association between enteral nutrition and
decreased mortality in older patients with dementia [15]. Secondary outcomes of weight loss, Body
Mass Index (BMI), haemocrit and cholesterol were not signiﬁcantly different between those receiving
enteral nutrition to those who were not, albumin levels were signiﬁcantly decreased in patients
receiving enteral nutrition [15]. No studies in this review explored the impact of enteral nutrition on
quality of life, behavioural or psychiatric symptoms of dementia. However, one study documented
the use of restraint, with 71% of patients being physically restrained to prevent removal of a PEG
compared to 55% of those not receiving enteral nutrition [16]. Sampson et al. [15] conclude that there is
insufﬁcient evidence to suggest enteral nutrition in patients with advanced dementia is beneﬁcial.
Clinical guidance reﬂects the evidence to date, National Institute for Health and Care Excellence
(NICE) guidance [17] suggests enteral nutrition may be considered if dysphagia in a patient with
dementia is deemed to be transient, but should not generally be used for patients with advanced
dementia who are disinclined to eat or have permanent dysphagia. European Society of Parenteral
and Enteral Nutrition (ESPEN) are shortly to realise their guidelines on Nutrition in Dementia [7].
ESPEN conﬁrm the use of enteral nutrition in patients with mild or moderate dementia if malnutrition
is predominantly the cause of a reversible condition and only for a limited time. Reversible conditions
are secondary concurrent illnesses such as depression, infection, over use of sedatives, pain or poor
oral health. ESPEN do not recommend the use of enteral nutrition in the terminal phase of dementia,
although acknowledge decisions are unique for each patient with dementia and should take into
consideration the patient’s general prognosis and preferences.
Decisions regarding enteral nutrition in advanced dementia remain ethically challenging for all
involved [4]. One challenge is the possible complications of enteral nutrition including aspiration
pneumonia and ﬂuid overload [13,18]. Further challenges include understanding the patient’s wishes
as they may be unable to communicate and are unlikely to have documented their wishes through
advance directives or advance care plans [19,20].
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However, evidence suggests the continued use of enteral nutrition in the older population
with dementia. A study in the United States found 34% of nursing home residents received enteral
nutrition [21] and 30% of PEG insertions were estimated to be in people with dementia [22]. In Japan,
elderly people receiving enteral nutrition is on the increase [23]. Many studies and reviews have
been completed exploring the immediate clinical effects of enteral nutrition for people with advanced
dementia [13–15,24]. However, methodologies, focus and outcomes of these studies have begun to
change and the need to explore further risk factors for patients with dementia receiving enteral nutrition
is required. Therefore the aim of this review is to explore recent data on both physical and nutritional
outcomes and the impact on quality of life of patients with dementia receiving enteral nutrition.
Objectives:
• Evaluate the impact of enteral nutrition on mortality, risk factors for mortality, pressure sores,
aspiration pneumonia and nutritional parameters for patients with dementia.
• Evaluate the impact of enteral nutrition on quality of life for patients with dementia.
2. Experimental Section
Published guidelines [25,26] were used to complete a systematic review. An initial scoping exercise
identiﬁed three relevant systematic reviews [13–15], which informed the criteria for the search. The
following electronic databases were searched: EBSCO Host, MEDLINE, PubMed, Cochrane Database
of Systematic Reviews and Google Scholar for publications from 1st January 2008 and up to and
including 1st January 2014. Search words included enteral nutrition, enteral feeding, artiﬁcial nutrition,
artiﬁcial nutrition, percutaneous endoscopic gastrostomy and dementia, with and/or Boolean operators (refer
to Table 1 Literature Search Strategy). All searchers were limited to “English Language”. In addition
bibliographies of identiﬁed articles were manually searched for relevant studies.
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2.1. Inclusion and Exclusion Criteria
In addition to the search strategy above the inclusion criteria were: measured outcomes of
mortality, aspiration pneumonia, pressure sores, nutritional parameters and quality of life, and a
separate analysis of patients with a primary diagnosis of dementia or neurological disease. Exclusion
criteria were: administration of enteral nutrition via nasogastric tubes, intravenous ﬂuids and short
term interventions. Two studies were excluded as analysis combined the outcomes of patients with
dementia receiving enteral nutrition via a nasogastric tubes and PEG tubes [27,28].
3. Results
A total of five studies were included in the systematic review and all had an observational design.
Two studies applied a prospective design [29,30] and three studies applied a retrospective design [31–33].
Studies were completed in Japan [31], USA [32], Sweden [29,33] and Germany [30]. Study sample sizes
ranged from 119–484, participants were categorized with a diagnosis of dementia [31,33] or a broader
definition of dementia as significant cognitive impairment and/or combined with other neurologic
disorders [29,30,32]. All studies included enteral nutrition administered via PEG tubes. All studies
included mortality following the commencement of enteral nutrition or the insertion of a PEG. Mortality
was analysed using Kapan-Meirer analysis, which is an estimate of the number of participants who
survive for a certain amount of time following a healthcare intervention [34]. Secondary outcomes
included predictors of mortality, serum albumin levels, aspiration pneumonia and general complications.
No studies reported outcomes relevant to pressure sores or quality of life (refer to Table 2 Summary of
studies reviewed).
3.1. Mortality
Kaplan-Meirer survival analysis were completed by all ﬁve studies [29–33]. No signiﬁcant
differences in mortality were demonstrated in two studies when patients with dementia were compared
to those without dementia or other neurological conditions [31–33]. Decreased mortality for patients
with dementia was demonstrated by one study when compared to patients with stroke, malignant
diseases and other neurological conditions [33]. Increased mortality for patients with dementia and
other neurological diseases was a signiﬁcant ﬁnding in two studies [20,30] when compared to patients
with tumours.
3.2. Predictors of Mortality
A low or decreasing serum albumin was a predictive factor of increased mortality in three
studies [29,31,32]. Increasing age, or age over 80 years were predictive factors of increased mortality
in four studies [29,31–33]. Further risk factors identiﬁed by individual studies included male [31],
an additional diagnosis of chronic heart failure [31] and a raised CRP [29].
3.3. Pressure Sores
No studies included in the review explored the impact of enteral nutrition and pressure sore
development and healing.
3.4. Aspiration Pneumonia
Pneumonia including aspiration pneumonia was explored by three studies [30–32]. Rates of
pneumonia whilst receiving enteral nutrition via a PEG tube was 5% and was not a risk factor of
mortality [30–32]. One study reported aspiration pneumonia rates were comparable across patients
with dementia and those without dementia receiving enteral nutrition [31]. One study reported
pneumonia rates, not linked to aspiration were comparable across patients with neurologic conditions
and tumours receiving enteral nutrition.
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3.5. Quality of Life
No studies included in the review explored the impact of enteral nutrition and quality of life for
patients with dementia.
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4. Discussion
In this review, the impact of enteral nutrition on mortality was equivalent for patients with
dementia, without dementia or diagnosed with other neurological conditions. However, patients
with dementia had decreased mortality compared to patients with a stroke and increased mortality
compared to patients with tumours. Risk factors for poor survival included decreased or decreasing
serum albumin levels, increasing age or over 80 years, and male gender. Limited evidence on
pneumonia was found, although did not impacted on mortality. No studies explored the development
or healing of pressure sores or quality of life.
Previous studies have failed to demonstrate enteral nutrition for patients with dementia prolongs
survival [18,35–37]. Current studies suggest mortality of patients with dementia receiving enteral
nutrition when compared to other conditions is dependent on the comparativeness of these conditions,
including stage of the disease and long term prognosis. The importance of the timing of the decision
with regards to the prognosis of the patient with dementia may be an inﬂuential factor, as enteral
nutrition is more frequently commenced in advanced dementia [33]. Patients with advanced dementia
may exhibit a low level of functionality over a long period of time, which contributes to general
frailty [38]. Illness trajectories and mortality in dementia are difﬁcult to predict due to low functionality
and frailty, which leads to discussions regarding enteral nutrition in the advanced stages of dementia
as end of life is difﬁcult to recognize [38,39]. Therefore, the possibility of some studies to include older
patients with more advanced dementia and the tendency to commence enteral nutrition in the late
stages of the disease process may have implications for mortality rates.
In the current review a decreased or decreasing serum albumin was a predictor of mortality [29,
31,32]. Decreased serum albumin levels (<3.0 mg/dL) have been associated with increased mortality in
enteral nutrition where analysis did not differentiate the diagnosis of patients [40,41]. Evidence for the
impact of the diagnosis of dementia and decreasing serum albumin levels for patients receiving enteral
nutrition is inconsistent. One study found serum albumin levels did not predict survival in patients
with dementia, but did predict survival in patients without dementia receiving enteral nutrition [42].
The impact of serum albumin levels in patients not receiving enteral nutrition needs to be considered,
as decreased serum albumin in critical illness was associated with increased mortality [43]. In the
healthy elderly serum albumin levels decreased with age and were predictive of mortality independent
of know disease [44]. Evidence regarding decreased or decreasing serum albumin levels suggests
an impact on mortality and therefore, needs to be considered in the provision of enteral nutrition
regardless of diagnosis but with consideration of age.
Aspiration pneumonia has been a recognised complication of advanced dementia and enteral
nutrition administered via PEG tubes [3]. Finucane et al. [13] reported no randomised controlled trials
had explored the reduction of aspiration pneumonia following the provision of enteral nutrition via a
PEG tube. In the current review one observational study reported aspiration pneumonia occurrence
at 5%, which was comparable for patients with and without dementia and was not a risk factor
of mortality [31]. Tentatively enteral nutrition delivered through a PEG tube does not increase the
risk of aspiration for patients with dementia compared to rates of aspiration pneumonia of other
disease cohorts.
The development and healing of pressure sores was not explored by the studies included in
this review. However, Martin et al. [27] explored the impact of enteral nutrition administered via
nasogastric tubes and PEG tubes reported pressure and reported that a ﬁfth of patients developed a
pressure sore during the provision of enteral nutrition, and the healing of pressure sores was correlated
with increased mortality. The development and lack of healing of pressure sores may correlate with
hypoalbuminemia, as this is a risk factor for the development of pressure sores and increases resistance
to treatment [45,46]. No further studies have explored the correlation between serum albumin and
pressure sores in patients with dementia receiving enteral nutrition. Martin et al. [27] reported enteral
nutrition in patients with dementia was effective in preserving but not signiﬁcantly improving serum
albumin levels.
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Limitations of the studies included in this review need to be acknowledged. Different clinical
practices and guidelines across continents may impact on the results of studies included. Practices
across continents were difﬁcult to identify only three studies reported PEG placement procedures and
none clariﬁed/deﬁned enteral nutrition. Prevalence of enteral nutrition in patients with dementia in
Japan may be higher than Western populations due to current guidelines. In Japan guidelines compiled
under the supervision of the Japan Gastroenterology Endoscopy Society recommend PEG insertion
for patients who cannot maintain their nutrition due to cerebrovascular disease or dementia [47].
The impact of these guidelines may be the earlier insertion of PEG tubes and the commencement
of enteral nutrition in patients with dementia leading to longer survival rates [31]. Higaki et al. [31]
reported survival at 12 months of 51% for patients with dementia of which 20% were still alive three
years, compared to 41% of patients with dementia at 12 months in a study completed in Sweden [33].
However, no longitudinal data was reported outside Japan and the challenges to this guidance and
Japanese health-care system reforms may impact on this prevalence [28].
Further limitations of the studies include small sample sizes and different categorization of
conditions. Dementia was categorized as a separate neurological condition in some studies, but
included with other neurological conditions in further studies. Diagnosis was generalised in some
studies to those with and without dementia, and more detailed in further studies with all conditions
categorized and therefore, direct comparison and interpretation of results is difﬁcult.
Ethical considerations of insertion of a PEG in a patient with dementia are important. ESPEN
and NICE guidelines do not recommend enteral nutrition in patients with advanced dementia and
only occasionally in patients in the earlier stages of dementia. Enteral nutrition is recommended
only to ensure adequate provision of nutritional needs, when under-nutrition is caused by reversible
conditions other than the dementia [48]. However, diagnostic overshadowing, a tendency to attribute
all symptoms to dementia thereby leaving a co-existing conditions undiagnosed has been recognised
and needs to be continually challenged [49].
Alzheimer’s Society supports the importance of quality of life rather than length of life. For the
person with dementia decreased quality of life has been associated with behavioural and psychological
disturbances, but no associations with dysphagia or cognition has been demonstrated to date [50]. A
recent a recent review by the Royal College of Physicians suggests the need for reluctance to commence
enteral nutrition in dementia, however state this cannot be translated into a blanket ban [51]. A
decision-making algorithm integrating medical and ethic dimensions regarding enteral nutrition in
dementia has been developed and may be helpful to healthcare professionals faced with this ethical
dilemma [52].
5. Conclusions
The studies included in this systematic review challenge the traditional view that enteral
nutrition administered through a PEG tube increases mortality in patients with dementia. The
recommendations from this review include the need for a holistic assessment of patients with dementia
when contemplating PEG insertion and enteral nutrition. A holistic assessment would include: the
patients’ diagnosis including comorbidities, current stage and impact of dementia on the need for
enteral nutrition, age and nutritional parameters. The impact of enteral nutrition on quality of life
for patients with dementia remains unclear, although complications are acknowledged. Enteral
nutrition within end of life care is not recommended, although this review acknowledges recognising
end of life within dementia is problematic. A further recommendation is early discussions with
patients with dementia and their family regarding nutrition needs in advanced dementia and the
documentation of the results of these discussions. However, decision making regarding PEG insertion
and enteral nutrition in patients with dementia currently remains ethically challenging and should
involve discussions around appropriate end of life care.
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Abstract: The aim of this review is to provide a global perspective of Home Enteral Tube Feeding
(HETF) and to outline some of the challenges of home enteral nutrition (HEN) provisions. It is well
established that the number of patients on HETF is on the increase worldwide due to advances
in technology, development of percutaneous endoscopic gastrostomy techniques, and the shift in
care provisions from acute to community settings. While the signiﬁcance of home enteral nutrition
in meeting the nutritional requirements of patients with poor swallowing reﬂexes and those with
poor nutritional status is not in doubt, differences exist in terms of funding, standards, management
approaches and the level of infrastructural development across the world. Strategies for alleviating
some of the challenges militating against the effective delivery of HETF including the development
of national and international standards, guidelines and policies for HETF, increased awareness and
funding by government at all levels were discussed. Others, including development of HEN services,
which should create the enabling environment for multidisciplinary team work, clinical audit and
research, recruitment and retention of specialist staff, and improvement in patient outcomes have
been outlined. However, more research is required to fully establish the cost effectiveness of the HEN
service especially in developing countries and to compare the organization of HEN service between
developing and developed countries.
Keywords: enteral tube feeding; community; global perspective; developing countries; developed
countries; home enteral nutrition
1. Introduction
This article aims to provide an overview of the worldwide perspective of home enteral tube
feeding (HETF) and outline some of the challenges of home enteral nutrition (HEN) provisions. Enteral
tube feeding is an effective method of providing nutrients for individuals who are unable to meet
their nutritional requirements in different healthcare settings across the world [1–3]. In a study by
Klek et al. [4] in Poland, implementation of HEN improved clinical outcomes and decreased health care
costs through weight gain in patients, reduced incidence of infectious complications and the number of
hospital admissions. In another study in Malawi, Brewster et al. [5] reported that routine tube-feeding
was associated with improved body weight gain in the treatment of kwashiorkor (protein deﬁciency).
A nutritional support team in Nigeria has used high calorie enteral feed in the management of protein
energy malnutrition in children [6]. On the other hand, HEN has been shown to improve the nutritional
status and quality of life in patients with advanced gastric cancer in China [7].
The use of HETF has become more common globally due to advances in technology, development
of percutaneous endoscopic gastrostomy (PEG) technique and governments’ policy of shifting
healthcare provisions from costly acute hospitals to community settings [8–11]. These have also
ensured that more individuals on enteral feeds now live in the community. In the UK, a 42.78%
increase over a 10-year period in patients receiving HEN has been reported [12], although there is
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evidence of a yearly increase (20%–25%) in the number of people on enteral feed [13]. According to
Moreno Villares [14], home enteral nutrition was developed after home parenteral nutrition, however,
it has grown rapidly in some countries. There are signiﬁcant international differences in prevalence
and growth rate of home enteral nutrition, in the organisation of nutritional support services, and in
ﬁnancial arrangements [15]. Although the incidence of HETF may be difﬁcult to determine, estimates
of 460 (United States) and 40 (Spain) patients per million inhabitants have been reported [14]. In most
countries around the world, neurological diseases, such as cerebrovascular accident, multiple sclerosis,
and cancer especially, head and neck cancer, are the most frequent indications for HETF [12,14].
In a previous study by Ojo [12] in the UK, 187 out of the 257 patients on HETF, representing 72.76%
were receiving enteral nutrition through percutaneous endoscopic gastrostomy. This value appears
similar in other parts of Europe, although this only occurs in 25% of cases in Spain [14].
Despite worldwide application of HETF, signiﬁcant differences remain between developed and
developing countries in terms of the challenges, especially with respect to funding, organisation,
infrastructure, procurement of feeds, pump, ancillary items, research and development, and
management of patients and related complications.
Organisation of Home Enteral Tube Feeding
Irrespective of the strategy for delivering HEN service, the procurement and supply of enteral
feeding pump, feed and ancillary items require an effective process in order to ensure a seamless
delivery and promotion of patients’ outcomes. This is essential because there should be continuity of
service provision and enteral nutrition management when patients are discharged home from hospital.
In the USA and UK, national standards require patients on HETF to be well trained, to have written
protocols for trouble-shooting and for undertaking routine procedures, and to have 24-h telephone
contacts in cases of emergency. While these have been developed in the US and UK, other countries
appear to have local standards [15].
Furthermore, in the USA, the role of companies in the supply and delivery of pumps, feed,
ancillary items, management of patients on HEN and associated complications is quite signiﬁcant
while in Europe, HEN is usually coordinated from regional or district hospitals [15]. Other approaches
to HEN in the USA have been outlined by Newton and Barnadas [3], who reported that home enteral
nutrition is often started without the usual resources of the hospital. In addition, dieticians working in
home care mostly assume primary role in patient care and management, and have to have knowledge
and expertise with the wide variety of enteral equipment and access devices.
In Poland, there is evidence that HEN includes complex monitoring by a nutrition support
team [4]. With respect to the UK, enteral feed, feeding accessories and pump are supplied to patients
in the community through different strategies and the management could be one or a combination of
the following; self care, carers, care home registered nurses, general practitioner (GP), Home enteral
feeding service provided by a dietician, community nursing service, Home care company and the
HEN team [16].
However, two of the most common methods of supplying patients with enteral feed, feeding
accessories and pump in the UK are Hospital Enteral Nutrition Service and Community or Home
Enteral Nutrition (HEN) Service.
Under the Hospital Enteral Nutrition service, the nutrition department or the nutrition team
based in hospital is responsible for the care and management of patients on HEN including the supply
of feed, feeding accessories and pump in hospital and home. The nutrition support team in hospital
often provides home visits or outpatient clinics and for those patients who have been discharged home
from hospital, the continued supply of feed and feeding accessories is usually by means of prescription
using the FP10 (prescription form) [16,17]. The delivery of the feeding pumps to HEN patients is often
through the community nursing. National Health Service (NHS) supplies organisations, or the receive
the equipment directly from the manufacturer and costs are charged back to the hospital budget [18].
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In contrast, the UK Community or Home Enteral Nutrition Service is usually multidisciplinary
team that consists of healthcare professionals and support staff who have diverse clinical qualiﬁcations,
skills, knowledge and experience [19]. These specialist healthcare professionals include the nutrition
nurse specialist, dietician, and speech and language therapist. One of the primary features of the
HEN service is that patients’ feeds are managed “off script” and therefore do not require the use
of FP10 [20]. The HEN service is the model of choice and requires a clear pathway between acute
and community care and other partners including companies in order to ensure an effective delivery
system [8,21,22]. In a study that compared hospital enteral nutrition and home enteral nutrition in
China, Wang et al. [23] reported that patients with intestinal ﬁstulae in the HEN group had shorter
hospital stay than patients in the hospital group. Furthermore, the cost of treatment was signiﬁcantly
lower and the quality of life signiﬁcantly improved in the HEN group compared with the Hospital
enteral nutrition group. In studies from a number of countries around the world reviewed by Majka et
al. [24], multiple intervention strategies were adopted in the management of enteral tube feeding.
Based on the above, the objective of this review is as follows;
• To explore the issues around home enteral tube feeding in providing nutritional support globally.
The research question is:
• Are there challenges in the use of home enteral tube feeding as a global strategy in nutritional
support provision?
2. Method
This review involved a literature search of articles on challenges of home enteral nutrition across
the globe. It included a general scoping of the databases, which found one systematic review on
international perspective on artiﬁcial nutritional support in the community published in 1995 by
Elia [15]. This review based its ﬁndings on evidence drawn from studies relating to both Home
parenteral and enteral nutrition. Since the publication, a number of other studies have been published
which form the basis for the current review.
The main data bases searched included EBSCO Host/Health Sciences Research databases
(encompassing Academic search premier, Medline, Psychology and Behavioural sciences collection,
PSYCINFO, SPORTDISCUSS and Cumulative Index to Nursing and Allied Literature (CINAHL) Plus,
PubMed and SwetsWise. The search terms included; challenges of enteral nutrition, challenges “and”
home enteral tube feeding, enteral nutrition “and” Europe, enteral nutrition “and” Africa, enteral
nutrition “and” South America, enteral nutrition “and” Asia, enteral nutrition “and” central America,
enteral nutrition “and” America, enteral nutrition “and” Australia.
2.1. Inclusion and Exclusion Criteria
Searches included articles published between 1995 and 2014 covering the areas of interest except,
one study that was published in 1988 and was included due to the limited studies published on
Africa. Only studies written in English language were included and those that did not meet the above
inclusion criteria were excluded from the current review.
2.2. Data Analysis
Based on the criteria outlined for exclusion and inclusion, eight studies on enteral nutrition
complications (Table 1) were selected. Seven studies on cost effectiveness of enteral nutrition (Table 2)
were also included although some of these studies were previously cited in Table 1. Most of these
studies were conducted in Europe, North America and Australia. While studies carried out in
developing countries in these aspects of enteral nutrition were limited, there were studies from around
the world that provided an overview of the challenges of enteral nutrition, which were included.
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3. Results
With respect to enteral nutrition complications, the results show that across the globe, the main
sources of enteral nutrition complications are due to stoma site infection, tube dislodgement, tube
blockage, tube leakage, diarrhoea, overgranulation, vomiting, and pneumonia (Table 1).
While formation of overgranulation tissue (67%) was the highest form of complication in
Canada [25], constipation (48%) was the highest in Ireland [26]. In Greece, inadvertent removal
of tube (45.1%) was highest and in Australia insertion site infection was 41% [27,28]. In Turkey, while
tube displacement was highest at 7.6%, wound infection was 3.3% [29]. Overgranulation of PEG site
was 26.7% compared with 6.7% for balloon gastrostomy site in the UK, while pneumonia was the most
frequent form of complication at 55.9% in Brazil [1,30].
With respect to the ﬁndings on the cost effectiveness of enteral nutrition, one study showed
variation in the daily overall costs of HEN from 7 to 25 Euros across Europe [31] (Table 2). On the other
hand, studies in Poland and the US showed signiﬁcant improvements in patient outcomes and cost of
hospitalisation following implementation of HEN and nutrition support clinic [4,32].
One study in the US revealed that HEN is signiﬁcantly cheaper compared with Home parenteral
nutrition [33]. The Australian study showed that inpatient cost of PEG patients was signiﬁcantly
more than for patients on nasogastric feeding tube (NGT) [28]. The UK study found that the cost
effectiveness of enteral tube feeding, where non-medical costs are paid privately, compares favourably
with other interventions, but it was not so when the state pays all non-medical costs [34]. The study
which compared the impact of home and hospital enteral nutrition in China found that the HEN group
had shorter hospital stay, signiﬁcant reduction in cost of treatment, improved quality of life although
no signiﬁcant difference in the incidence of complications [23].
4. Discussion
4.1. Challenges of Current Organisation of Home Enteral Tube Feeding
In developed countries of Europe and the USA, where organised HEN services exist, challenges in
the areas of funding, the number of HEN services, research and development, multidisciplinary team
working, managing the HEN service including problems with delivering enteral feed and accessories
and complications due to pump, feed and stoma site are often the main issues of concern [1,12,27,32,
35,36]. Details of these difﬁculties of the HEN service globally have been fully outlined in Table 1. For
example, in the UK, many National Health Service (NHS) Trusts do not have a HEN team and this will
limit their capacity for service improvement and delivery [19].
Funding is a major challenge in the management of HETF anywhere in the world and with the
on-going economic crisis inﬂuencing health care, its cost-effectiveness has been questioned [4]. British
Artiﬁcial Nutrition Survey (BANS) reports that 40% of centres have no budget allocated speciﬁcally for
enteral nutrition support [10].
According to Elia [15], the use of home enteral nutrition in different countries appears to be
generally related to the overall expenditure on health (government and private), and percentage of the
gross domestic product (GDP) expended on health. In Asian countries such as India and Pakistan, and
in many parts of Africa, where the ﬁgure is less than 4%–5% of the GDP, home enteral nutrition is not
common [15]. By contrast, in the USA where the GDP expended on health from private expenditure
alone was 11.7% in 1991, home enteral nutrition is used more than anywhere else in the world [15].
This is followed closely by Western European countries where expenditure on health is usually 6%–9%
of GDP although estimates from eastern European countries with limited information is likely to be
low [15]. For example, in the UK based hospital enteral nutrition service, the effective management of
feed, pump and ancillary items, and patients on HEN may be affected because there is no dedicated
team in the community to follow up in the care and maintenance of the service. Under this method,
the unit cost of feed is much higher because individual patient in the community rely on the use of
FP10 (prescription form) to procure their feed compared to when feeds and feeding accessories are
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purchased in larger quantities [18]. In addition, due to conﬂicting pressures dietetic support may not
be routinely available for patients on HETF, even on outpatient basis.
Although the community home enteral nutrition service purchases feed “off script” and thus can
save money from the bulk purchase of feeds, challenge of multidisciplinary team working can militate
against effective service delivery. For example, although the roles and responsibilities of the different
HCPs are distinct, there are areas of overlap, which may become sources of friction. The number of
different HCPs working within the HEN team who visit the patients regularly for assessment and
reviews can become blurry and confusing to the patients due to their number and different times of
visits [19].
Due to the specialist nature of the HEN service, recruitment and retention of qualiﬁed staff are
some of the difﬁculties providers have to address. Therefore, it is not uncommon to ﬁnd some HEN
services having developmental roles such as Nutrition Support Nurse, Nutrition Nurse Specialist
working alongside the Clinical Lead Nutrition Nurse Specialist [8].
Despite the worldwide recognition of HETF as a useful method of meeting the nutritional
requirements of patients and as a life-saving procedure, difﬁculties often arise during and post tube
insertion. These problems appear to the similar globally although the levels of prevalence may
vary [25,26,28–30,37] (Table 1).
Other possible challenges confronting the HEN service include the supply of feed, pump and
ancillary items. Evans et al. [38] reported that 20% of patients receiving HEN were not contacted until
seven days or more after discharge in the UK. In addition, 47% of patients did not receive a delivery
until seven or more days after discharge, while 41% reported missing equipment from their ﬁrst
delivery. In the same study, 17% of patients reported difﬁculty getting their GP to write a prescription.
Those patients whose deliveries were not organised directly with the home delivery company by
the hospital were more likely to have delayed delivery of seven or more days after discharge (63%
compared with 21% of those directly organised by regional hospital) [38].
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4.2. Cost Effectiveness of Home Enteral Nutrition
The cost effectiveness of home enteral nutrition may be assessed based on the service being
provided and strategies for delivering the service [28,31,32,34]. Details of the cost-effectiveness of the
HEN service are clearly outlined in Table 2. In a systematic review and meta-analysis of studies across
the world, Majka et al. [24] showed that 93.3% of the studies reviewed reported beneﬁcial effects in
terms of patients’ outcomes, staff outcomes and costs of care due to care coordination and/or team
approach. These views are related to the ﬁndings of the current review which show that the HEN
service provide signiﬁcant improvement in patients’ outcomes [4,23,33].
Patient outcomes may be based on mortality, quality of life scores, infections and hospital
admissions [28,31,32,34]. According to Majka et al. [24], the average hospital cost per patient was
reduced by $623.08. In another review conducted by Michael et al. [39] in the USA, it was reported
that the average savings from enteral nutrition due to reduced adverse event risks was about $1500
per patient and savings from reduced hospital length of stay was about $2500 per patient. It was
noted that shifting 10% of adult patients in the USA managed parenterally to enteral nutrition would
save $35 million annually due to reduced adverse events and another $57 million from shorter stays in
hospital [39].
Pritchard et al. [40] reported that observational non-randomised studies that compared groups
receiving parenteral and enteral nutrition found few differences in clinical outcomes between groups
but showed lower costs in enteral nutrition patients. For example, while in 19 US patients about to
have major abdominal surgery, mean daily costs for enteral nutrition were just under half the costs of
parenteral nutrition of about $100 pay, in 24 UK patients undergoing orthotopic liver transplantation,
there was a 10-fold difference (£7 per day compared with £75–85) [40].
Wilhelm et al. [41] carried out a theoretical cost analysis between inpatients and outpatients on
percutaneous endoscopic gastrostomy in the US. According to the authors, the actual outpatient charge
was $135 per patient compared to $1155 per patient for a theoretical admission. A potential cost savings
of $29,120 in 26 out-patient procedures and a projected average cost savings per patient of $1020 were
reported by Wilhelm et al. [41].
5. Strategies for Improving Home Enteral Tube Feeding
There is urgent need to develop the infrastructure for HEN service in developing countries in
Africa, Asia and South America in order to meet the needs of the patients who may require these
services. With respect to developed countries of Europe and North America, there is the need to
improve cooperation and communication between nurses in hospitals and in communities, as well
as for increasing nurses’ level of knowledge, to make home enteral tube feeding work in a safe
way [42]. In addition, the roles and responsibilities should be clariﬁed between the different healthcare
professionals who should also understand guidelines for the care of tube feeding and discharge
process [43–45]. There should also be clear pathways of referral and communication between acute,
community, companies and patients.
The establishment of national regulations and legislation (or even regional regulations within
a country) should be encouraged because they provide important advantages, including a uniform
distribution of specialist HEN services across the country and clear ﬁnancial guidelines, which should
ensure that appropriate standards for selection and management are attained ensuring that government
departments are fully aware of the issues involved [15].
In addition, it is essential to build trust between the different professions in the team, and support
colleagues to take on new roles that are not normally associated with their traditional roles [26,46]. As
part of the building of effective multidisciplinary HEN team, it will be useful to have regular training,
away days, caseload review meetings and a team charter in place.
Creating the enabling environment for HCPs working within the HEN service to conduct
research and clinical audits will no doubt provide the opportunity for service improvement and staff
development. The issue of inappropriate placements of enteral feeding tubes and/or overprescription
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of enteral feed and ancillary items could have far reaching implications in terms of costs to the health
service. A useful strategy could be to ensure appropriateness of indications of enteral nutrition
provisions and the range of feeding tubes and accessories.
6. Conclusions
Home enteral tube feeding is a useful method of supporting the nutritional needs of patients
in the community who are unable to meet their nutritional requirements through oral intake alone.
Although its use has been globally acclaimed, differences exist in home enteral nutrition provisions
across the world.
The factors militating against the effective delivery of HEN service include; funding, level of
organisation, lack of national and international standards and infrastructure, problems of procurement
of feeds, pump, ancillary items, research and development, and management of patients and associated
complications including tube and stoma complications.
In order to address these problems, there has to be development of national and international
standards, guidelines and policies for enteral nutrition provisions, increased awareness and funding
by government at all levels, development of HEN services that will provide the enabling environment
for multidisciplinary team work, clinical audit and research, recruitment and retention of specialist
staff, and improvement in patient outcomes. However, more research is needed to fully establish the
cost effectiveness of the HEN service especially in developing countries and to compare the prevalence
of complications, cost implications and organization between developed and developing countries.
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Abstract: An elevated serum phosphorus (P) has been anecdotally described in premature infants
receiving human milk fortiﬁed with donor human milk-derived fortiﬁer (HMDF). No studies have
prospectively investigated serum P in premature infants receiving this fortiﬁcation strategy. In this
single center prospective observational cohort study, extremely premature infants ≤1250 grams (g)
birth weight (BW) were fed an exclusive human milk-based diet receiving HMDF and serum P levels
were obtained. We evaluated 93 infants with a mean gestational age of 27.5 ± 2.0 weeks (Mean ±
SD) and BW of 904 ± 178 g. Seventeen infants (18.3%) had at least one high serum P level with
a mean serum P of 9.2 ± 1.1 mg/dL occurring at 19 ± 11 days of life. For all infants, the highest
serum P was inversely correlated to the day of life of the infant (p < 0.001, R2 = 0.175) and positively
correlated with energy density of HMDF (p = 0.035). Serum P was not signiﬁcantly related to gender,
BW, gestational age, or days to full feeds. We conclude that the incidence of hyperphosphatemia
was mild and transient in this population. The risk decreased with infant age and was unrelated to
gender, BW, or ethnicity.
Keywords: neonate; phosphorus; hyperphosphatemia; human milk; exclusive human milk-based
diet; human milk-derived fortiﬁer; prematurity; creatinine; donor milk; very low birth weight
1. Introduction
Human milk is the optimal source of nutrition for all infants, including preterm ones. The
American Academy of Pediatrics (AAP) recommends that all infants <1500 g birth weight (BW) should
receive human milk appropriately fortiﬁed [1]. An exclusive human-milk based diet is deﬁned as
mother’s own milk (or pasteurized donor milk when mother’s own milk is unavailable) fortiﬁed with a
donor human milk-derived fortiﬁer (HMDF), containing no preterm formula or cow milk protein-based
fortiﬁers. This approach provides advantages over cow milk-containing products providing optimal
growth rates, a lower rate of necrotizing enterocolitis, and decreased days of parenteral nutrition.
Additionally, such an approach leads to lowered sepsis rates, decreased mortality, and shorter hospital
stays [2–7].
Extremely premature infants are susceptible to growth failure, metabolic growth abnormalities,
and poor neurodevelopmental outcomes [5,8–11]. Common metabolic derangements of extremely
premature infants including hypocalcemia, hyperphosphatemia, and hypomagnesemia are usually
secondary to immature hormone responses and renal dysfunction [8]. There are no published reports
investigating the sequential early postnatal mineral serum chemistries of very low birth weight infants
receiving an exclusive human milk-based diet with HMDF. This study aimed to evaluate how an
exclusive human milk-based diet with HMDF can affect the risk of electrolyte abnormalities, speciﬁcally
serum phosphorus.
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There have been anecdotal reports of hyperphosphatemia associated with HMDF in extremely
low birth weight infants and some health care providers may be limiting their use of this product
because of this concern. Because of the potential beneﬁts of using an exclusive human milk-based diet,
but concern about phosphorus metabolism, we chose to evaluate the incidence of hyperphosphatemia,
hypophosphatemia and hypocalcemia in all infants <1250 g BW receiving this diet.
2. Experimental Section
Extremely premature infants were consecutively followed in this single-center prospective
observational cohort study from August 2010 to December 2011. Inclusion criteria were: premature
infants <37 weeks gestation, BW <1250 g, admitted within 48 h of birth, receiving an exclusive human
milk-based diet, and achievement of full enteral feedings by 4 weeks of age. Infants were excluded
who died within the ﬁrst week of life and those who had major congenital anomalies. Infants were
followed from birth until discharge and data were prospectively collected for growth and nutrition
using pre-study deﬁned variables and deﬁnitions [3].
As approved by the Institutional Review Board of Baylor College of Medicine and Afﬁliated
Hospitals, consent was waived for this observational study. Our primary outcome of this study was to
evaluate the metabolic derangements in phosphorus levels for infants receiving an exclusive human
milk-based diet with HMDF. Speciﬁcally, study outcomes included the number of phosphorus levels,
mean phosphorus level drawn per infant, mean peak phosphorus level, percentage of infants with
hyperphosphatemia (serum phosphorus > 8.0 mg/dL), percentage of infants with hypophosphatemia
(serum phosphorus < 4.8 mg/dL), the incidence of hyperphosphatemia in relationship to serum
creatinine, the incidence of hypocalcemia during hyperphosphatemia, and the day of life of peak
phosphorus levels.
2.1. Standardized Feeding Protocol
Infants received a standardized feeding protocol which has been previously published by our
group [3]. Human milk was fortiﬁed with HMDF Prolact +4, Prolact +6, Prolact +8, or Prolact +10
(Prolacta Bioscience, Industry, CA, USA) with ﬁnal energy concentrations of 24 kcal/oz, 26 kcal/oz,
28 kcal/oz, and 30 kcal/oz, respectively, based on expected human milk energy concentration of 20
kcal/oz. Each fortiﬁer adds 64 mg/dL of phosphorus and 122 mg/dL of calcium. This is comparable
to most cow milk protein-based human milk fortiﬁers with phosphorus contents ranging from 26
mg/dL to 67 mg/dL and calcium contents ranging from 38 mg/dL to 138 mg/dL [2,12].
2.2. Data Collection
Serum phosphorus levels were collected per unit protocol three days after stopping parenteral
nutrition and repeated one week later if serum phosphorus was >8.0 mg/dL. Further serum
phosphorus values were collected at the discretion of the attending clinician. The peak phosphorus
level (or single highest phosphorus level for one infant) was recorded along with the corresponding the
day of life, degree of calorie fortiﬁcation (energy density), and the number of days after discontinuation
of parenteral nutrition. All infants with serum phosphorus levels >8.0 mg/dL were assessed with a
serum creatinine, serum calcium, and serum alkaline phosphatase level within three days if available.
Normal and low serum phosphorus levels in all infants were collected with corresponding day of life.
Serum phosphorus levels were treated as one value if separated by less than 2 days.
Only serum phosphorus levels drawn during the use of the HMDF were used in this study.
Of infants with multiple serum phosphorus levels on record, the highest level was considered the
peak serum phosphorus level. Of infants with only one serum phosphorus level on record, that level
was used.
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2.3. Statistical Analyses
Relationships among variables were evaluated using general linear modeling in which
hyperphosphatemia was the primary outcome. Regression analysis was used to compare relationships
between peak serum phosphorus and day of life, energy density of HMDF, and days to achieve
full feeds. Additionally, comparisons between serum phosphorus and gender, BW, gestational age,
race, and >750 g or below 750 g BW were completed with univariate regression analysis. Statistical
signiﬁcance was deﬁned as p < 0.05. A t-test was performed to compare the serum phosphorus and
serum creatinine between an infant group within ﬁve days of discontinuation of parenteral nutrition
and a group ﬁve days after discontinuation of parenteral nutrition. Analyses were completed using
SPSS 22.0 (SPSS Inc., Chicago, IL, USA). All data are mean± standard deviation unless otherwise noted.
3. Results
Of 124 infants identiﬁed who initially met the inclusion criteria, 93 were included for the analysis.
(Figure 1). The demographics and outcomes are shown in Tables 1 and 2. In total, 356 serum
phosphorus values were drawn among the 93 infants. On average, serum phosphorus levels were
drawn 3.8 times per infant. Sixteen infants had only one serum phosphorus level checked, while 29
infants had serum phosphorus levels drawn over four times during their course (Table 3). Of 356
discrete levels during the use of HMDF, 291 (81%) serum phosphorus levels were within normal
limits. The mean peak serum phosphorus was 7.2 ± 1.3 mg/dL. One infant was excluded for extreme
hyperphosphatemia (serum phosphorus 17.8 mg/dL) at 48 days of life and was considered an outlier
secondary to developing an incarcerated hernia at that time. Two infants also had hypocalcemia at the
time of a high serum phosphorus level.
Figure 1. Infants receiving the exclusive human milk-based diet were prospectively followed.
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Table 1. Infant demographics and characteristics.
Demographics and Characteristics Cohort n = 93
Birth weight, g 904 ± 178 *
Gestational age, weeks 27.5 ± 2.0
Male gender, n (%) 47 (51)
Race, % Black/White/Hispanic/Other 36, 25, 22, 10
Number of days to full 140 mL/kg/day feeds 16.0 ± 4.0
Inborn, n (%) 53 (57)
Antenatal steroids, n (%) 67 (72)
* Mean ± SD.
Table 2. Outcomes.
Outcomes Cohort n = 93
Total serum phosphorus levels obtained 356
Mean number of serum phosphorus levels per infant 3.8 ± 2.5 *
Mean peak serum phosphorus level of all infants (mg/dL) 7.2 ± 1.3 *
Infants with high serum phosphorus (>8 mg/dL), n (%) 17 (18.3)
Total high serum phosphorus levels, n (%) 23 (7)
Infants with multiple high serum phosphorus levels, n (%) 5 (5)
Average high serum phosphorus level (mg/dL) 9.2 ± 1.1 *
Infants with low serum phosphorus (<4.8 mg/dL), n (%) 19 (20)
Total low serum phosphorus values (<4.8 mg/dL), n (%) 42 (13)
Infants with no serum phosphorus abnormalities, n (%) 64 (69)
Hypocalcemia occurring with high serum phosphorus level (serum
calcium < 7.0 mg/dL or ionized calcium < 1.0 mmol/L), n 2
* Mean ± SD.
Table 3. Number of serum phosphorus levels recorded while on human milk-derived fortiﬁer.
Number of Serum Phosphorus Levels Recorded
Per Infant
n = 356
Only 1 level 16
2–3 levels 36
>4 levels 29
>6 levels 11
In the cohort, 17 infants (18.3%) had at least one laboratory result indicating hyperphosphatemia.
Of these, ﬁve (5%) infants had more than one high level. Additionally, 19 (20%) infants had at least
one episode of hypophosphatemia. Sixty-four (69%) of infants had all normal serum phosphorus
levels. Of the infants with multiple high serum phosphorus levels, three infants had a serum creatinine
over 1.0 mg/dL. Four of these infants received interventions (Table 4).
Ten (43%) of the high serum phosphorus levels were found to be within ﬁve days of transitioning
off of parenteral nutrition. Eleven (45%) of the high serum phosphorus levels were associated with
normal creatinine levels of <1 mg/dL, and of these 9 (81%) were within ﬁve days of the transition
off of parenteral nutrition. Of the high serum phosphorus levels found ﬁve or more days after the
transition off parenteral nutrition (12, 52%), half were associated with creatinine levels >1 mg/dL
(Figure 2). Of the six high serum phosphorus levels associated with an elevated serum creatinine, the
mean number of days from the transition off parenteral nutrition was 10.5 ± 5.0 days (Table 5). This is
signiﬁcantly different than the 11 high serum phosphorus levels associated with a normal creatinine
found to be 4.9 ± 4.2 days from discontinuation of parenteral nutrition, p = 0.026.
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Table 4. Outcomes of infants with multiple high serum phosphorus levels.
Infant Serum Phosphorus Intervention Outcome Serum Creatininewithin 3 Days
Calorie Fortiﬁcation
(kcal/oz)
1
2 high values on day of
life (DOL) 18 and 24
(both 8.2 mg/dL)
None Serum phosphorusnormalized on DOL 31 None
DOL 18: +4
DOL 24: +8
2
3 high values on DOL 13,
14, 19 (9.6, 8.1, and
9.3 mg/dL)
Treated for sepsis, found
to have Klebsiella
bacteremia
Serum phosphorus
normalized on DOL 34
High creatinine 1.1 and
2.2 mg/dL, lowered
DOL 24 (0.89 mg/dL)
DOL 13: +6
DOL 14: +8
DOL 19: +10
3 2 high values on DOL 12,19 (8.4 and 10 mg/dL)
Worked up for sepsis.
Cultures negative
Serum phosphorus
normalized in
subsequent checks on
DOL 31, 52, 80
High creatinine 1.1
mg/dL lowered DOL 33
(0.55 mg/dL).
DOL 12: +6
DOL 19: +8
DOL 20: +10
4 2 high values on DOL 32,45 (8.6 and 10.0 mg/dL)
Stopped HMDF for 1
day, worked up for
sepsis
Serum phosphorus
normalized in on DOL
50
High creatinine 1.3
mg/dL, normalized 0.4
mg/dL on DOL 114 (on
formula)
DOL 32: +10
DOL 45: +10
5 2 high values on DOL 15,23 (11.8 and 10.5 mg/dL)
HMDF held 1 day, DOL
16. Infant received IV
calcium for
hypocalcemia
Serum phosphorus
normalized on DOL 20
and was normal on DOL
30 after resuming HDMF
Creatinine 0.74 and 0.91
mg/dL. Ionized calcium
0.84 mmol/L
DOL 15: +4
DOL 23: +10
Figure 2. Comparison of creatinine levels in early vs. late hyperphosphatemia.
Table 5. Comparison of serum creatinine and high serum phosphorus levels.
Serum Creatinine (± 3 Days of
High Serum Phosphorus Level)
Number of High Serum
Phosphorus Levels (n = 17)
Mean Days after Parenteral
Nutrition Discontinued
High (≥1 mg/dL) 6 10.5 ± 5.0 *
Normal (<1 mg/dL) 11 4.9 ± 4.2 *
* Signiﬁcant difference between groups p = 0.026.
The serum phosphorus levels were closely associated with the age (day of life) of the infant
(p < 0.001, R2 = 0.1746) (Figure 3a,b). The serum phosphorus levels were also signiﬁcantly correlated
to energy density concentration of HMDF used (p = 0.035). The number of days the infant needed to
achieve full feeds (140 mL/kg/day) and any intrinsic characteristics of the infant including gender,
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BW, gestational age, race, or ≥750 g or < 750 g BW were not signiﬁcantly associated with the risk
of hyperphosphatemia.
Of 23 high serum phosphorus levels, 12 (52%) had serum calcium values drawn within three
days. Ten of 12 levels were within normal limits. Two infants had laboratory evidence of hypocalcemia
deﬁned as < 7.0 mg/dL. One infant had a serum calcium level of 5.4 mg/dL and required a calcium
infusion with the calcium level subsequently normalizing the next day. This infant had a creatinine
level of 0.91 mg/dL and multiple high serum phosphorus levels. The other infant had a serum calcium
level of 6.6 mg/dL which resolved three days later without supplementation. Alkaline phosphatase
activity within 3 days was also recorded in 14 of the infants with high serum phosphorus levels and
was found mildly elevated at 495 ± 215 mg/dL.
Figure 3. (a) Peak phosphorus level declines with day of life; (b) All serum phosphorus levels
in 93 infants.
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Very limited interventions were used in the infants with high serum phosphorus. The infants
with multiple high serum phosphorus levels were more likely to receive interventions (Table 4) and
often associated with high energy fortiﬁcation (+8 and +10 kcal/oz). In four of the 17 infants with
hyperphosphatemia, a decrease in daily feeding volume was made or the HMDF was stopped brieﬂy
(<3 days). These interventions coincided with a patent ductus arteriosus ligation and a clinically
identiﬁed ileus associated with proven bloodstream infection for two infants. Most infants did not
receive interventions, and all evidence of hyperphosphatemia resolved.
4. Discussion
Among 93 infants receiving an exclusive human milk-based diet, all serum phosphorus levels
were analyzed with a focus on hyperphosphatemia. The average peak serum phosphorus level of
infants receiving HMDF was <8.0 mg/dL. All infants received rapid advancement of feedings and
increasingly high enteral phosphate loads.
Infants are susceptible to hypocalcemia and hypophosphatemia during prolonged parenteral
nutrition and are oftenweaned to oral feedings rapidly as treatment [12]. Preterm infants fed unfortiﬁed
mother’s milk early in life develop hypophosphatemia and elevated alkaline phosphatase levels
leading to rickets [12–16]. Supplementation may protect against hypophosphatemia as premature
infants have a limited body pool of phosphorus from their soft tissues risking demineralization
leading to fractures [12]. Both hypophosphatemia and hyperphosphatemia occurred at similar rates in
this study.
Seventeen (18%) infants in this study had hyperphosphatemia. The hyperphosphatemia was mild
and transient occurring mostly early in life after the discontinuation of parenteral nutrition with few
exceptions. In 17 infants with high serum phosphorus levels, 13 (76%) did not require intervention.
The four interventions were minor dietary changes (slowing, stopping feeds or HMDF) for a short
period of time. Two infants also had a patent ductus arteriosus ligation and clinically identiﬁed ileus
at the time of intervention.
Hyperphosphatemia largely occurred within ﬁve days from the discontinuation of parenteral
nutrition, at approximately 10–15 days of life. The risk of hyperphosphatemia decreased as the
infant aged. Several mechanisms could contribute to early peak serum phosphorus levels including
increasing feeding volumes, high absorption (bioavailability) of the phosphorus loads and suppression
of parathyroid function by calcium in parenteral nutrition [12]. Parathyroid hormone surges are
smaller in very low birth weight infants but function improves with postnatal age as nephrogenesis
continues through 34 weeks post-gestational age [8,17].
Hyperphosphatemia occurring more than ﬁve days after the discontinuation of parenteral
nutrition (late) was often associated with serum creatinine ≥1 mg/dL, possibly signifying renal
dysfunction and an inability to excrete ingested phosphorus [17,18]. Our study also found that the
higher energy density of HMDF was signiﬁcantly associated with hyperphosphatemia (p = 0.025).
Feeds were highly fortiﬁed (+8 kcal/oz or +10 kcal/oz) after evidencing poor weight gain on
full (140–150 mL/kg/day) feeds. Poor weight gain is an independent marker of underlying renal
dysfunction [18]. Renal function should be investigated in infants with late hyperphosphatemia.
Multiple high serum phosphorus levels were also a risk factor for intervention. One infant received
a calcium infusion secondary to hypocalcemia during an episode of hyperphosphatemia. Alkaline
phosphatase activity was mildly high on average, however it is a not a highly speciﬁc marker for bone
mineral defects in premature infants [12].
A limitation of this observational study was the non-randomized nature of this cohort. The
prospective nature of this study was its strength, investigating a large cohort of premature infants
that were only using an exclusive human milk-based diet, while analyzing serum phosphorus as
an outcome.
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5. Conclusions
An exclusive human milk-based diet provides phosphorus, supporting bone growth safely.
Hyperphosphatemia was seen early in life with interventions being minor. Hypophosphatemia
occurred with a similar frequency in this cohort. The risk of high serum phosphorus decreased with
infant age unrelated to gender, BW, or ethnicity. An interesting point of this study was the correlation
of high creatinine and late hyperphosphatemia. A clinician should be sensitive to serum phosphorus
as a herald to renal dysfunction in these infants. When interpreting these interventions, recall that
infants had comorbid renal dysfunction, sepsis, impending surgeries or a patent ductus arteriosus
and had enteral feeds discontinued for those reasons rather than to treat hyperphosphatemia. Special
consideration should be paid to electrolyte abnormalities when infants transition off of parenteral
nutrition or demonstrate multiple high serum phosphorus levels as underlying renal dysfunction or
rarely hypocalcemia may also be present. Monitoring serum phosphorus to assure a normalizing trend
for this subset of premature infants receiving HMDF is supported.
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Abstract: Pancreaticoduodenectomy (PD) is considered the gold standard treatment for
periampullory carcinomas. This procedure presents 30%–40% of morbidity. Patients who have
undergone pancreaticoduodenectomy often present perioperative malnutrition that is worse in the
early postoperative days, affects the process of healing, the intestinal barrier function and the number
of postoperative complications. Few studies focus on the relation between enteral nutrition (EN) and
postoperative complications. Our aim was to perform a review, including only randomized controlled
trial meta-analyses or well-designed studies, of evidence regarding the correlation between EN and
main complications and outcomes after pancreaticoduodenectomy, as delayed gastric emptying
(DGE), postoperative pancreatic ﬁstula (POPF), postpancreatectomy hemorrhage (PPH), length of
stay and infectious complications. Several studies, especially randomized controlled trial have shown
that EN does not increase the rate of DGE. EN appeared safe and tolerated for patients after PD, even
if it did not reveal any advantages in terms of POPF, PPH, length of stay and infectious complications.
Keywords: Enteral nutrition; pancreaticoduodenectomy; delayed gastric emptying; postoperative
pancreatic ﬁstula; postpancreatectomy hemorrhage
1. Introduction
Gastrointestinal surgery involving intestinal resection and anastomosis often requires a period
of starvation or “nil by mouth”, while new anastomosis heal. The aim of this strategy is
to allow time for intestinal motility to return to normal, and to protect anastomosis from the
stress of introducing oral ﬂuids and diet [1]. Hepatobiliary surgery is usually performed in
malnourished patients, and this condition if severe can be associated with a higher incidence of
complications [2,3]. Pancreaticoduodenectomy (PD) is considered the gold standard treatment for
periampullary carcinomas. This procedure is one of the most invasive operations in abdominal surgery
and postoperative morbidity ranges between 30% and 40% [4]. PD results in a loss of gastric pacemaker
and a partial pancreatic resection, and leads to a high incidence of postoperative malnutrition. The
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surgical trauma increases immune system suppression. The surgical injury as well as the malnutrition
can provide bad postoperative outcomes. The malnutrition is worse in the early postoperative
days, affects the process of healing, the intestinal barrier function and the incidence of postoperative
complications [5,6]. Perioperative nutrition supplements, including enteral nutrition (EN) and total
parental nutrition (TPN), have demonstrated to be effective in improving clinical outcomes and in
decreasing the incidence of postoperative complications in major abdominal surgery [7,8], repairing
immune function and reducing risk of sepsis, especially early EN [9,10].
Postoperative nutritional support can improve clinical outcome in patients underwent PD
resolving the malnutrition status of the patients. Early EN after PD can inﬂuence both the endocrine
and the exocrine function of the gland and can stimulate the pancreatic and bile secretion [11].
On the other hand, several studies reported different results and this is clear by reading the
current nutritional guidelines. The current guidelines of the European Society for Parenteral and
Enteral Nutrition recommend routine use of early enteral nutrition in patients undergoing major
gastrointestinal surgery for cancer, including PD [12]. In contrast, the current American Society for
Parenteral and Enteral Nutrition guidelines recommend postoperative nutritional support only in
patients who are unlikely to meet their nutrient needs orally for a period of 7–10 days, which is not
necessarily the case after PD [13]. Both of these guidelines are based on a few studies concerning
pancreatic cancer.
The aim of this review is to focus on speciﬁc evidence regarding the enteral feeding strategy and
the correlation between EN, main complications and outcomes after PD.
2. Enteral Nutrition and Outcomes after Pancreaticoduodenectomy
In 2006, Goonetilleke and Siriwardena published a systematic review regarding perioperative
nutritional support after PD. The Authors examined 10 studies, investigating nutritional support after
PD, and concluded favorably about EN, also showing that early mandatory, postoperative TPN was
not associated with improved outcomes. The review of the Authors also implied that administration
of postoperative EN helps to decrease infectious complications [14].
Further studies have been published after 2006, focusing on the relation between EN and
postoperative complications, like delayed gastric emptying (DGE), postoperative pancreatic ﬁstula
(POPF), postpancreatectomy hemorrhage (PPH), infectious complications or clinical outcome, such as
length of hospitalization.
2.1. Delayed Gastric Emptying (DGE)
Gastroparesis is one of the most important complications after PD, with a reported incidence
between 19% and 44% even in centers dedicated to pancreatic surgery [15,16].
According to the International Study Group of Pancreas Surgery (ISGPS), delayed gastric
emptying (DGE) is deﬁned as the need of a nasogastric tube (NGT) for >3 days or the need of
reinsert the NGT for persistent vomiting after surgery [17]. The ISGPS also classiﬁes the severity of
DGE as grade A: NGT required for 4–7 days or reinsertion after postoperative day (POD) 3 or inability
to tolerate solid oral intake by POD 7; grade B: NGT required for 8–14 days or inability to tolerate
solid oral intake by POD 14; grade C: NGT required for >14 days or inability to tolerate solid food by
POD 21 [17].
The pathophysiological mechanism contributing to the development of gastroparesis is unknown.
The mechanism is probably multifactorial. Likely factors involved in DGE after PD may be
the presence of pancreatic ﬁbrosis [18], intraperitoneal inﬂammation secondary to postoperative
complications [19,20], gastrointestinal reconstruction [21,22], removal of the duodenum [23] or
extended lymph node dissection [24,25]. Several authors suggest that DGE is also caused by gastric
denervation due to the loss of parasympathetic nerves, resulting in the reduction of peristalsis and
secretion of motilin [26]. Ligation of the right gastric and gastroduodenal arteries could be responsible
for pylorus and antrum ischemia contributing to postoperative pylorospasm in pylorus-preserving
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PD [27]. When gastroparesis occurs it is very difﬁcult to anticipate the need for nutritional support,
but feeding can be administrated directly to the jejunum [28].
Some studies reported no increase or even decrease in the incidence of gastroparesis after PD
with early EN [29]. Tien et al. performed a prospective randomized trial to test the effectiveness of
biliopancraetic diversion with modiﬁed Roux-en-Y gastrojejunostomy reconstruction and of EN to
minimize impacts of DGE after PD. In total 257 patients with periampullay tumors were randomized
and underwent PD. DGE occurred in 20 patients (16.3%) in the EN group and 27 patients (21.7%) in the
control group. Although statistical analysis revealed no difference (p = 0.27) in DGE between groups,
ISGPS grades of gastric stasis were signiﬁcantly lower in the modiﬁed group than in the control group
(p = 0.001) [30].
In another randomized controlled trial, Mack et al. reported the beneﬁt of gastric decompression
and enteral feeding through a double-lumen gastrojejunostomy tube. Prolonged gastroparesis occurred
in 4 controls (25%) and in none of the patients who had gastrojejunostomy (p = 0.03). In the author’s
experience, the insertion of this kind of tube was found to be safe and feasible [31]. Although operative
time was longer, no major problems occurred during tube insertion. Anyway, it is not clear if this
result was due to the tube itself or to the efﬁcacy of enteral nutrition.
In 2008 Grizas, comparing in a randomized controlled trial the effectiveness of the early enteral
and natural nutrition after PD, did not notice any statistically signiﬁcant difference in clinical or
radiological manifestation of DGE between the two groups [32].
A recent meta-analysis of randomized controlled trial has been conducted to evaluate the safety
and effectiveness of early enteral nutrition for patients after PD. Only four studies published in 2000 or
later have been included in the analysis, involving 246 patients who underwent EN and 238 patients
who underwent other nutritional routes. The rate of DGE in EN and other nutritional routes groups
after PD was 15.9% and 18.9% respectively. Meta-analysis showed no statistically signiﬁcant difference
in DGE between EN and other nutritional routes group (OR, 0.89; 95% CI, 0.36–2.18; p = 0.79) [11].
Therefore, early EN would be tolerable for patients after PD, without increased gastroparesis. These
results are in line with the previous studies regarding the effect of EN to DGE. However, this
meta-analysis presents some limitations, due to the lack of relevant information in the original works.
First of all, the deﬁnition of gastroparesis in the included studies was not always in according to DGE
deﬁnition of ISGPS; the kind of tube placed in the jejunum and used for EN differed in the studies; the
type of EN, cyclical or continuous, is important and it was not speciﬁed; van Berge Henegouwen et al.
performed a randomized trial showing that in patients undergoing pylorus-preserving PD, the use of
cyclical infusion of EN (stopped for 6 h overnight) had some advantages over continuous (24 h) EN [33].
Finally, the content of nutritional supplementation signiﬁcantly inﬂuences the outcome. Gianotti et al.,
performing randomized trial, reported that an enteral formula enriched with arginine, omega-3
fatty acids and RNA statistically reduced postoperative complications and length of hospitalization
compared to standard enteral nutrition or TPN [34]. In addition, one of the studies in the meta-analysis
did not report the nutritional route of the control group [31].
As reported, DGE is a multifactorial complication and still remains unclear which factors are
related to gastroparesis. DGE incidence has been shown to be closely associated with postoperative
pancreatic ﬁstula, hemorrhage and abdominal collection [19]. In the study of Rayar et al., protective
factors reducing DGE were reported to be EN (p = 0.047, OR = 0.56) as well as the patient’s age (p < 0.01,
OR = 1.01) and acute pancreatitis history prior to PD (p = 0.013, OR = 0.32) [35]. According to the
authors, potential mechanisms of EN may be the mechanical effects of the nasojejunal tube across the
anastomosis, which can stimulate the motility of the stomach and jejunum, or the stimulation of bowel
peristalsis by the input of nutritional liquids [35,36].
It is clear therefore that even if some authors reported in previous study that EN was associated
with a higher frequency of DGE [37], recent studies, especially randomized controlled trials, have
shown that EN does not increase the rate of DGE [30–32,34]. Further studies and well-designed trials
need to be conducted to demonstrate if EN is superior to early oral intake in preventing DGE after PD.
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2.2. Postoperative Pancreatic Fistula
Postoperative pancreatic ﬁstula (POPF) is another common complication in PD patients, with
rates up to 12% in specialized centers [38].
According to ISGPS deﬁnition, POPF is deﬁned as output via an operatively placed drain (or
a subsequently placed percutaneous drain) of any measurable volume of drain ﬂuid on or after
postoperative day 3, with an amylase content greater than three times the upper serum value [39].
Okabayashi et al. investigating 100 patients who underwent PD from 1999 to 2007, identiﬁed, as
independent parameter correlating with occurrence of POPF, not having early EN through the
jejunostomy catheter (p = 0.007) [40]. In the series, this ﬁnding indicates that early EN was associated
with a reduced incidence of ﬁstula. The same Author, in a previous study, compared the outcome
of patients underwent PD and were then either managed with early EN (starting on the day after
surgery) or late EN (starting 7–14 days after surgery). In that study, early EN was associated not only
with a decreased incidence of POPF, but also with sustained serum concentration of total protein and
albumin, maintenance of body mass index, early restoration of peripheral lymphocyte count, and a
shorter period of hospitalization [29].
In his retrospective study, Rayar did not detect any difference in the incidence of POPF between
patients received EN until total oral alimentation compared to patients who did not receive EN and
were orally fed after removing the nasogastric tube [35]. However, the incidence of POPF in control
group may have been underestimated because routine amylase dosage in abdominal drain has only
been performed since 2005.
Liu et al. observed a low rate of POPF in EN group compared to TPN group (p = 0.039). The
reason of this difference remains unclear and requires further studies, hopefully with a major number
of patients [41].
No difference in POPF rate has been reported in trials conducted comparing EN with other
nutritional routes [30–32,42,43], even if only two studies reported the use of ISGPS deﬁnition of
POPF [30,42]. Also, the meta-analysis of Shen, including POPF in intra-abdominal complication,
showed no signiﬁcant difference in intra-abdominal complications between EN and other nutritional
routes [11]. However, in these studies EN appeared safe and tolerated for the patients after PD, even if
it did not reveal any advantages in terms of POPF rate.
2.3. Postpancreatectomy Hemorrhage
Postpancreatectomy hemorrhage (PPH) is one of the most important complications after PD, with
a reported incidence between 1% and 8% even in centers specializing in pancreatic surgery [44].
In 2007, the International Study Group of Pancreatic Surgery (ISGPS) proposed a new classiﬁcation
system of PPH with the aims to allow a proper diagnosis and to evaluate the severity of the hemorrhage;
three different grades of PPH (grades A, B, and C) were deﬁned according to the time of onset, site of
bleeding, severity, and clinical impact [44]. As well known, PPH is also signiﬁcantly related to many
risk factors, such as POPF [45].
The retrospective study of Rayar reports a statistically signiﬁcant difference in the incidence of
PPH between the EN group and the control group (8% vs. 20%, respectively, p = 0.008). No signiﬁcant
differences were reported regarding grade and localization of the hemorrhage [35].
Concerning the protective factors for PPH, in 2011 Liu, comparing in randomized controlled trial
the effectiveness of early enteral vs. total parental nutrition after PD, noticed that the incidence of PPH
was signiﬁcantly reduced in the EN group (1 case vs. 9 cases, respectively, p = 0.021) [41]. However
the study was based on a small cohort (60 patients), and the inclusion criteria was so strict that most
patients were in relatively good health conditions.
The meta-analysis of Shen reported only the rate of intra-abdominal complications, including also
the PPH. Meta-analysis showed no statistically signiﬁcant difference in intra-abdominal complications
between EN and other nutritional routes (OR, 0.82; 95% CI, 0.53–1.26; p = 0.37) [11]. Due to the lack
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of relevant information in the original works, a subgroup analysis on PPH was not be performed;
moreover, only one study used ISGPS’s deﬁnition to grade hemorrhage [30].
Regarding the inﬂuence of EN on the incidence of PPH, more studies are required, involving
more patients and using the recommendations and the grades of ISGPS.
2.4. Length of Stay
One hundred and twenty-one patients with suspected operable upper gastrointestinal cancer
(including 54 esophageal, 38 gastric and 29 pancreatic neoplasms) were randomized to receive early
EN or control management (nil by mouth and IV ﬂuids) in a prospective multicentre randomized
controlled trial [43]. The results showed a clear advantage for EN in terms of length of stay (LOS) both
intention-to-treat and per-protocol analysis (16 days vs. 19 days, p = 0.023 and p = 0.011, respectively)
and there were no statistically signiﬁcant differences between the two groups for hospital readmission
after discharge. Even if it did not include only patients with pancreatic cancer, the importance of this
study is that it represents the ﬁrst adequately powered prospective randomized trial of early EN vs. “nil
by mouth” in patients undergoing upper gastrointestinal resectional surgery in the United Kingdom.
Regarding the use of EN after PD to reduce the LOS, while several retrospective studies did not
report any clear advantages compared to other nutritional route [35,46], Zhu et al. demonstrated
a lower LOS combining EN with parental nutrition compared to TPN postoperative regimen
(13.2 days vs. 16.8 days, p < 0.05) [47].
More evidence could be obtained from the meta-analysis of randomized controlled trial conducted
by Shen [11]. Only two trials provided information regarding postoperative hospital stay, involving 388
patients [30,34]. EN was not associated with a signiﬁcantly shorter LOS than other nutritional route
(p = 0.74). As we have reported, this meta-analysis presents some limits, ﬁrst of all, one of the two
trials examined was published in 2000 [34], and several improvements have been obtained from 2000
to the present days regarding the postoperative management after PD. In addition, the trial of Tien
included patients underwent biliopancreatic diversion with modiﬁed Roux-en-Y gastrojejunostomy
reconstruction, so it is difﬁcult to establish if the results are due to the modiﬁed surgical procedure or
to the EN [30].
In a randomized controlled trial by Mack et al., LOS was reduced by routine double-lumen
gastrojejunostomy tube feeding compared to “standard care” (11.5 days vs. 15.8 days respectively,
p = 0.01). However, it was not speciﬁed what the “standard care” meant, in fact patients in the control
group were treated in according to the operating surgeon’s routine, including insertion of nasogastric
tube and administration of nutritional support if the surgeon felt it was indicated, and the route of
administration was also dictated by the surgeon’s routine practice [31]. It remains unclear how the
results seen in the study were secondary to the tube itself or to the effects of EN. Furthermore, this
study appeared to be underpowered (only 36 patients enrolled) to demonstrate improvements in
outcomes typically studied in enteral feeding trial.
In the systematic review of Gerritsen et al., including 15 studies of different feeding route after
PD (7 randomized trials, 7 cohort studies and 1 case-control study), mean length of hospital stay was
shorter in the oral diet and gastrojejunostomy tube groups, both at 15 days, followed by 19 days in
jejunostomy tube, 20 days in the TPN and 25 days in the nasojejunal tube groups [48].
Several large studies found good results with a normal oral diet (without routine nutritional
support) after PD. Yermilov et al. reviewed the California Cancer Registry (1194–2003) for outcomes
of 1873 patients who underwent PD for adenocarcinoma receiving either parental feeding (14%),
jejunostomy tube feeding (23%) or an oral diet without supplemental nutritional support (63%). They
showed a signiﬁcantly shorter LOS in the normal diet cohort [49].
A recent review suggested that implementation of a fast-track protocol, including early oral
feeding, in pancreatic surgery could lead to reduce LOS and reduced costs without an increase in
morbidity, mortality or readmission rates [50].
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Future randomized studies should compare outcomes of a routine oral diet (with on demand
nasojejunal feeding) with routine nasojejunal feeding after PD.
2.5. Infectious Complications
Several studies reported that the use of EN reduced the risk of infections. A meta-analysis by
Braunschweig et al., combining 27 randomized controlled trials (n = 1828), found a signiﬁcantly lower
risk of infections with enteral nutrition (RR = 0.64) compared to parental feeding. [51].
A systematic review and meta-analysis of randomized controlled trials comparing any type
of enteral feeding started within 24 h after surgery with nil by mouth management in elective
gastrointestinal surgery showed that early EN reduced the risk of any type of infection (relative
risk 0.72, 95% conﬁdence interval 0.54 to 0.98, p = 0.036) [52].
In the prospective randomized controlled trial by Barlow et al. of early EN vs. “nil by mouth”
in patients undergoing upper gastrointestinal resectional surgery, operative morbidity was less
common after early EN compared to control management (nil by mouth and IV ﬂuids) (32.8% vs. 50.9
respectively, p = 0.044). In particular the study showed a signiﬁcantly difference in the rate of wound
and chest infections (p = 0.017 and p = 0.036, respectively) [43].
Even if these data suggest that the use of EN presents some advantages in terms of reduction of
infectious complications, these studies did not include patients underwent only PD. Regarding the
use of EN after PD, only two trials revealed advantages in terms of infectious complications [32,34].
Gianotti et al. performing randomized trial, reported that an enteral formula enriched with arginine,
omega-3 fatty acids and RNA reduced statistically the infectious complications compared to TPN
(8.4% vs. 22.1% respectively, p = 0.04) [34]. As well Grizas, comparing the effectiveness of the early
enteral and natural nutrition regimen (from liquid to solid diet in the ﬁrst ﬁve postoperative days) after
PD, noticed a higher rate of postoperative complications in the natural nutrition group (53.3% vs. 23.3%
respectively, p = 0.03) with an odds ratio of 3.8. This difference seems to occur due to higher incidence
of infectious complications in the natural nutrition group (46.7% vs. 16.7% respectively, p = 0.025), with
an odds ratio of 4.4 [32].
Hypothesis that EN is beneﬁcial in reducing infectious complications is supported by the evidence
that modiﬁcations in the mucosal defense have been implicated as important factors affecting infectious
complications in critically ill patients [53]. EN inﬂuences the ability of gut-associated lymphoid tissue
to maintain mucosal immunity. Both route and type of nutrition inﬂuence antibacterial respiratory
tract immunity [54].
Despite these data, the recent meta-analysis of a randomized controlled trial by Shen et al. showed
no signiﬁcant difference in infections between early EN and other nutritional routes after PD [11].
Further and more powerful trials are probably required to understand the real beneﬁt of EN in
the reduction of infectious complications.
3. Conclusions
This review summarized the available evidence on early EN after PD, which appears to be safe
and tolerated in patients but does not have clear advantages reducing DGE, POPF, PPH, infectious
complications and LOS. Future large-scale, high-quality, multicenter trials are still required to clarify
the role of early EN after PD.
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Abstract: We examined esophageal cancer patients who received enteral nutrition (EN) to evaluate
the validity of early EN compared to delayed EN, and to determine the appropriate time to start EN.
A total of 208 esophagectomy patients who received EN postoperatively were divided into three
groups (Group 1, 2 and 3) based on whether they received EN within 48 h, 48 h–72 h or more than 72 h,
respectively. The postoperative complications, length of hospital stay (LOH), days for ﬁrst fecal
passage, cost of hospitalization, and the difference in serum albumin values between pre-operation
and post-operation were all recorded. The statistical analyses were performed using the t-test, the
Mann-Whitney U test and the chi square test. Statistical signiﬁcance was deﬁned as p < 0.05. Group 1
had the lowest thoracic drainage volume, the earliest ﬁrst fecal passage, and the lowest LOH and
hospitalization expenses of the three groups. The incidence of pneumonia was by far the highest
in Group 3 (p = 0.019). Finally, all the postoperative outcomes of nutritional conditions were the
worst by a signiﬁcant margin in Group 3. It is therefore safe and valid to start early enteral nutrition
within 48 h for postoperative esophageal cancer patients.
Keywords: early enteral nutrition; delayed enteral nutrition; esophageal cancer;
postoperative complication
1. Introduction
Esophageal cancer is one of the common malignant tumors in the upper digestive system, which
is currently listed as the world’s ninth most serious malignant disease [1–3]. Although curative
surgery, radiotherapy and chemotherapy improve survival, the ﬁve-year survival rate of patients
with esophageal cancer is still less than 50% [4]. Factors, such as preoperative diet restrictions,
difﬁculty swallowing and the highly invasive nature of the treatment, cause patients to be prone to
malnutrition after esophagectomy [5,6]. During the period that patients cannot take enough food orally,
nutrient support plays an important role [7–10]. Nutrition support can be divided into parenteral
nutrition and enteral nutrition. As complications of parenteral nutrition are more serious than those of
enteral nutrition [11], thoracic surgery doctors use enteral nutrition as the main method of nutrition
support. Past studies show that compared with those administered total parental nutrition, early
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postoperative total enteral nutrition (TEN) in high-risk surgical patients could reduce septic morbidity
rates (TPN) [12–15]. Another study indicated that initiating enteral nutrition (EN) within 24 h had
no advantage for the postoperative course of the patients with esophageal cancer compared with
starting EN at 24–72 h [16]. For early enteral nutrition, opinions vary widely on the extent to which
enteral nutrition should begin early. The term “early” was deﬁned as EN started within three days
after surgery [17]; however, more recently, “early” has been deﬁned as EN started within 48 or
24 h after surgery [18]. The validity and safety of early EN after esophagectomy has remained
controversial [7,16,19]. The aim of the present study is to verify the effectiveness and safety of early
EN for the postoperative course and to determine an appropriate time to start enteral nutrition.
2. Patients and Methods
2.1. Patient Selection
Study subjects were selected from patients with esophageal cancer who were admitted for
thoracic surgery in the Shandong provincial hospital, afﬁliated with Shandong University, between
January 2013 and October 2014. The study protocol was approved by the Shandong university school
of nursing science research project ethics committee (approval number 2012796). Esophageal cancer
was diagnosed by gastroscopy. Patients suffering from diabetes or underlying cardiopulmonary
diseases, whose body weight loss was more than 10% of the original, were excluded. All patients
included in the study did not receive preoperative chemoradiotherapy. Moreover, the patients whose
tumor staging was Stage IV (the cancer had spread to other parts of the body) were also excluded
because they had lost the chance for curative surgery [20]. All patients received thoracotomy and
extensive lymph node dissection during surgery. More speciﬁcally, the dissected lymph node included
groups 2, 4, 7, 8, 9, 10 on the right side and groups 5, 6, 7, 8, 9, 10 on the left side. Mediastinal lymph
node grouping was established according to the International Association for the Study of Lung
Cancer (IASLC2009). A total of 208 patients were enrolled in the study. A total of 101 patients in the
eastward department of thoracic surgery who received postoperative enteral nutrition within 48 h were
included in Group 1. A total of 87 patients in the westward department who received postoperative
enteral nutrition within 48–72 h were included in Group 2. For the patients of the two wards, who
received early EN and who received very early EN was randomly determined. Twenty patients were
included in Group 3 who suffered diarrhea, vomiting or had other adverse reactions after receiving
early postoperative enteral nutrition who received enteral nutrition after 72 h.
2.2. Methods
The postoperative patients were given peripheral intravenous nutrition support before EN. Then
the Enteral Nutritional Emulsion (TPF-T) (500 mL bag−1) made by Sino-Swed Pharmaceutical Corp.
Ltd was used as the nutrition solution for enteral nutrition. The TPF-T was given by nutrition pump
uniformly at the same temperature and speed through a nasojejunal tube, which was placed in the
jejunum during the operation. The Fat Emulsion, Amino Acids (17) and Glucose (1%) Injection (1440
mL bag−1) made by Sino-Swed Pharmaceutical Corp. Ltd was used as the parenteral nutrition injected
by central venous indwelling catheter.
The day before received enteral nutrition, patients were given 150–200 mL 5% glucose and sodium
chloride pumping at a speed of 20–25 mL h−1. At the same time, researchers observed the reaction of
the patients. If there were no adverse reactions, such as abdominal distention, nausea, or vomiting,
the nutrient solution would be started the next day. The total daily calories for all the patients should
reach 125.52 kJ (30 kcal) kg−1 [21], and insufﬁcient energy would be supplied by parenteral nutrition.
On the ﬁrst day of EN, the patients would be given a total of 500 mL nutrient solution, at a speed
of 20–25 mL h−1. The EN dose was increased 500 mL every 24 h if there were no problems related
to EN, and reached a maximum dose of 1500 mL every day. The patients (Group 3) who could
not tolerate early enteral nutrition were given postoperative enteral nutrition after 72 h. Peripheral
120
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intravenous infusions of 5% glucose with electrolyte solutions were also performed to supply water
and electrolytes in the three groups. EN continued until the anastomotic healing was conﬁrmed by
upper gastrointestinal barium, which would usually be done on the seventh postoperative day [22]. If
one developed anastomotic leakage, the amount of time the patient received EN would be extended.
2.3. Clinical Assessment
Clinical factors included age, sex, tumor stage according to the tumor-node-metastasis
classiﬁcation of the International Union against Cancer (7th edition) [20], pathological type, tumor
location, surgical stress expressed by operation time (min) and blood loss during surgery (mL).
Length of hospital stay (LOH), bowel movement recovery expressed as days for ﬁrst fecal passage,
cost of hospitalization, thoracic drainage volume(mL) were also recorded. The difference of
albumin (g L−1) (Δalbumin), total protein (g L−1) (Δtotal protein) and absolute value of lymphocyte
(×109 L−1) (Δlymphocyte) between postoperative day 3 and pre-operation, and the difference in
weight (Δ’ weight), albumin (g L−1) (Δ’ albumin), total protein (g L−1) (Δ’ total protein) and
absolute value of lymphocytes (×109 L−1) (Δ’ lymphocyte) between postoperative day 7 and
pre-operation were important outcome indicators. Postoperative complications including infectious
and noninfectious complications and mortality were also recorded. The infectious complications
were those accompanying infections, such as pneumonia or wound infection, and the non-infectious
complications were those such as anastomotic ﬁstula or arrhythmia.
2.4. Statistical Analysis
The statistical analyses were performed using the Mann-Whitney U test and adjusted chi-square
test. The exact chi-square test was also used if individual cell size was less than 5 counts. The statistical
signiﬁcance was deﬁned as p < 0.05. The quantitative data of normality underwent variance analysis
and the quantitative data that did not meet normality criteria were analyzed using the rank sum test.
Qualitative data were analyzed using the chi-square test. When multiple comparisons were needed,
the rank sum test and the chi-square test inspection levels would correct to 0.0125 (0.05/4 = 0.0125) [23].
3. Results
3.1. Pre- and Peri-Operative Clinical Features
Among the 208 patients, 101 patients were categorized into Group 1, 87 patients were categorized
into Group 2 and 20 patients were categorized into Group 3. There was no signiﬁcant difference in
mean age, sex, tumor stage, pathological type, tumor location, surgical stress expressed by operation
time and blood loss, preoperative nutritional conditions expressed by body weight, or serum total
protein values among the three groups. However, serum albumin values were signiﬁcantly lower in
Group 2 of the three groups (p = 0.001). Preoperative immune conditions expressed by the absolute
value of lymphocyte were also comparable among the groups (Table 1).
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Table 1. Pre- and peri-operative clinical features among the three groups.
Group1 (n = 101) Group2 (n = 87) Group3 (n = 20) p value (One-way ANOVA)
Age (years) a 58.6 ± 7.5 59.5 ± 8.4 60.3 ± 9.7 0.602
Body weight (kg) a 65.2 ± 9.9 64.5 ± 10.4 64.7 ± 6.3 0.89
Operative time (min) a 212.7 ± 27.2 204.8 ± 20.0 213.3 ± 34.7 0.083
Blood loss (mL )a 213.6 ± 21.9 206.7 ± 17.9 214.5 ± 26.7 0.055
Albumin (g L−1) a 42.3 ± 4.7 40.6 ± 3.7 44.2 ± 3.4 0.001
Total protein (g L−1) a 69.6 ± 5.4 68.0 ± 5.0 69.9 ± 4.9 0.086
Absolute value of
lymphocyte (×109 L−1) a
1.89 ± 0.51 1.85 ± 0.48 1.86 ± 0.32 0.808
p value (Chi square test)
Sex 0.509
Male 90 77 16
Female 11 10 4
Stage 0.998
0~IIB 60 52 12
III 41 35 8
Pathological type 0.125
Adenocarcinoma 4 0 1
squamous carcinoma 97 87 19
Group1 (n = 101) Group2 (n = 87) Group3 (n = 20) p value (Chi square test)
Tumor location 0.173
upper thoracic portion 30 23 2
mid-thoracic portion 36 42 10
lower thoracic portion 35 22 8
a Data and mean ± standard deviation.
3.2. Postoperative Complications and Mortality
Postoperative complications were observed in 116 patients (55.77%) and there was a signiﬁcant
difference in whole complications among the three groups (p = 0.01). Using a partition of the chi-square
method to do multiple comparisons, the result showed that there was a signiﬁcant difference between
Group 1 and Group 3 (p = 0.006 < 0.0125). Furthermore, postoperative complications were categorized
into two groups: infectious and non-infectious. There was signiﬁcant difference in the frequency of
infectious complications; they were observed most frequently in Group 3 (p = 0.008). The frequency of
pneumonia observed in the present study was signiﬁcantly higher in Group 3 out of the three groups
(p = 0.019). Using a partition of the chi-square method to do multiple comparisons, we found that
the difference was rooted in Group 1 and Group 3 (infectious: p = 0.003 < 0.0125; pneumonia: p =
0.008 < 0.0125). On the other hand, there was no signiﬁcant difference in non-infectious complications,
including anastomotic ﬁstula (p = 0.801) and arrhythmia(p = 0.353). Perioperative death was observed
in only one patient in Group 3. The mortality among the three groups was comparable (p = 0.096)
(Tables 2 and 3).
Table 2. Postoperative complications and mortality.
Group1 (n = 101) Group2 (n = 87) Group3 (n = 20) p value
Postoperative complications 47 53 16 0.01
Infectious 39 44 15 0.008
Pneumonia 38 43 14 0.019
Wound infection 2 1 1 0.527
Non-infectious 11 15 4 0.353
Anastomotic ﬁstula 6 6 2 0.801
Arrhythmia 5 9 2 0.353
Mortality 0 0 1 0.096
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Table 3. Multiple comparison among groups (p value).
Pneumonia (p value) Infectious (p value) Postoperativecomplications (p value)
Group1 Group2 0.103 0.1 0.049
Group3 0.008 0.003 0.006
Group2 Group3 0.096 0.048 0.108
α’= 0.05/4 = 0.0125.
3.3. Postoperative Outcomes Among Group1, Group2 and Group3
There was a signiﬁcant difference in the indicators of nutritional conditions including Δ’ weight,
Δalbumin, Δtotal protein, Δ’ albumin, and Δ’ total protein among the three groups (Table 4). The
results of further multiple comparisons showed that all the outcomes of nutritional conditions were
the highest in Group 3 of the three groups and there was no signiﬁcant difference between Group 1
and Group 2 except Δ’ albumin (5.79 vs. 7.62; p = 0.01 ) (Table 5). Δlymphocyte and Δ’ lymphocyte that
showed the immune conditions of three groups were comparable (p = 0.245; p = 0.744). There was a
signiﬁcant difference among the three groups in thoracic drainage volume (p = 0.004). The results of
further multiple comparisons indicated that the thoracic drainage volume in Group 1 was the lowest
of the three groups (Group 1 vs. Group 2, p = 0.008; Group 1 vs. Group 3, p = 0.009). However, the
volumes in Group 2 and Group 3 were comparable (p = 0.195). The ﬁrst fecal passage was observed
the earliest in Group 1 and latest in Group 3. LOH and hospitalization expenses were the lowest in
Group 1 and the highest in Group 3.
Table 4. Postoperative outcomes among 3 groups.
Group 1 Group 2 Group 3 p value
Δ’ weight (kg) b 1 ± 2 1 ± 3 5 ± 3 0.000
Thoracic drainage volume (mL) b 680 ± 562.5 920 ± 571.25 1065 ± 737.5 0.004
First fecal passage (day) a 4.03 ± 0.71 4.93 ± 0.85 6.5 ± 0.95 0.000
LOH (day) a 20.82 ± 3.91 23.85 ± 7.80 26.80 ± 5.11 0.000
Hospitalization expenses (yuan) a 48,658.71 ± 4823.95 63,218.60 ± 16299.913 76972 ± 7132.38 0.000
Δalbumin (g L−1) a 9.88 ± 5.01 10.30 ± 4.54 13.75 ± 5.36 0.006
Δtotal protein (g L−1) a 13.01 ± 6.05 14.55 ± 6.62 19.46 ± 8.70 0.000
Δlymphocyte (×109 L−1) a 1.02 ± 0.44 0.99 ± 0.45 0.83 ± 0.35 0.245
Δ’ albumin (g L−1) a 5.79 ± 4.77 7.62 ± 5.05 10.74 ± 4.32 0.000
Δ’ total protein (g L−1) a 6.44 ± 6.04 7.05 ± 6.93 10.72 ± 6.11 0.027
Δ’ lymphocyte (×109 L−1) a 0.50 ± 0.47 0.53 ± 0.46 0.57 ± 0.34 0.744
a Data and mean ± standard deviation; b Median ± range interquartile; Δ: the difference between day 3 and
pre-operation; Δ’: the difference between day 7 and pre-operation; LOH: length of hospital stay.
4. Discussion
As the results showed in the baseline level of patients, aside from the preoperative albumin levels
among the groups having a signiﬁcant difference (P = 0.001, Group 1 = 42.3g L−1, Group 2 = 40.6 g L−1,
Group 3 = 44.2 g L−1), there was no signiﬁcant difference in the general situation of the patients, such
as age, gender, pathological type, tumor location, tumor staging and the indexes reﬂecting the immune
condition of nutrition. Surgical stress expressed by operation time and blood loss was also comparable
among the three groups. However, the present study was a quasi-experimental research, and the
differences before and after the operation were the key point rather than the absolute values. Therefore,
the inﬂuence of the inconsistency of preoperative baseline levels on the results was small.
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Table 5. The results of the multiple comparison (p value).
Δweight (kg) Thoracic drainagevolume (mL)
First fecal passage
(day) LOH (day)
Hospitalization
expenses (yuan)
Group1 Group2 0.483 0.008 0.000 0.001 0.000
Group3 0.000 0.009 0.000 0.000 0.000
Group2 Group3 0.000 0.195 0.000 0.047 0.000
Δ albumin (g L−1) Δtotal protein (g L−1) Δ’ albumin (g L−1) Δ’ total protein (g L−1) –
Group1 Group2 0.562 0.113 0.01 0.522 –
Group3 0.001 0.000 0.000 0.007 –
Group2 Group3 0.005 0.003 0.01 0.022 –
α’ = 0.05/4 = 0.0125.
The postoperative complications included pulmonary infection (45.67%), incision infection
(1.92%), anastomotic ﬁstula (6.73%) and arrhythmia (7.69%). Atrial ﬁbrillation was the most common
arrhythmia. There was a signiﬁcant difference among the groups in terms of pulmonary infection
(p = 0.019 < 0.05), and the multiple comparison showed that statistical differences existed between
Group 1 and Group 3 (p = 0.008 < 0.0125, Group 1 = 80.85%, Group 3 = 87.5%). There was no signiﬁcant
difference among groups in the other three kinds of complications. The results were inconsistent with
those of Kazuaki Kobayashi et al. [7]. In the research of Kazuaki Kobayashi, there was only a difference
in the incidence of anastomotic dehiscence (p < 0.01, Group E = 33.33%; Group L = 9.84%) between the
two groups and the incidence of pulmonary infection did not differ between the two groups (p > 0.05,
Group E = 16.67%; Group L = 16.39%). The author gave the following explanation: “A possible
explanation for this was that the patients in Group E received damage by preoperative chemotherapy,
which was more frequently observed in Group E compared with Group L. The damage to cell recycling,
vascularization, and tissue regeneration may affect the anastomotic failure, which was more frequent
in Group E.” The patients in this study did not receive preoperative systemic chemotherapy and
radiotherapy, so there was no difference in this aspect among the groups. Inconsistent results for the
incidence of pulmonary infection of the two studies may be associated with the different grouping of
the two studies. In Kazuaki Kobayashi’s study, the patients were divided into two groups: Group E
contained the patients who received EN by postoperative day 3, and Group L contained the patients
who received EN after postoperative day 3. However, the present study included three groups:
postoperative EN started within 48 h, 48–72 h or after 72 h. The difference of the incidence of the
pulmonary infection among the groups existed between Group 1 (within 48 h) and Group 3 (after 72 h).
In other words, the incidence of the pulmonary infection of Group 1 was greater than that of Group 3.
Consequently, the earlier enteral nutrition began, the lower the incidence of pulmonary infection
would be. Moreover, decrease of incidence of pulmonary infection could not only reduce the use
of antibiotics after operation, but could also shorten the duration of hospitalization and reduce its
cost [24].
Beyond that, there were signiﬁcant differences in the indicators of nutritional conditions including
deviations in weight, albumin and total protein preoperatively and postoperatively among the three
groups. The results of further multiple comparisons showed that statistical differences existed between
Group 1 and Group 3 as well as Group 2 and Group 3, but no signiﬁcant difference existed between
Group 1 and Group 2 in all the outcomes of nutritional conditions except the difference in serum
albumin values between day 7 and pre-operation (Δ’ albumin). In other words, the results of the two
early enteral nutrition groups (Group 1 and Group 2) were better than the delayed enteral nutrition
group (Group 3), but there was no signiﬁcant difference between the two early enteral nutrition
groups. A possible explanation for this is as follows: (1) For the outcomes used to describe the
difference between day 3 and pre-operation, comparison among the three groups was equivalent to
the comparison between enteral nutrition and parenteral nutrition because the patients of Group 3
received parenteral nutrition within three days after the operation. Parenteral nutrition simply led to
the recovery of patients of Group 3 slower than that of patients of Group 1 and Group 2 [9]. (2) For the
outcomes used to describe the difference between day 7 and pre-operation, the nutritional status of the
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patients in Group 3 was still worse than the patients in Group 1 and Group 2 due to the delayed start
time of enteral nutrition. (3) Considering difference in the start time of enteral nutrition for Group 1
and Group 2 was only about 24 h, the indicators of nutritional conditions were not very sensitive.
Consequently, there was no signiﬁcant difference between Group 1 and Group 2. Moreover, the results
of further multiple comparisons of ﬁrst fecal passage, LOH and hospitalization expenses showed
that there was signiﬁcant difference in the any two groups of the three groups. More speciﬁcally, the
results of Group 1 were the best of the three groups: the time for ﬁrst fecal passage was the earliest,
LOH was the shortest and the hospitalization expenses were the lowest. Group 2 ranked second and
Group 3 ranked the last. Thus, it could be seen that the earlier enteral nutrition started, the faster
gastrointestinal function recovered. Moreover, one of the factors affecting hospitalization expenses was
hospitalization time. The longer the length of time, the higher the expenses, so there was an inherent
relationship between the two outcomes.
In summary, if the patients can adapt well, enteral nutrition should be started within 48 h after the
operation. There are three reasons for this: (1) Although there was no signiﬁcant difference between
Group 1 and Group 2 in the indicators of nutritional conditions, the time for ﬁrst fecal passage was
earlier in Group 1, which showed that early enteral nutrition could promote intestinal function recovery.
As the view that as long as intestines are functioning, we should use enteral nutrition has become
popular in China, we should start enteral nutrition as early as possible. (2) Considering the economic
perspective, the cost of enteral nutrition liquid was less than the parenteral nutrition solution, so enteral
nutrition should be started as early as possible in order to reduce the economic burden of patients. (3)
The safety coefﬁcient of parenteral nutrition is lower than that of enteral nutrition. Parenteral nutrition
easily leads to long-term catheter infection, high nutritional and metabolic disorders and respiratory
and intestinal complications for patients [11]. Therefore, considering patient safety, enteral nutrition
should be started as early as possible.
Finally, under the conditions of clinical work, the present study was a quasi-experiment. Grouping
was not random, so it might have led to the occurrence of bias. Especially, non randomisation of
the subjects in Group 3 may affect the validity of the results. It was suggested that the experimental
design of future research should be improved. Randomized controlled trials of large samples and
multicenter studies are needed to provide reliable evidence for implementing early enteral nutrition
safely and effectively.
5. Conclusions
Early enteral nutrition within 48 h is safe and valid for postoperative esophageal cancer
patients and has advantages in reducing the incidence of postoperative pulmonary infection,
improving postoperative nutrition status, promoting early recovery of intestinal movement, shortening
hospitalization time and reducing the cost of hospitalization.
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Abstract: Enteral immunomodulatory nutrition is considered as a promising therapy for the treatment
of acute lung injury and acute respiratory distress syndrome (ALI/ARDS). However, there are still
some divergences, and it is unclear whether this treatment should be recommended for patients
with ALI/ARDS. Therefore, we conducted this systematic review and meta-analysis to assess the
efﬁcacy and safety of an enteral immunomodulatory diet on the clinical outcomes of ALI/ARDS
patients. Methods: We retrieved potentially relevant clinical trials though electronic databases. All
trials of enteral immunomodulatory diet for ALI/ARDS were included. Analyses of the overall
all-cause mortality, 28-day ventilator-free days and 28-day intensive care unit (ICU) free days were
conducted. Results: In total six controlled trials were evaluated. The pooled results did not show a
signiﬁcant reduction in the risk of all-cause mortality (M-H RR (the overall Mantel-Haenszel relative
risk), 0.81 (95% CI, 0.50–1.31); p = 0.38; 6 trials, n = 717) in ALI/ARDS patients treated with the
immunomodulatory diet. This treatment also did not extend the ventilator-free days and ICU-free
days. However, patients with high mortality might beneﬁt from this treatment. Conclusions: The
enteral immunomodulatory diet could not reduce the severity of the patients with ALI/ARDS.
Whereas, for ALI/ARDS patients with high mortality, this treatment might reduce the all-cause
mortality, but its use should be treated with discretion.
Keywords: enteral nutrition; immunomodulatory diet; acute respiratory distress syndrome; acute
lung injury; critical care; mortality
1. Introduction
Since its ﬁrst description in 1967, acute lung injury (ALI) and acute respiratory distress syndrome
(ARDS) have been known as common and lethal diseases. With mortality ranging from 25%–40% [1],
ALI/ARDS is a life-threatening disorder that cannot be ignored. It is mainly caused by predisposing
disorders such as pneumonia, aspiration, shock, and severe sepsis [2]. Beneﬁting from the exploration
of the pathophysiology of ALI/ARDS, we know that after having been affected by these diseases,
neutrophils will inﬁltrate into the alveolar space and pulmonary mesenchyme, where they will release
pro-inﬂammatory cytokines and eventually cause ALI/ARDS [2], which is characteristic of leakage of
edema ﬂuid and mismatch of ventilation and perfusion [2,3].
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Although we know much about the pathophysiologic change of ALI/ARDS, very little
improvement in patient outcomes has been achieved. The main treatment is supportive care, including
maintaining oxygenation and avoiding complications [1,2]. There are no speciﬁc and effective
treatments for ALI/ARDS [4], although many ventilation strategies and medicines have been tried.
Thus, it is urgent to ﬁnd an effective treatment for ALI/ARDS. Over the past two decades, some
trials [5–7] and meta-analyses [8,9] have suggested that the enteral use of an immunomodulatory diet
(omega-3 fatty acid, γ-linolenic acid and antioxidant supplementation) might be a promising therapy.
This immunomodulatory diet is mainly combined with anti-inﬂammatory elements (such as
eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and gamma-linolenic acid (GLA)) and
antioxidants (such as vitamin C, vitamin E and beta-carotene). It has been reported that Omega-3 (EPA
and DHA) could modulate inﬂammatory processes, such as by reducing leukotriene production [10,11]
and decreasing the synthesis of prostaglandin E2 [12]. It can also reduce the permeability of the
alveolar-capillary membrane [13]. As for the antioxidants, they can scavenge free radicals, as we all
know, and thus reduce the inﬂammation [14].
Using enteral nutrition for ALI/ARDS patients has been demonstrated to improve oxygenation
and extend 28-day ventilator-free days and 28-day intensive care unit (ICU) free days [5,7]. It has even
been associated with reduced mortality [6,7]. Some meta-analyses [8,9] have also shown its effect.
However, one trial conducted by Rice et al. [15] revealed that an enteral inﬂammation-modulating
diet did not improve the outcomes of ALI/ARDS patients and might be harmful. This conclusion
compelled us to re-evaluate the effectiveness and safety of this treatment.
Therefore, we conducted this systematic review and meta-analysis to re-evaluate the effectiveness
and safety of enteral use of the immunomodulatory diet (omega-3 fatty acid, γ-linolenic acid and
antioxidant supplementation) vs. standard enteral nutrition on the mortality and clinical outcomes in
patients with ALI/ARDS and to guide further research in this area.
2. Methods
The work, including the literature search, study selection and data extraction, was conducted
according to standard strategies described below. Two reviewers (CCL and LYB) completed this
work independently, and all discrepancies were solved by discussion or consultation with the senior
reviewer (FGJ). Ethical approval was not required to conduct this meta-analysis.
2.1. Search Strategy
An extensive computer search of the relevant literature was performed by the two reviewers
independently using databases including MEDLINE (PubMed), Embase and the Cochrane Central
Register of Controlled Trials. We also retrieved potentially relevant literature manually, including
conference abstracts published in the American Journal of Respiratory and Critical Care Medicine,
Critical Care Medicine and Chest. All articles and conference abstracts about enteral nutrition
therapies for patients with ALI or ARDS were identiﬁed regardless of language. The search terms we
used were critically ill patients, acute lung injury, ALI, acute respiratory distress syndrome, ARDS,
mechanical ventilation, sepsis, immunomodulatory diet, ﬁsh oil, antioxidants, omega-3 fatty acids,
eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and γ-linolenic acid (GLA).
2.2. Study Selection
Studies were included if they fulﬁlled all of the inclusion criteria. (1) Participants: patients had
to be diagnosed with ALI/ARDS or have respiratory failure that required mechanical ventilation.
(2) Type of studies: studies were eligible only if they were randomized controlled trials. (3) Type
of interventions: studies used enteral nutrition therapies (omega-3 fatty acids, γ-linolenic acid and
antioxidants). Studies were excluded if they did not provide outcomes related to mortality, 28-day
ventilator-free days or 28-day ICU-free days. Crossover studies were also excluded.
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2.3. End Points and Data Extraction
The primary end point was all-cause mortality, and the secondary end points were 28-day
ventilator-free days, 28-day ICU-free days and adverse effects. For all-cause mortality, we used 28-day
mortality. If 28-day mortality could not be acquired, we used ICU or hospital mortality instead. We
also extracted and collected the relevant information about each study, such as the characteristics of
the studies, characteristics of the participants, enteral immunomodulatory therapy strategies and types
of outcomes.
2.4. Quality Assessment
The quality levels of the included trials were also evaluated independently by two authors
(CCL and LYB). We assessed the risk of bias (including selection bias, performance bias, attrition
bias, detection bias, reporting bias and other bias) using the assessment table recommended by the
Cochrane Reviewers’ Handbook [16]. We also evaluated the methodological quality of the included
trials using the Modiﬁed Jadad Scale [17], where the full score is 7, and scores of 4–7 are regarded as
high quality and 1–3 as low quality.
2.5. Data Processing and Statistical Analysis
First, we examine the heterogeneity of the included studies using the I2 statistic and Chi2 test,
with signiﬁcant heterogeneity if p ≤ 0.10 for the Chi2 test or I2 ≥ 50%. If signiﬁcant heterogeneity
was obtained, we would use the random-effects model for the following analysis; otherwise, the
ﬁxed-effects model would be used.
Second, we pooled the treatment effects of enteral nutrition on the all-cause mortality to estimate
the summary effect. As the mortality outcome was dichotomous, we calculated the relative risk
(RR) and 95% conﬁdence interval (CI) of every included trial and then pooled them to estimate the
overall Mantel-Haenszel (M-H) RR and the 95% CI. For the continuous variables, we calculated the
standardized mean difference (SMD). To test the robustness of the results, we performed a sensitivity
analysis by excluding each individual study and re-analyzing. The funnel plot was calculated to
evaluate the publication bias.
The results were considered statistically signiﬁcant if (1) the two-sided p-value ≤ 0.05, (2) the
conﬁdence interval for RR did not include 1, and (3) the conﬁdence interval for SMD did not include 0.
The data synthesis and sensitivity analyses were performed using Review Manager (version 5.1).
3. Results
3.1. Study Selection and Quality Assessment
We identiﬁed six studies [5–7,15,18,19] that fulﬁlled our inclusion criteria out of 2274 potential
articles though searching the relevant databases (see Figure 1). All of them were included in our
analysis. Five relevant papers [20–24] were excluded based on the reasons described in Table S1.
The major characteristics of the six included trials are summarized in Table 1. In short, the trials
encompassed a total of 717 patients, with 365 patients in the experimental groups and 352 patients in
the control groups. The mean age of the patients ranged from 51.0 to 65.1. The mortality of the control
groups ranged from 12.5% to 57.14%. When stratiﬁed by the compositions of the immunomodulatory
diet, two studies included treatment with EPA + GLA + antioxidants, and four studies included
treatment with EPA + DHA + GLA + antioxidants. When stratiﬁed by the blind strategies, four trials
were double-blind, one trial was single-blind and one trial was unblinded.
We evaluated the quality of the included trials using the Modiﬁed Jadad Scale and Cochrane’s risk
of bias assessment table. As shown in Table S2, all of the included studies were high quality, and most
of them had low risk of bias in the generation of random sequence, allocation concealment, incomplete
outcome data and selective reporting. Only two trials were high risk in terms of the blinding of
participants and personnel.
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
Flow Diagram.
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3.2. Effect on Mortality
Because signiﬁcant heterogeneity was found across the included trials (χ2 = 14.61, df = 5 (p = 0.01);
I2 = 66%), we used the random-effects model to analyze the overall effect of immunomodulatory
nutrition on mortality. As shown in Figure 2, there was no signiﬁcant difference between the two
groups (M-H RR, 0.81 (95% CI, 0.50–1.31); p = 0.38; six trials, n = 717) that is, the pooled result did not
showed a signiﬁcant reduction in the risk of all-cause mortality in ALI/ARDS patients treated with
immunomodulatory nutrition. The overall mortality of the six trials was 25.24%, and the mortality of
the experimental groups was 23.56% compared with 26.99% for the control groups.
Figure 2. Forest plot of the association between enteral immunomodulatory diet and all-cause mortality
among patients with ALI (acute lung injury)/ARDS (acute respiratory distress syndrome).
Because of the heterogeneity of the mortality in the control groups across the included trials, we
conducted a subgroup analysis by stratifying the previous meta-analyses according to the mortality
of the control groups. The analyses (M-H RR, 1.16 (95% CI, 0.70–1.91); p = 0.56; three trials, n = 97)
revealed that for patients with low mortality, this treatment could not reduce the overall mortality
in ALI/ARDS patients (see Figure 3). The results (M-H RR, 0.56 (95% CI, 0.40–0.80); p = 0.001; two
trials, n = 198) indicated that patients with high mortality might beneﬁt from this treatment, and there
was a signiﬁcant subgroup difference (χ2 = 5.36, df = 1 (p = 0.02); I2 = 81.4%). However, they were
something that need our attention. The quality of the trials in this subgroup was lower than most of
others (as shown in Table S2).
3.3. Effect on 28-Day Ventilator-Free Days and 28-Day ICU-Free Days
We also pooled the data about the 28-day ventilator-free days and 28-day ICU-free days. The
outcomes of 568 participants from four trials were available when assessing the effect of enteral
nutrition on ventilator-free days and ICU-free days. As shown in Figures 4 and 5, enteral nutrition did
not extend the ventilator-free days (M-H RR, −0.33 (95% CI, −0.90–0.24); p = 0.25; four trials, n = 568)
and ICU-free days (M-H RR, −0.30 (95% CI, −0.82–0.22); p = 0.26; four trials, n = 568). Because of
the signiﬁcant heterogeneity of the included trials ((χ2 = 30.79, df = 3 (p < 0.00001); I2 = 90%) and
(χ2 = 25.76, df = 3 (p < 0.0001); I2 = 88%)), the random-effects model was selected.
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Figure 3. Forest plot of the association between enteral immunomodulatory diet and all-cause mortality
among patients with ALI/ARDS, stratiﬁed by discrepancy of mortality.
Figure 4. Forest plot of the association between enteral immunomodulatory diet and 28-day
ventilator-free days among patients with ALI/ARDS.
Figure 5. Forest plot of the association between enteral immunomodulatory diet and 28-day ICU-free
days among patients with ALI/ARDS.
3.4. Sensitivity Analyses
To test the robustness of the results, we conducted sensitivity analyses. We excluded each
individual study, re-analyzing and comparing with the original results. When excluding the trial
conducted by Rice T. et al. [15], the overall effect was M-H RR, 0.63 (95% CI, 0.47–0.85); p = 0.0.003;
ﬁve trials, n = 445 (see Figure S1). When excluding other trials, the results were consistent with the
previous one.
3.5. Adverse Effects
To test the safety of this treatment, we also analyzed the adverse effects of the enteral
immunomodulatory diet. The majority of adverse events were gastrointestinal events such as diarrhea,
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dyspepsia and nausea. As shown in Figure 6, there was no signiﬁcant difference between the two
groups (M-H RR, 0.92 (95% CI, 0.57–1.47); p =0.72; three trials, n =333).
Figure 6. Forest plot of the association between enteral immunomodulatory diet and adverse events
among patients with ALI/ARDS.
3.6. Publication Bias
No evidence of publication bias was detected by funnel plots (see Figure S2).
4. Discussion
In conducting this systematic review, we searched the relevant literature comprehensively without
language limitation. The pooled results from all six independently conducted trials revealed that an
enteral immunomodulatory diet (omega-3 fatty acid, γ-linolenic acid and antioxidant supplementation)
could not improve all-cause mortality, ventilator-free days or ICU-free days in patients with ALI/ARDS.
Overall, patients could not beneﬁt from enteral immunomodulatory diet, and its use should be treated
with discretion.
It was believed previously that the immunomodulatory diet could suppress the elevated
inﬂammatory reactions during ALI/ARDS [5], and patients could beneﬁt from it [6]. Preclinical
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studies reported that Omega-3 (EPA and DHA) could reduce leukotriene synthesis and the production
of prostaglandin E2, which could be beneﬁcial in ALI/ARDS [3,11,13]. The antioxidants could also
reduce the inﬂammation through scavenging free radicals [25]. Several clinical trials conﬁrmed these
results [5–7], and demonstrated an association between the usage of enteral immunomodulatory diet
and improved outcomes in ALI/ARDS patients [5–7]. Two meta-analyses [8,9] also demonstrated this
effect. However, some trials conducted recently achieved a contrary result [15,18], showing that enteral
inﬂammation-modulating diet did not improve the outcomes and might be harmful. Our results were
similar. However, some results needed extra attention. As shown in the characteristics of the included
studies, the mortality of the control groups varied widely (from 12.50% to 57.14%), and the test for
heterogeneity was also signiﬁcant for mortality. This result may be due to the different severity of
the illness and improved treatment strategies [2]. To decrease its inﬂuence on the ﬁnal results, we
used the random-effects model for analysis, and we also conducted a subgroup analysis stratiﬁed
according to the mortality of the control groups. The result revealed that enteral immunomodulatory
nutrition could only beneﬁt ALI/ARDS patients with high mortality. For patients with low mortality,
this treatment had no effect and might be harmful. From this perspective, it is important to clarify
the indications of this treatment, and for future trials about this aspect, the enrolled patients could
be restricted to severe cases. However, the quality of the two trials included in the high-mortality
subgroup was lower than most of the others, and the results of these studies might be affected.
The drop-out proportions of most included studies were large. Undoubtedly, the reliabilities of
the ﬁnal results achieved by these trials were inﬂuenced by this factor [16]. The main reason that people
left the studies was that the patients could not tolerate the rate of continuous enteral infusions because
of gastrointestinal complications [5,7]. However, the study conducted by Rice T. et al. [15] solved this
problem by using bolus delivery, namely small-volume supplementation, to deliver the supplements.
The results indicated that this method was more tolerable. However, given 120 mL ﬂuid once might
increase the risk of aspiration, especially for patients who already have respiratory compromise.
In this review, we demonstrated that ALI/ARDS patients could not beneﬁt from enteral
immunomodulatory diet through including some newly reported trials. However, we still need
further exploration of the following issues. During sensitivity analyses, we found that the results
were not very robust. The ﬁnal conclusion was seriously affected by the trial conducted by Rice T. et
al. When we excluded this study, re-analyzed and compared with the previous results, the opposite
conclusion was obtained. This condition was more or less due to the discrepancy of the controlled
nutrition, and the calorie intake was quite low in Rice T. et al.’s trials [26]. However, the reason is still
unclear, and we should be aware that the conclusion is not certain. Further improved randomized
clinical trials are needed.
Some limitations in this report should be mentioned. First, the heterogeneity tests of the all-cause
mortality, ventilator-free days and ICU-free days were positive. Although we tried to reduce their
inﬂuence methodologically (using a random-effects model and subgroup analyses), they might still
cause some biases. Second, the sample sizes of the included trials were small, and only three trials
had more than 100 patients available. Even worse, the drop-out proportions were large in the majority
of the included trials. Third, there was also some variability in the patient types, outcome types, and
route of intervention administration. When trying to solve this problem, we found clues indicating
that the effects of enteral nutrition may be related to the severity of the ALI/ARDS. Finally, we did not
assess the discrepancy of the ratio of partial pressure arterial oxygen and fraction of inspired oxygen
(PaO2/FiO2 ratio) because of inadequate information. As one of the most frequently used indicators
of oxygenation and respiratory function, the PaO2/FiO2 ratio is a good predictor of the condition of
ALI/ARDS patients. Thus, further trials should report more information about it.
5. Conclusions
Overall, based on the existing data, the enteral immunomodulatory diet (omega-3 fatty acid,
γ-linolenic acid and antioxidant supplementation) could not reduce the mortality of patients with
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ALI/ARDS and also could not extend the 28-day ventilator-free days or 28-day ICU-free days.
However, the subgroup analysis showed that enteral immunomodulatory nutrition could beneﬁt
ALI/ARDS patients with high mortality, but it should be used with discretion. More well-designed
clinical trials are urgently needed to verify this conclusion.
Appendix Supplementary Information
Table S1: Studies excluded from the meta-analysis of clinical trials involving enteral nutrition
treatment for ALI/ARDS.
Table S2: Risk of bias of the included studies.
Figure S1: Sensitivity results (overall effect when excluding the trial conducted by Rice T. et al.).
Figure S2: Funnel plot of the standard error by log relative risk of all-cause mortality.
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